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General introduction I 
therosclerosis, the principal cause of ischemic heart disease, stroke and pe-
ripheral arterial disease, is the fllost important cause of morbidity and Inor-
tality in \Vestern countries. Atherosclerosis and cardiovascular disease are 
diseases of the elderly. Demographic data predict that the number of elderly 
people in our countIy as well as in most \Vestern countries, will increase in the coming 
years, especially among women. 111is means the absolute number of deaths from car-
diovascular disease in women is bound to increase, and an increasing awareness of the 
importance of cardiovascular disease as a major issue in women is warranted. 
Premenopausal women seem to be protected from cardiovascular disease com-
pared to postmenopausal women. What part menopause plays in the increased risk of 
cardiovascular disease after middle age is still debated,l-3 One might expect that 
women experiencing an early menopause have more time to develop atherosclerosis 
and thus cany a high risk of coronary heart disease. But data on the association be-
tween menopause and coronmy heart disease are conflicting. The inconsistency might 
be the result of a methodological problem; incidence of cardiovascular disease in 
women shortly after menopause is quite low, and increases only after age 70. This lag 
time of 10 to 20 years between menopause and the occurrence of coronalY healt dis-
ease in women makes the effect of menopause difficult to disentangle from that of age. 
A better approach to study the role of menopause might be to study its association with 
atherosclerosis, as the latter is present long before symptomatic coronmy hemt disease 
develops. Only few studies have focussed on non-invasively measured atherosclerosis 
in relation to menopause. 
Obselvational studies consistently show a marked reduction of coronalY heart 
disease associated with the use of hormone replacement therapy. Although results 
from observational studies are strong, consistent and biologically plausible, potential 
biases are large and most would be expected to spuriously enhance the observed car-
dioprotective effect. Nonetheless, because coronmy healt disease is the most conunon 
and most deadly disease of women, any significant reduction in coronaty hean disease 
risk due to hormone replacement therapy would strongly affect the benefit-risk scale. 
111e mechanisms by which hormone replacement therapy exerts its effect on the car-
diovascular system have not yet been fully explained. It is not known, whether the ef-
fect is based on influencing atherosclerosis or on other, direct effects, and whether 
these effects remain present after discontinuation of therapy. 
'I11e ain] of this thesis is to gain insight into the role of menopause in the increase 
of cardiovascular disease in women after middle age. FUlthermore, in search of possi-
bilities for prevention, it addresses the effect of hormone replacement therapy. 
In chapter 2.1, in order to assess the effect of menopause on risk factors for coro-
nmy healt disease, we examined cardiovascular risk factors in a meticulously selected 
population in which the contrast in estrogen status between pre- and postmenopausal 
women of the same age was maxiInised. In chapter 2.2, the difference in alterial dis-
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tensibility between pre- and postmenopausal women was studied, in the same study 
population of pre- and postmenopausal women. In chapter 2.3 we investigated the 
association between age at menopause and the presence of non-invasively measured 
atherosclerosis in the aorta, the carotid arteries and peripheral arteries, as weB as the 
presence of myocardial infarction in 4853 postmenopausal women, aged 55 and over, 
palticipating in the Rotterdam study. 
111e results of two obselvational studies on the effects of hormone replacement 
therapy are described in chapter 3. In chapter 3.1 the associations between current and 
past use of hormone replacement therapy and peripheral arterial disease are repOlted, 
using the obselYational data from 11,e Rotterdam Study. The association between hor-
mone replacement therapy and intima-media thickness of the common carotid 31telY 
was studied in chapter 3.2. In chapter 4 of this thesis results from a randomised inter-
vention trial (ROMEO I), are repOlted. Two studies were conducted to examIne 
whether combined hOlm one replacement therapy would affect arterial stiffness and 
intima-media thickness of the com111on carotid 31telY. In the general discussion the re-
sults described in this thesis are briefly summarised. Some methodological problems 
are discussed. Our findings are addressed in the light of the hypotheses on the effects 
of menopause and hormone replacement therapy on atherosclerosis and cardiovascu-
lar disease in women, and finally, some suggestions for flllther research are given. 
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Abstract 
Objectives - Changes in cardiovascular risk factors with menopausal status are difficult to study, 
due to the high correlation of menopausal status with age. Therefore we examined cardiovascular 
risk factors in a meticulously selected population in which the contrast in estrogen status between 
pre- and postmenopausal women of the same age was maximised. 
Design - Risk factors were compared in 93 premenopausal and 93 postmenopausal women who 
were matched on age (range 43-55 years). 
Setting - The women were selected from respondents to a mailed questionnaire about the 
menopause, which was sent to all women aged 40 to 60 years in the Dutch town of Zoetermeer 
(n = 12,675; response 54 %). 
Subjects - Postmenopausal women who were at least three years after menopause or whose 
menses had stopped naturally before age 48 were age-matched with premenopausal women with 
regular menses and without menopausal complaints. 
Results - Compared to premenopausal women, postmenopausal women had significantly in-
creased levels of total cholesterol (10.0%, 95% confidence interval 5.1 - 14.0), low density lipo-
protein (LOL) cholesterol (14.0%, 6.9 - 19.9), and apolipoprotein B (8.2%, 0.6 - 15.5). The differ-
ence was present within three years after onset of menopause and did not show a trend towards 
an increase with the number of postmenopausal years. No differences were found in high-density 
lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein A 1, blood glucose, insulin, body 
mass index, waist-to-hip ratio, and systolic and diastolic blood pressure. 
Conclusions - The results of this study add to the evidence that total cholesterol, LOL cholesterol 
and apolipoprotein B are the primary cardiovascular risk factors affected by menopause. 
8 
Menopausal status and risk factors for cardiovascular disease I 
INTRODUCTION 
The incidence of cardiovascular disease in women rises sharply after middle age. Al-
though results of large follow-up studies are inconsistent, menopause is thought to be 
a major determinant of this increase.1-3 The mechanism through which menopause 
exelts its effect on the cardiovascular system is still unknown. Increased levels of se-
lUm total cholesterol after cessation of menses have been found in most studies on 
menopause and risk factors.4-16 Inconsistent results, however, have been repOlted with 
respect to HDL_cholesteroI8-1O,12-14,17, apolipoprotelns7,8,12,1~18, blood pres-
sure4-6,8,9,17,19-22, waist-to-hlp ratio 23,24 and insulin.25-27 A difficulty with studying ef-
fects of menopause is the high correlation between menopausal status and age. Studies 
that included women in a broad age range may not be able to validly remove the con-
founding effect of age.13,16,19,24 Studies in a restricted age range around the meno-
pause wiH include premenopausal women who have irregular menses and postmeno-
pausal women who only recently passed menopause, which reduces the contrast in 
estrogen status. 17,21 
In the present study, we examined the relations between natural menopause and 
several atherogenic factors in a highly selected population in which the contrast in es-
trogen status between pre- and postmenopausal women of the same age was maxi-
mised. 
MATERIALS AN D METHODS 
Study population 
Selection of participants in this study was aimed at maximising the contrast in estrogen 
status, in pre- and postmenopausal women of the same age (figure O. A questionnaire, 
including questions about menopausal status, medical histOlY, medication use, and 
smoking behaviour, was sent by mail to all women aged 40 to 60 years and living in 
the town of Zoetermeer, 11,e Netherlands (n=12,675). 11,e response rate was 54%. Se-
lection of pre- and postmenopausal women was based on the questionnaire. '''omen 
with a hysterectoluy andlor uni- or bilateral ovariectomy and women with missing in-
formation on type or date of menopause (n=233) were excluded from the study popu-
lation (n=1,551). Women were considered premenopausal if they had one or more 
bleedings in the past 12 months (n=3,829). Premenopausal women who reported no 
longer having monthly bleedings (n=938) and women who reported the presence of 
clinlacteric symptoms, defined as perspiration and/or hot fiushes (n=1,645) were ex-
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Figure 1 - Schematic presentation of the selection procedure of the study population. 
(1) Eligible were women with regular menses and no climacteric symptoms, who did not use 
hormone replacement therapy or oral contraceptives in the past 6 months. Subsequently 
women who smoked, who had diabetes mellitus or used antihypertensive or cholesterol low-
ering drugs were excluded. (2) Eligible were women whose menses had ceased naturally 
more than 12 months ago and who had not used hormone replacement therapy. Subsequent-
ly women who smoked, who had diabetes mellitus, Of who used antihypertensive or chal-
esterallowering drugs were excluded. (3) Women who no longer fulfilled the criteria at the 
moment of examination were excluded. 
eluded. FlIlthelTI10re, premenopausal women who repOlted use of hormone replace-
ment therapy or use of oral contraceptives within 6 months prior to the clinical exami-
nation were excluded (n~423). 
The total number of premenopausal women exeluded for the above mentioned 
reasons was 2,191, leaving 1,638 eligible premenopausal women. 
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Women were considered to have had natural menopause if their menses had 
ceased naturally for at least 12 months (n=1,242). Postmenopausal women who re-
ported a histOlY of hormone replacement therapy for over six months or use of female 
hormones within six months prior to the clinical examination and women who re-
ported cessation of bleedings in1medlately upon stopping hormones were excluded 
(n=241). The total number of postmenopausal women excluded, including those with 
missing values on hOlTIlone use was 284, leaving 958 eligible postmenopausal women. 
Of these women, we additionally excluded women repOiting diabetes mellitus (13 
(0.8%) premenopausal versus 160.7%) postmenopausal women), use ofantihyperten-
sive medication (31 (1.9"Al) versus 35 (3.7%)), use of cholesterol-lowering drugs (3 
(0.2%) versus 20 (2.1%)) and current smoking of 5 or more cigarettes per day (302 
08.4%) versus 218 (22.8%)). 
Pre- and postmenopausal women were matched on age, while maximIsIng the 
contrast in estrogen status. Postmenopausal women who were at least three years after 
menopause or whose menses had stopped at least three years before the average age 
of menopause (51 years) were age-matched with premenopausal women wUh'a regu-
lar menses and without menopausal complaints. If it was not possible to find a match 
within the same year of age, a match was taken from an adjacent year. If one of a 
matched pair was unwilling to participate a new match was sought. Women were in-
vited for study palticipation on average 15 months after return of the questionnaire. 
Out of 424 invited women, 140 were excluded because they no longer fulfilled the in-
clusion criteria (regular menses, no climacteric symptoms, no hormone replacement 
therapy or cardiovascular disease) or no proper replacement match could be found. 
sixty-two women 05%) were unwilling to participate and 36 could not be reached. 
11,is left 93 pre- and 93 postmenopausal women, aged 43 to 55 years, who palticipated 
in the study. All women gave written informed consent, and the study was approved 
by the medical ethical committee of the Erasmus University Medical School. 
Measurements 
During a visit at the research centre, a medical histOlY was taken by a physician. 
Height, weight, and waist and hip circumference were measured with indoor clothes 
without shoes. Body mass index (weight/height') and waist-to-hip ratio were com-
puted. Alcohol drinking habits and cigarette smoking histOlY were obtained by a stan-
dardised questionnaire. Blood pressure was assessed 4 tin1es at the right upper ann 
after a 5 minutes1 rest in the supine position, with a Dinamap automatic blood pressure 
recorder (Critikon, Inc, Tampa, Florida, USA) and the mean was used In the analyses. 
Venous blood samples were drawn from each subject after a 12 hours fast. 11,e sam-
ples were stored at -80°C, and subsequently selum parameters were determined using 
11 I 
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a Kone Specific Analyzer (Kone Instruments, Espoo, Finland). Total cholesterol was 
measured with an automated enzymatic method28, using the CHOD-PAP High Per-
fonnance reagent kit from Boehringer Mannheim (Germany). HDL-cholesterol was 
measured by the phosphotungstate method according to Burstein29 with a minor 
modification as described by Grove30. The overall coefficients of variation for total 
cholesterol and HDL-cholesterol were 2.9% and 3.7%, respectively. LDL-cholesterol 
was computed with the Friedewald formula. 3l Serum triglycerides were determined by 
using a reagent kit from Boehringer Mannheinl (Germany) after enzymatic hydrolysis 
of the triglycerides with subsequent determination of liberated glycerol by colorimetlY. 
No correction was made for serum free glycerol. 111e overall coefficient of variation of 
this method did not exceed 3.2%. Apolipoprotein Al and B were measured by an 
automated turbidimetric immuno-assay using the reagent kits of Orion Diagnostics 
(Espoo, Finland). Glucose was enzymatically determined by the Hexokinase method 
Onstruchemie, Hilversul11, 111e Netherlands). Serum insulin was determined by Metric 
assay (Biosource Diagnostics, FleurisJ Belgium). This assay has no cross-reactivity with 
either pro-insulin or C-peptide. 
Statistical analysis 
'I11e two sample t test was used to compare general characteristics of pre- and post-
menopausal women. Differences in frequencies of smoking status and alcohol drinking 
were tested by the Chi-square test. AnalysiS of covariance was used to compare risk 
factors in pre- and postmenopausal women. Since the distribution of insulin was highly 
skewed, it was natural-log transformed for the analyses. Differences in risk factors were 
expressed as percentages, and confidence intervals for these percentages were calcu-
lated. If a woman could not recall the exact date of onset of menopause, but only the 
year, the date of menopause was approximated and set on the first of July of that year. 
For the risk factors shown to differ significantly between pre- and postmenopausal 
women, additional analyses were performed. The age-adjusted means of these risk 
factors were calculated within three groups of postmenopausal women defined accord-
ing to the number of postmenopausal years: 1.0-2.9 (n=23), 3.0-6.0 (n=39) and <: 6.0 
(n=31). A new ordinal variable was created, comprising the values 1, 2, and 3, corre-
sponding with the three categories of postmenopausal years. TI,e relation between the 
risk factors and time since menopause was estimated using linear regression analysis, 
with the ordinal variable as the independent variable. A test of significance for the co-
efficient of this ordinal variable was considered to be a test for u·end. 
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RESULTS 
TIle number of postmenopausal years was on average 5.4 (SO=3.0), and ranged from 
1.3 to 12.8. 'Ihe postmenopausal women were slightly older (mean 51.1, range 43.3 to 
54.7) than the premenopausal women (mean 50.6, range 44.1 to 55.3) (Table 1). 'Ihe 
group means of height, weight, body mass index, waist-to-hip ratio, and alcohol con-
sumption showed no significant differences (Table 1). Percentages of current smokers 
and ex-smokers did not differ significantly between the groups. 
Significantly higher levels of serum total cholesterol, LOL-cholesterol and apolipo-
protein B were found in postmenopausal women compared with premenopausal 
women, after adjustment for age (Table 2). Levels of HOL-cholesterol, trIglycerIdes, 
apolipoprotein AI, blood glucose, insulin, and systolic and diastolic blood pressure 
were not signIfIcantly different between the two groups. AddItional adjustment for 
body mass index, waist-to-hip ratio, cigarette smoking and alcohol consumption influ-
enced the results only slightly. No significant linear trend with number of postmeno-
pausal years was obselved for the lipids, apolipoproteins levels and insulin levels, after 
adjustment for age (figure 2). 
Table 1 
General characteristics of pre- and postmenopausal women. 
Mean (SD) 
Age (yrs) 
Mean (SD) 
Height (em) 
Weight (kg) 
Body Mass Index (kg/m') 
Waist-to-hip ratio 
Alcohol (grams/wk) 
Percentage (n) 
Current smoking (%)' 
Past smoking (%)' 
Premenopausal 
(n = 93) 
50.6 (2.4) 
166.8 (5.7) 
68.8 (11.1) 
24.7 (3.8) 
0.77 (0.05) 
45 (57.0) 
6 (6) 
42 (39) 
Postmenopausal 
(n = 93) 
51.1 (2.2) 
165.6 (7.3) 
68.6 (11.5) 
25.0 (4.1) 
0.77 (0.05) 
45 (57.1) 
6 (6) 
39 (36) 
t Subjeds who smoked 5 or more cigarettes per day were excluded from study participation 
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Table 2 
Risk factors for cardiovascular disease in premenopausal and postmenopausal women. 
Pre- Post- 95 % 
Mean (SE)' hlenopausal menopausal Difference Confidence (%) interval for the (n ~ 93) (n ~ 93) % difference 
Total cholesterol (mmol/l) 5.89 (0.10) 6.48 (0.10) , 10.0 % (5.1 ; 14.0) 
LDL-cholesterol (mmol/l) 3.78 (0.09) 4.32 (0.09) , 14.0 % (6.9; 19.9) 
HDL-cholesterol (mmolll) 1.58 (0.04) 1.64 (0.04) 3.7 % (-2.9; 10.3) 
Triglycerides (mmol/l) 1.16 (0.06) 1.16 (0.06) 0% (-13.5; 13.9) 
Apolipoprotein Al (mgldl) 1.53 (0.03) 1.56 (0.03) 1.9 % (-3.8; 8.0) 
Apolipoprotein B (mgldl) 0.89 (0.03) 1 .06 (0.03) , 8.2 % (0.6; 155) 
Glucose (mmolll) 5.56 (0.06) 5.55 (0.06) -0.01 % (-2.9; 2.6) 
Insulin (picomolll)' 45.7 (1.05) 44.9 (1.05) -1.8 °lrs (-11.2; 14.8) 
Systolic blood pressure (mmHg) 120.8 (1.5) 120.6 (1.5) - 0.16 % (-3.4; 3.2) 
Diastolic blood pressure (mmHg) . 67.7 (1.0) 68.6 (1.0) 1.3 %, (-2.8; 5.5) 
• Adjusted for age 
§ Skewed data, therefore geometric mean is shown 
t p<O.OS 
I p<O.OOl 
8 mmol/l gil 2 
6 1.5 
4 
2 0.5 
o o 
TC HDL·C LDL-C TG ApoAl Apo B 
.. Premenopausal m < 3 PMY Cl3-6 PMY Cl> 6 PMY 
Figure 2 - Mean lipid levels in 93 premenopausal women and 93 postmenopausal women in 3 
categories of time since menopause « 3 yr n=23, 3-6 years 0=39, ~ 6 years 0=31). 
TC ~ total cholesterol; HDL-C - high density lipoprotein cholesterol; LDL-C ~ low density 
lipoprotein cholesterol; TG ~ triglycerides; Apo ~ apo/ipoprotein; PMY ~ postmenopausal 
years. 
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DISCUSSION 
In the present study we found that mean levels of semm total cholesterol, LDL-choles-
terol and apolipoprotein B were significantly higher in postmenopausal women than in 
premenopausal women of the same age. These higher levels were established within 
three years after the onset of menopause and did not change over postmenopausal 
tinle. Levels of triglycerides, HDL-cholesterol, apolipoproteln AI, blood glucose, insu-
lIn, body mass index, waist-to-hip ratio and systolic and diastolic blood pressure, were 
not significantly associated with natural menopause. 
In studying the effect of menopause, age is an inlportant confounding factor. In 
most cross-sectional studies) the study population includes women in an age-range that 
encompassed the extreme ages of menopause.7,8,1O,13,14,16,19 Such a study population 
comprises premenopausal women who have irregular menses and postmenopausal 
who only recently passed menopause) which decreases the contrast in estrogen status 
between the two groups. On the other hand, when a large proportion of women is 
aged in a range with little overlap between pre- and postmenopausal women, it is 
questionable whether age-adjustment by statistical modelling gives valid results. In 
some cross-sectional studies) pre- and postmenopausal women were matched in cate-
gories of age.4,9,12 \Vithin age groups) however) the postmenopausal women are still 
likely to be older than their premenopausal counterparts, reSUlting in residual con-
founding. In only one cross-sectional study were women matched on age in one-year 
categories.21 In longitudinal studies) women who went through menopause during 
follow-up were compared with women of the same age who remained premeno-
pausaI5 ,6,17,32,33 111ese studies decrease the within-subject variation but at the expense 
of contrast in estrogen status: most premenopausal women who go through meno-
pause will have irregular menses at baselIne and will only recently have passed meno-
pause at follow-up. By a careful matching procedure in the present study, we com-
posed a population of age-matched pre- and postmenopausal women. 
111e WOluen in our study were selected form responders to a mailed question-
naire. \Ve assume) however) that the results from our study are generalisable to the 
general population even if some selection has taken place) because we have no reason 
to assume that the relation between menopause and biological factors will be different 
in responders and non-responders. 
To ensure that the results are due to true associations between natural nlenopause 
and cardiovascular risk factors) bias due to other factors has also to be considered as a 
possible explanation. \Ve excluded women' currently using hormone replacement ther-
apy or oral contraceptives. Moreover, after age-matching and exclusion of wonlen 
smoking 5 cigarettes per day or more, residual confounding by age, smoking, body 
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mass index and alcohol drinking habilS was dealt with by adjustment in the analyses. 
Some other determinants of early menopause were not measured in this study. For ex-
ample, socia-economic status, genetic factors or parity, Illay have been related to early 
menopause and the difference in lipid levels" This seems unlikely, however, as al-
though socia-economic status and parHy have been shown to be associated with in-
creased lipid levels, the reported effects of these factors are not large enough to ex-
plain the difference found in our study. Because of our stringent in- and exclusion cri-
teria, the effect of possible misclassification of menopausal status is likely to be small. 
Misclassification of age of menopause and number of postmenopausal years might 
have occurred, as these assessments were based on self-repOlts. 
nle obselvation of an increased total cholesterol level in postmenopausal COI11-
pared to premenopausal women is in agreement with rnost other studies, both cr055-
sectionaI4,7-1O,12-J6,26 and longitlldinaI.5,6,1l,17,32 We found age-adjusted levels to be 
increased by lO.O%j in other cross-sectional studies the difference ranged from 8% to 
13%.7,8,10,13,\4,16 In accordance with some groups who investigated linear trends in 
total cholesterol levels with postmenopausal years cross-sectionally4,8,13 or longitudl-
nally5, we found that these higher levels were established within the first years after 
menopause and did not change thereafter. 
The results with respect to LDL-cholesterol in our and other studies are consistent 
with the findings for total cholesteroI7,8,12-15. In accordance with our observation, HDL-
cholesterol was often found not to be associated with menopause8,10,12,14, but in some 
cross-sectionaI9,13 and longitudinal studies17 a slightly lower HDL-cholesterol was 
found in postmenopausal women. The apparent inconsistency may be due to small 
opposing effects of estrogen deprivation on the HDL subfractions. 13,34 
In contradiction to obselvations in many cross-sectional studies in which an ele-
vated level of triglycerides after menopause was found6,8,13,15,16, we found no signifi-
cant difference in triglycerides between the pre- and posunenopausal women. We 
have no explanation for this discrepancy. Some other studies, however, including one 
cross-sectional and one longitudinal study in which subjects were matched on age, 
found no menopausal effect on trlglycerldes.14,17,21 
Few studies examined the relation between menopause and apolipoproteins Al 
and B. Findings include a small increase l6, a decrease7 or no changeS,17,18 in apolipo-
protein At. Apolipoprotein B, which is a strong marker for coronalY athero~clerosis in 
women, was increased in postmenopausal women in some8,12,16,18, but not all stud-
iesP Our finding that apolipoprotein Al was not different and apolipoprotein B was 
higher in post- compared with premenopausal women is consistent with our observa-
tionsof the associated lipoproteins HDL-cholesterol and LDL-cholesterol. 
Our finding that blood glucose and insulin levels were not associated with meno-
pause Is consistent with results of other stlldies.5,S,16,17,21,33 One cross-sectional study 
did find higher levels of insulin In postmenopausal women compared to premeno-
16 
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pausal women of the same age35 and one longitudinal study found lower levels.26 Our 
finding of comparable insulin levels in pre- and postmenopausal women does not ex-
clude the possibility that menopause does have an effect on glucose metabolism. An 
increased pancreatic insulin secretion in postmenopausal women, together with a 
compensatOlY decreased insulin clearance has been suggested.36 Two studies have 
suggested an age-independent reduction of insulin sensitivity with tinle after meno-
pausey,38 In our study we did not find an increase in insulin levels with tinle since 
menopause. 
Although body mass index increases in the perimenopausal period, body mass 
index does not seem to be affected by menopause after adjustment for age. 5,6,14,16,17,20 
Data on changes in fat distribution with menopause are scarce. In a cross-sectional 
study the propol1ion of upper body fat was higher in women after menopause, but the 
results were not adjusted for age. 23 In one small longitudinal study central adiposity 
increased with menopausal transition, compared to women who remained premeno-
pausal.32 In the Healthy Women's Study, unadjusted differences in waist-to-hip ratio 
between pre- and postmenopausal women were present cross-sectionally, but not lon-
gitudinally.24 11,e latter finding agrees with our observation of no difference between 
the two groups. 
Although conflicting results on the relations between menopause and blood pres-
sure have been found, our observation that blood pressure was not associated with 
menopause is consistent with most cross-sectlonaI9,14 and longitudinal studles.5,6,17 In 
most cross-sectional studies only the diastolic or only the systolic component was af-
fected by menopause.4.8,16,19 In a follow-up study, systolic blood pressure was ob-
served to decline from 2 years before until 6 years after menopause, but no control 
group of premenopausal women was present. 20 One study suggests that menopause 
affects stress-induced levels of systolic and diastolic blood pressure.39 
In conclusion, we selected age-matched pre- and postmenopausal women from a 
large general population in order to maximise the contrast in estrogen status. The re-
sults of our study suggest that total cholesterol, LDL-cholesterol and apolipoprotein B 
are the primary risk factors affected by menopause. Because increased cholesterol 
levels were established soon after cessation of menses, preventive measures aimed at 
reduction of healt disease in women should be initiated in early menopause. 
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Abstract 
Although several studies have shown that exogenous estrogens have beneficial effects on arterial 
characteristics, the effect of endogenous estrogen on the vascular system is still unknown. In this 
study distensibility, an indicator of arterial elasticity, of the common carotid artery was compared 
in pre- and postmenopausal women. The study comprised 93 premenopausal and 93 postmeno-
pausal women of similar age (range 43-55 years). Women were selected from respondents to a 
mailed questionnaire about the menopause, which was sent to all women aged 40 to 60 years, in 
the Dutch town of Zoetermeer (n ~ 12,675). 
Postmenopausal women who were at least 3 years past natural menopause or whose men-
ses had stopped naturally before age 48, were age-matched with premenopausal women with 
regular menseS and without menopausal complaints. The selection aimed at maximising the con~ 
trast in estrogen status between pre- and postmenopausal women of the same age. Distensibility 
of the carotid artery was measured non~invasively with B~mode ultrasound and a vessel wall 
movement detector system. Arterial distensibility is expressed as the change in arterial diameter 
(distension, AD) with the cardiac cycle, adjusted for lumen diameter, pulse pressure and mean 
arterial blood pressure. Compared to premenopausal women, postmenopausal women had sig-
nificantly lower arterial distension (liD 370.5 ~tm (SE 9.5) versus 397.3 ~m (SE 9.6)). These results 
suggest that the distensibility of the common carotid artery is negatively affected by natural 
menopause in presumed healthy women. 
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INTRODUCTION 
TI,e incidence of cardiovascular disease In women rlses sharply after middle age, and 
menopause is thought to be a major determinant of this increase.1-3 TI,e mechanism 
through which menopause exerts its effect on the cardiovascular system remains 
largely unexplained. Unfavourable effects on lipid metabolism have been considered a 
major intermedialY. However, recent studies have increasingly emphasised the direct 
beneficial effects of estrogens on the arterial wall. In experimental studies in an~nals, 
estrogen replacement had direct vasodilatOlY effects4-6 and was shown to affect the 
stmcture and mechanical properties of large arteries. Improved endothelial function 
has been shown after hormone replacement therapy in women7-9 and after estrogen 
use in transsexual men,lO,ll Use of estrogens in premenopausal women with coronalY 
artery disease had a beneficial effect on exercise induced myocardialischemia. 12 
Few studies have addressed the effects of endogenous estrogens and natural 
menopause on the dynamic characteristics of the arterial system. Although changes in 
distensibility were not found during the menstrual cyclen, going through menopause 
has shown to negatively affect the elastic properties of the aOitic root in hypertensive 
women 14, and time since menopause was inversely related to the pulsatillty index in 
the carotid atteries 15 and several parameters of aortic flow. 16 In the current study, we 
examined the relation between natural menopause and alteriai distension in the com-
mon carotid artelY. 
METHODS 
Study population 
Selection of participants in this study was ainled at maximising the contrast in estrogen 
status, in pre- and postmenopausal women of the same age (figure I), A questionnaire 
was sent by mail to all women aged 40 to 60 years living in the Dutch town of Zoeter-
meer, 11le Netherlands (n~12,675). The questionnaire included questions about meno-
pausal status, medical history, medication use, and smoking behavIour. TI,e response 
rate was 54%. The selection of pre- and postmenopausal women was based on the 
questionnaire. Women with a hysterectomy and/or uni- or bilateral oophorectomy 
(n~1,551) and women with missing information on type or date of menopause (n~233) 
were excluded. Women who had 1 or more bleedings in the past 12 months were con-
sidered premenopausal (n~3829). Premenopausal women who repOlted irregular 
monthly bleeding (n~938) and women who repOlted the presence of climacteric symp-
23[ 
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1,638 
eligible 
premenopausal women I 
93 
premenopausal women 
12,675 
source popu lation 
1 
6,845 
respondents to 
mailed questionnaire 
(54%) 
958 
eligible 
postmenopausal women2 
AGE MATCHtNG 
424 
women matched 
~ 
additionallyexeluded' 140 
refused 62 
not reached 36 
93 
postmenopausal women 
Figure 1 - Schematic presentation of the selection procedure of the study population. 
(1) Eligible were women with regular menses and no climacteric symptoms, who did not use 
hormone replacement therapy or oral contraceptives in the past 6 months. Subsequently 
women who smoked, who had diabetes mellitus or used antihypertensive or cholesterol law-
ering drugs were excluded. (2) Eligible were women whose menses had ceased naturally 
more than 12 months ago and who had not used hormone replacement therapy. Subsequent-
ly women who smoked, who had diabetes mellitus, or who used antihypertensive or chol-
esterollowering drugs were excluded. (3) Women who no longer fulfilled the criteria at the 
moment of examination were excluded. 
toms, defined as perspiration and/or hot flushes (n=1,645), were excluded for the pres-
ent study. 
Furthermore, premenopausal women who repOlted use of hormone replacement 
therapy or use of oral contraceptives within 6 months before the onset of the clinical 
examination were excluded (n=423). The total number of premenopausal women 
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INTRODUCTION 
111e incidence of cardiovascular disease in women rises sharply after middle age, and 
menopause is thought to be a major determinant of this increase l -3 The mechanism 
through which menopause exelts its effect on the cardiovascular system remains 
largely unexplained. Unfavourable effects on lipid metabolism have been considered a 
major intermedialY. However, recent studies have increasingly emphasised the direct 
beneficial effects of estrogens on the alterial wall. In experimental studies in anin1als, 
estrogen replacement had direct vasodilatolY effects4-6 and was shown to affect the 
structure and mechanical propelties of large alteries. Improved endothelial function 
has been shown after hormone replacement therapy in women7-9 and after estrogen 
use in transsexual men.10,1l Use of estrogens in premenopausal women with coronary 
altery disease had a beneficial effect on exercise induced myocardial ischemia.!2 
Few studies have addressed the effects of endogenous estrogens and natural 
menopause on the dynamic characteristics of the arterial system. Although changes In 
distensibility were not found during the menstrual cycle!3, going through menopause 
has shown to negatively affect the elastic propelties of the aOltic root in hypertensive 
women!", and time since menopause was inversely related to the pulsatility index in 
the carotid alteries15 and several parameters of aOltic flow. 16 In the current study, we 
examined the relation between natural menopause and alterial distension in the com-
mon carotid artelY. 
METHODS 
Study population 
Selection of palticlpants in this study was aimed at maxin1islng the contrast in estrogen 
status, in pre- and postmenopausal women of the same age (figure 1). A questionnaire 
was sent by mail to all women aged 40 to 60 years living in the Dutch town of Zoeter-
meer, 11,e Netherlands (n~12,675). The questionnaire included questions about meno-
pausal status, medical histOlY, medication use, and smoking behaviour. The response 
rate was 54%. The selection of pre- and postmenopausal women was based on the 
questionnaire. Women with a hysterectomy and/or unl- or bilateral oophorectomy 
(n~I,551) and women with missing information on type or date of menopause (n~233) 
were excluded. Women who had 1 or more bleedings in the past 12 months were con-
sidered premenopausal (n~3829). Premenopausal women who reported irregular 
monthly bleeding (n~938) and women who repolted the presence of climacteric symp-
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Figure 1 - Schematic presentation of the selection procedure of the study population. 
(1) Eligible were women with regular menses and no climacteric symptoms, who did not use 
hormone replacement therapy or oral contraceptives in the past 6 months. Subsequently 
women who smoked, who had diabetes mellitus or used antihypertensive or cholesterollow-
ering drugs were excluded. (2) Eligible were women whose menses had ceased naturally 
more than 12 months ago and who had not used hormone replacement therapy. Subsequent-
,y women who smoked, who had diabetes mellitus, or who used antihypertensive or ehal-
esterollowering drugs were excluded. (3) Women who no longer fulfilled the criteria at the 
moment of examination were excluded. 
toms, defined as perspiration and/or hot flushes (n~1,645), were excluded for Ihe pres-
ent study. 
Furthermore, premenopausal women who reported use of hormone replacement 
therapy or use of oral contraceptives within 6 months before the onset of the clinical 
examination were excluded (n~423). 111e total number of premenopausal women 
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excluded for the above mentioned reasons was 2191, leaving 1638 eligible 
premenopausal women. 
\\fomen were considered to have had natural menopause if their menses had 
ceased naturally for at least 12 months (n=1242). Women who reponed a histOlY of 
hormone replacement therapy for over 6 months or use of female hormones within 6 
months prior to clinical examination and women who reported cessation of bleeding 
immediately upon stopping hormones were excluded (n=241). The total number of 
postmenopausal women excluded, including those with missing values on hornlone 
use was 284, leaving 958 eligible postmenopausal women. 
Of the remaining women, we additionally excluded women repOlting diabetes 
mellitus 03 (0.8%) premenopausal and 160.7%) postmenopausal women), use of an-
tihypertensive medication (31 (1.9%) and 35 0.7%», use of cholesterol lowering drugs 
o (0.2%) premenopausal and 20 (2.10/0) postmenopausal women), and current smok-
ing of 5 or more cigarettes per day (302 (18.4%) premenopausal and 218 (22.8%) 
posunenopausal women). 
To create a sharp contrast in estrogen status we selected women with either an 
early or a late natural menopause. Postmenopausal women who were at least 3 years 
after menopause or whose menses had stopped at least 3 years before the average age 
of menopause (51 years) were age-matched with premenopausal women with regular 
menses and without menopausal complaints. If it was not possible to fInd a match 
within the same year of age, a match was taken from an adjacent year. If one of a 
matched pair was unwilling to participate a new match was sought. Women were in-
vited for study participation on average 15 months after return of the questionnaIre. 
Out of 422 invited women, 138 were excluded because they no longer fulfIlled the in-
clusion criteria, or no proper replacement match could be found. The primary reasons 
for no longer fulfilling the inclusion criteria were irregular menses or climacteric 
symptoms (n=62) and use of female hormones (n=26). Additionally, we excluded 
women with a histol)' of cardiovascular disease (1 woman with myocardial infarction 
and 1 with stroke). Sixty-two women (15%) were unwilling to participate and 36 could 
not be reached. 11,is left 93 pre- and 93 postmenopausal women, aged 43 to 55 years 
who participated in the smdy. All women gave written Informed consent, and the study 
was approved by the appropriate local instiItltional committees on ethical practice. 
Measurements 
During a visit at the research centre a medical history was taken by a physician. Height, 
weight, and waist and hip circumference were measured with indoor clothes without 
shoes. Body mass index (weight/height') and waist to hip ratio were computed. Data 
on alcohol drinking habits and cigarette smoking history were obtained by a question-
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naire. Serum total cholesterol was measured with an automated enzymatic method, 
using the CHOD-!' AP High Perfomlance reagent kit from Boehringer Mannheim. 
The vessel waH motion of the right common carotid altelY was by means of a Du-
plex scanner (An Ultramark IV, operating frequency 7.5 MHz) connected to a vessel 
wall movement detector system (Wall Track System). The details of this technique have 
been described elsewhere,17,18 Briefly, this system enables the transcutaneous assess-
ment of the displacement of the alterial walls during the cardiac cycle and, hence, the 
time-dependent changes in alterial diameter relative to its diastolic diameter at the stalt 
of the cardiac cycle. Subjects were instructed to refrain from smoking and consuming 
coffee, tea, alcohol or pain-medication on the day of measurement and from taking 
alcohol on the day before. Subjects were placed in supine position, with the head tilted 
slightly to the contralateral side for the measurements in the carotid artelY. A region at 
1.5 cm proximal to the origin of the bulb of the carotid artery was identified using B-
mode ultrasonography. Based on the B-mode recording an M-line perpendicular to the 
artelY was selected, and the received radIo frequency signals were recorded over 5 
cardiac cycles and digitally stored. The displacement of the arterial walls was obtained 
by processing the radio frequency signals originating from 2 selected sample volumes 
positioned over the anterior and posterior walls. 11,e successive values of the end-dia-
stolic diameter, the absolute stroke change in diameter during systole (I\.D), and the 
relative stroke change in diameter ((I\.D)/end-diastolic diameter) were computed from 
the recording during 5 cardiac cycles. With this system a wall displacement of a few 
mfcrometers can be resolved,17 All measurements were perfomled by a single ob-
selver. A reproducibility study was performed in which 14 participants undelwent a 
second examination within 1 month from the initial examination of the right carotid 
artelY. The coefficient of variation for the absolute diameter change and the lumen di-
ameter was 8.5% and 1.2%, respectively. Measurements were restricted to the right side 
to save time, as no significant differences in altery wall properties between the right 
and the left common carotid altery were found in previous studies by the authors. 
At the tinle of the ultrasound examination blood pressure was measured with a 
Dinamap automatic blood pressure recorder. Blood pressure was read 4 times at the 
right upper ann during the measurement session, and the mean was taken as the sub-
jects reading. Pulse pressure was defined as systolic blood pressure minus diastolic 
blood pressure. Mean arterial pressure was calculated as diastolic blood pressure + (1/3 
x pulse pressure). 
Statistical analysis 
Linear regression analysis, with adjustment for age, was used to estinlate the differ-
ences in characteristics between pre- and postmenopausal women. The difference in 
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distension of the carotid al1eries between pre- and postmenopausal women was also 
estimated using linear regression analysis, with distension as the dependent variable. 
Adjusunents were made for diastolic lumen diameter and pulse pressure by including 
these parameters as independent variables in the regression model. This component 
model allows the inclusion of mean arterial pressure as an additional covariate to ac-
count for its effect as well as for pulse pressure.19-21 Also, additional adjustment could 
be made for age. 
In a separate analysis the relation between distension and time since Inenopause 
was estimated using linear regression analysis, adjusting for age, diastolic lumen di-
ameter, pulse pressure and mean arterial pressure. As the independent variable a new-
ly created ordered variable was used which consisted of 3 groups of postmenopausal 
women: women up to 4 years after menopause, women 5 to 8 years after menopause 
and women 9 to 12 years after menopause. A test of significance for the coefficlent of 
this ordered variable was considered to be a test for trend. If a woman could recall the 
year but not the exact date of onset of menopause, the date was approximated and set 
on the first of July of that year. Statistical significance was considered to be present 
when p < 0.05. 
RESULTS 
General characteristics of pre- and postmenopausal women are outlined in Table 1. 
Among postmenopausal women the mean number of years after menopause was 5.4 
(SD~3.0), and ranged from 1.3 to 12.8. Age, height, weight, body mass index, waist hip 
ratio, alcohol consumption, smoking, blood pressure, and pulse pressure and fre-
quency were not significantly different between the 2 groups (Tables 1 and 2). Total 
cholesterol was significantly higher in postmenopausal women. 11,e end-diastolic lu-
men diameter was larger in postmenopausal women (6.73 mm) compared to pre-
menopausal women (6.59 mm), but this difference did not reach statistical significance 
(Table 2). 
When comparing the 2 study groups, a significant 7.2% decrease in distension was 
found in postmenopausal women (l'iD 370.5 ~lIn (SE 9.5» compared to premenopausal 
women (l'iD 397.3 ~un (SE 9.6», adjusted for age, diameter during diastole, pulse pres-
sure and mean arterial pressure (Table 2). 
\Vhen women were categorised in 3 groups by time since menopause, distension 
in women up to 4 years after menopause was 379.6 ~m (SE 15.9), in women 5 to 8 
years after menopause distension was 371.0 ~lm (SE 15.4) and in women 9 to 12 years 
after menopause distension was 359.6 ~lIn (SE 22.9), adjusted for age, diastolic lumen 
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Table 1 
General characteristics of pre- and postmenopausal women. 
Mean (SD) 
Age (yrs) 
Height (em) 
Weight (kg) 
Body Mass Index (kglm') 
Cholesterol (mmoll/) 
Alcohol (gramsiwk) 
Percentage (n) 
Current smoking (%)t 
Past smoking (%)t 
Premenopausal 
(n ~ 93) 
50.6 (2.4) 
166.8 (5.7) 
68.8 (11.1 ) 
24.7 0.8) 
5.9 (1.0) 
45 (57.0) 
6 (6) 
42 (39) 
Postmenopausal 
(n ~ 93) 
51.1 (2.2) 
165.6 (7.3) 
68.6 (11.5) 
25.0 (4.0) 
6.5 (0.9)' 
45 (57.1) 
6 (6) 
39 (6) 
t Subjects who smoked 5 or more cigarettes per day were excluded from study participation 
t p<O.OOl 
Table 2 
Arterial characteristics in pre- and postmenopausal women. 
Pre-
menopausal 
(n ~ 93) 
Post~ 
menopausal 
(n ~ 93) Difference 
Mean (SE) Mean (SE) 
dO (~m)' 397.3 (9.6) 370.5 (9.5) 
dOiO (%)' 6.0 (0.14) 5.6 (0.14) 
Diastolic lumen diameter (mm)t 6.6 (0.06) 6.7 (0.06) 
Systolic blood pressure (mmHg)t 120.8 (1.5) 120.6 (1.5) 
Diastolic blood pressure (mmHg): 67.7 (1.0) 68.6 (1.0) 
Mean arterial pressure (mmHg)* 85.4 (1.1) 86.0 (1.1) 
Pulse pressure (mmHg)t 53.0 (1.1) 52.0 (1.1) 
Pulse frequency (beats pimin)' 67.4 (0.1) 67.0 (0.1) 
* Adjusted for age, pulse pressure, mean arterial pressure and diameter 
t Adjusted for age, pulse pressure and mean arterial pressure 
.:j: Adjusted for age 
CI = confidence interval; SE = standard error; 0 = lumen diameter 
-26.8 
·0.39 
0.14 
-0.14 
0.90 
0.55 
-1.04 
-0.43 
(95% CI) 
(-53.5, -0.19) 
( -0.78 , 0.00 ) 
( ·0.04 , 0.32 ) 
(-4.30,4.01 ) 
(-1.97,3.77 ) 
(-2.50,3.60 ) 
(-4.02, 1.93) 
(-2.92, 2.06) 
Distension 
(~m) 
600 
500 
400 
300 
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Figure 2 - Distensionl adjusted for diastolic lumen diameterr pulse pressure and mean arterial 
pressure, in premenopausal and three groups of postmenopausal women (test for trend, 
p = 0.22). 
diameter, pulse pressure and mean arterial pressure (figure 2). This shows that disten-
sion tended to decrease with time since menopause, but the changes did not reach sta-
tistical significance (test for trend p=O.22). 
DISCUSSION 
11,e results of the current study show that the distensibility of the common carotid af-
telY is significantly lower in postmenopausal women than in premenopausal women of 
the same age, indicating increased arterial stiffness after menopause. 
[n studying the effect of menopause, age is an important confounding factor. By a 
rigorolls selection procedure in the present study, we composed a population of age-
matched pre- and postmenopausal women, from a general population. Because of QUI' 
stringent inclusion and exclusion criteria, the effect of misclassification of menopausal 
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status is likely to be small. Some misclassification of age of menopause may have oc-
curred, as these assessments were based on self-reports. The slight age difference be-
tween the study groups after age matching was dealt with by further adjustment in the 
analyses. To exclude potential bias due to other factors, such as smoking, lipid lower-
ing medication, antihypeltensive medication, current or recent use of hormone re-
placement therapy or oral contraceptives, or diabetes, we excluded all women with 1 
or more of these confounders and furthermore restricted the study to women who had 
experienced a natural menopause. 
\Ve measured distension in the carotid altelY and adjusted for pulse pressure 
measured in the brachial attety. \Ve thereby assume that pulse pressure measured in 
the brachial altelY is representative of pulse pressure in the carotid altelY. In dogs, it 
has been demonstrated that pulse pressure in the brachial artery is linearly related to 
blood pressure in the carotid artelY over a wide range of blood pressures.22 It is known 
that the arterial pressure-waves undergo transformation in the al1erial tree, and there-
fore, the pulse pressure is higher in the brachial attelY than in more central vessels.23 
\Vith increasing age, however, this difference between central and peripheral pulse 
pressure decreases. It is not known whether the overestimation of pulse pressure 
measured at the brachial altelY differs between pre- and postmenopausal women. If, in 
line with the decreasing difference seen with age, the overestinlatlon of pulse pressure 
is less in postmenopausal women, then the true difference in distensibility between the 
2 groups would be even larger than estinlated in our study. 
Various studies suggest sex-differences in mechanical propelties of the large ar-
teries during the reproductive years, but not thereafter24-26, and a steeper decline in 
distenSibility in women dIan in men in the age range of 45 to 60 years. 27 11lis suggests, 
but does not yet definitively prove the influence of menopause on altelY wall proper-
ties. Studies ainled directly on the relation between natural menopause and artery wall 
properties are limited. GangaI' et al. found that the pulsatillty index, representing im-
pedance to blood flow distal to the point of measurement in the internal carotid artelY, 
decreased with time since menopause.15 Taquet could not show a relationship be-
tween menopausal status and aOltic pulse wave velocity in 429 women, but the popu-
lation consisted of perimenopallsai women and therefore the contrast in estrogen lev-
els between pre- and postmenopausal women may have been small. 28 In one study a 
decrease of elastic properties of the aorta was found in a small group of hypertensive 
women going through menopause during 3 years of follow-up, compared to age-
matched women who remained premenopausal during the same period. 14 In our study 
decreased distensibility after natural menopause is demonstrated among presumed-
healthy women. 
111e mechanisms through which menopause affects mechanical properties of the 
alteries are largely unknown. Specific binding of estrogens to receptors in endothelial 
and vascular smooth muscle cells has been demonstrated in different vascular beds in 
Menopausal status and distensibility of the common carotid artery 
animals and in humans.29,30 Estrogen might change the structure of the arterial wall. In 
vitro investigations as well as animal studies showed that estrogens decrease collagen 
production and decrease the elastin/collagen ratio,31-33 We found a slightly increased 
lumen diameter in postmenopausal compared to premenopausal women, which may 
be Indicative of remodelling of the vessel wall,34 
Whether loss of distensibility is an early marker for asymptomatic atherosclerotic 
changes or whether it reflects other stlUcmral changes of the alterial wall is still a mat-
ter of debate.35-38 Decreased distensibility is unfavourably associated with age27,39 and 
with several cardiovascular risk factors, like choiesterol40 and hypeltenslon.28,41 Loss 
of distensibility in elastic arteries has been shown to be associated with an increased 
risk of cardiovascular disease in cross-sectional studies.42,43 Longitudinal data on the 
effect of decreased distensibility on cardiovascular morbidity or mortality are, however, 
still awaited. 
In conclusion, our findings suggest that natural menopause adversely affects the 
distensibility of the C01111110n carotid artelY. This may indicate one of the mechanisms 
through which menopause adversely affects cardiovascular disease risk in women after 
middle age. 
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Abstract 
Background - The rise in coronary heart disease in elderly women is thought to be related to the 
relative estrogen deficiency after menopause. On the relation between menopause and 
atherosclerosis little is known. 
Methods and results - Associations were examined in the Rotterdam Study, a population-based 
cohort study including 4853 postmenopausal women aged 55 and over. Atherosclerosis was 
assessed by ultrasonography of the carotid arteries, by radiographic assessment of the aorta, by 
measurement of the ankle-arm systolic blood pressure index in the peripheral arteries, and by a 
compound score of these measures. Early menopause was defined as menopause before age 40, 
except for peripheral arterial disease and for myocardiocardial infarction « age 45). Adjusted 
odds ratios for early natural menopause were 2.75 (95% confidence interval 1.13 - 6.67) for ca-
rotid atherosclerosis, 1.67 (1.02 - 2.74) for peripheral arterial disease, 3.24 (1.37 - 4.23) for aor-
tic atherosclerosis, 2.41 (1.37 - 4.23) for moderate atherosclerosis (compound score), 5.30 (2.12 
- 13.2) for severe atherosclerosis (compound score), compared to women with menopause at or 
after age 55. Early bilateral oophorectomy, but not early hysterectomy with or without unilateral 
oophorectomy, was associated with an increased risk of atherosclerosis at all sites. After exclu-
sion of ever-smokers, the increased risk of aortic atherosclerosis with early natural menopause 
disappeared, but not that with early bilateral oophorectomy. Associations were also found be-
tween early menopause and an increased risk of myocardial infarction. 
Conclusion - This study shows that women with early menopause, either naturally or after 
bilateral oophorectomy, remain at increased risk of atherosclerosis at several sites many years 
after menopause. 
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INTRODUCTION 
Premenopausal women are protected from cardiovascular disease compared to post-
Iuenopausal women. \'X'hether the rise in coronalY heart disease in older women is re-
lated to menopause is still debatedI -3 Several studies have shown an inverse associa-
tion between age at natural menopause and risk of cardiovascular disease4-1O, but oth-
ers did not. 11-15 111e inconsistency might be explained by a methodological problem; a 
lag time of 10 to 20 years between menopause and the occurrence of coronalY healt 
disease in women makes the effect of menopause difficult to disentangle from that of 
age, and the accompanying change in other risk factors. 
11,e mechanisms through which menopause might exert its effect on the cardio-
vascular systenl are not entirely clear. As atherosclerosis is present long before symp-
tomatic coronaty healt disease develops, studying the association with atherosclerosis 
might be a sensible approach to study the role of menopause, as accurate risk assess-
ment will not be hampered by low rates of cardiovascular events. Few studies have 
focussed on non-invasively measured atherosclerosis in relation to menopause. In 
these reports no differences were found in the presence of carotid atherosclerosis be-
tween pre- and postmenopausal women.16-18 However, women were relatively young 
« 55 years), and the postmenopausal period might have been too shOlt for an effect to 
become evident. 
\'X'e investigated the association between age at menopause and the presence of 
non-invasively measured atherosclerosis in the carotid arteries, the peripheral atteries 
and the aOlta, as well as the presence of myocardial infarction in 4853 postmenopausal 
women, aged 55 and over, participating in the Rotterdam Study. 
METHODS 
The Rotterdam Study 
11,e Rotterdam study is a prospective population-based coholt study in 7983 subjects 
aged 55 and over that aims to assess the occurrence of chronic diseases in an ageing 
population, and to clarify their detenninants.19 During the first sUlvey, from 1990 to 
1993, all palticipants were intelviewed at home by a trained research assistant, and 
subsequently visited the study centre twice. 11,e study was approved by the Medical 
Ethical Committee of Erasmus UniverSity, and informed consent was given by all par-
ticipants. 
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Measurements 
Interview information, including medical history, current medication, alcohol intake, 
SJlloking habits, use of hormone replacement therapy (HRT), and duration of use, was 
obtained by a trained research assistant. As an indicator of socia-economic status the 
highest attained level of education was assessed. At the study centre, height and body 
weight were measured. Two blood pressure measurements were taken with a random 
zero sphygmomanometer with the subject in sitting position, and averaged. A twelve 
lead ECG was recorded and stored digitally. Serum total cholesterol and HOL-choles-
terol values were assessed by an automated enzymatic procedure in a non-fasting 
blood sample. 
Ascertainment of age and type of menopause 
Data on age and type of menopause were collected during the home-interview. For 
women repOlting natural menopause, age at menopause was defined as the self-re-
pOlted age of last menstruation. For all women repOlting menopause after gynecologic 
surgery or radiation therapy and for those reporting any other operations before age 50 
that might have lead to menopause, information on the exact date and type of 
operation were verified using general practitioners (GP) records. Of 955 women re-
pmting artificial menopause, 901 following surgery and 54 following radiation therapy, 
in 97.5 percent of the cases the medical records could be retrieved, and in 84,7 percent 
information about the date and type of gynecologic operation or radiation therapy was 
found. 
Of all records in which information on the above interventions was found a his-
tmy of surgical menopause was refuted in 39 women (9.8 percent) and could be con-
finned in 862 women (90.2 percent). In 307 women a letter from the gynecologist de-
scribing the operation was found. In the other cases information on the type of opera-
tion was taken from notes or deduced from other information in the record. In women 
for whom we found the exact type of menopause from her gynecologist or for whom 
information from the GP records) sometimes in combination with interview infofll1a-
tiOIl} was unambiguous, the type of menopause was classified as definite. In all other 
cases information from the GP records type of menopause was classified as probable. 
In case no information was found the self-repmted type of operation was taken, and 
type of menopause was classified as possible. In 52 percent of women with hysterec-
tomy, 69 percent of women with hysterectomy plus unilateral oophorectomy and in 45 
percent of women with bilateral oophorectomy, the type of operation was classified as 
definite. Age at operation was taken from the record when the exact date was found 
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(61.2 percent of women with early surgical menopause); otherwise the self-reported 
age was used. 
Among women for whom a letter from the gynecologist was found 69.6 percent of 
the women who had reported a bilateral oophorectomy had correctly repOlted their 
ovarian status. For women who reported conservation of one, or both ovaries, these 
percentages were 65.4 percent and 91.2 percent respectively. 
Assessment of atherosclerosis and coronary heart disease 
Carotid atherosclerosis was assessed by B-mode ultrasonography of the carotid arter-
ies, using a 7.5 MHz linear array transducer (ATL, Uhramark IV). The common and in-
ternal carotid artery and the carotid bifurcation were both on-line and off-line evalu-
ated for the presence or absence of atherosclerotic lesions, according to the Rotterdam 
Study ultrasound protocol. 20 In the analyses, carotid plaque was defined as the pres-
ence of plaques at the near or far wall at one or more sItes. Intima-media thickness has 
Figure 
Detection of aortic atherosclerosis (arrow) on a lateral x-ray of the abdomen. Examples of 
mild atherosclerosis (left) and severe atherosclerosis (right). 
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only been measured in digitised unages in a sUbsample of the population and was not 
analysed. AOItlc atherosclerosis was judged present when linear densities were clearly 
visible in an area parallel and anterior to the lumbar spine (Ll-L4) on a lateral x-ray of 
the abdomen. 21 ,22 The extent of atherosclerosis was scored in categories according to 
the length of the involved area: no calcification (0 or ,c; 1 em), moderate calcification (2-
5 em) and severe calcification (> 5 em). Radiographic assessment of atherosclerosis has 
been shown to be highly specific by comparison with assessments made on necropsy 
material and CT scans. 22,23 Systolic blood pressure was measured at both the left and 
the right posterior tibial anelY using an 8 MHz continuous wave Doppler probe (Hunt-
leigh 500D, Huntleigh Technology, Bedfordshire, UK) and a random zero sphygmo-
manometer, with the subject in supine position. Peripheral alterial disease (PAD) was 
considered present when the ankle-aml systolic blood pressure index (AAl) was lower 
than 0.9 on at least one side, and categorised as moderate (~ 0.7 AAl < 0.9) or severe 
PAD (AAI < 0.7). A histOlY of myocardial Warction was based on self-repOited infor-
mation checked with GP or hospital records and/or on ECG evidence. Infarctions de-
tected by the Modular ECG analysis system (MEANS)) without evidence of symptoms 
(silent myocardial infarctions), were verified by an experienced cardiologist 24,25 Myo-
cardial infarctions that occuned before menopause (7 cases) were not included in the 
analysis. 
Population for analysis 
In The Rotterdam Study 4853 women were postmenopausal at baseline. For this analy-
sis women were excluded who reported a histolY of HRT for one year or longer (n~ 
348), andlor cessation of menses after stopping HRT or oral contraceptives, as in these 
cases the exact age at menopause can not be defined (n =188). Furthennore, women 
who could not recall age at natural menopause (n~446), and who did not visit the re-
search centre (n~ 601) were excluded. After excluding women who fulftlled one or 
more of the exclusion criteria 3384 women remained for analyses. For each analysis, 
subjects with missing data on the relevant outcome variables were excluded. Missing 
data were primarily due to logistic reasons. 
Data analysis 
The association between age at menopause in 5 categories and the presence of athero-
sclerosis was assessed lIsing logistic regression analysis. Multivariate analyses were 
adjusted for current age, smoking status (current, fOlmer and never) and number of 
pack-years (number of years of smoking times number of cigarettes smoked daily di-
vided by twenty, for current and fonner smokers), body mass index (weight/height', in 
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three categories), education level (in fOllf categories: primalY education, lower general 
education/lower vocational education, intermediate vocational education, and higher 
education/university) and alcohol intake (in four categories). Missing value indicators 
were made for women lacking data on confounders.26 A composite measure of athero-
sclerosis was constructed, which resulted in a score ranging from zero to six. Points 
were given to the atherosclerosis score according to the following algorithm: one point 
for moderate 0-3 carotid plaques) and two pOints for severe (4-6 carotid plaques), one 
point for moderate and two points for severe PAD and one point for moderate and two 
points for severe aOltic calcifications. We defined atherosclerosis on the basis of this 
score into moderate 0-2 points) or severe (3-6 points). Subjects with missing values for 
one or more measures of atherosclerosis were coded missIng on the atherosclerosis 
score. 
To rigorously exclude confounding by smoking, we fe-examined the associations 
among never-smokers only (n ~ 1880 for natural menopause, 55%, n ~ 1078 for artifi-
cial menopause, 56%). The presence of a log-linear trend in odds ratios (OR) across 
exposure categories was evaluated using the categories as an ordinal variable, with 
values from 1 (,,55 yrs) to 5 «40 yrs). All odds ratios are presented with 95 percent 
confidence intervals (el), and all P values are two-sided. 
RESULTS 
Baseline Characteristics 
Menopause had been reached naturally by 2713 women (80.2 percent), surgically by 
628 women 08.6 percent) and by radiation therapy by 43 women 0.3 percent). Re-
p0l1ed age at natural menopause varied from 25 to 60 years (mean 49.6, median 50.0). 
Women who rep0l1ed to have passed menopause before age 45 were statistically sig-
nificantly older than women in the reference group consisting of women with meno-
pause at or after age 55, and were statistically significantly more often current and for-
mer smokers (table 1). 
Women in the earliest categOlY of age at menopause had a slightly higher blood 
pressure than the women in the reference group, but these differences did not reach 
statistical significance. \Vomen with hysterectomy with or without unilateral oopho-
rectomy were statistically Significantly younger than women in the reference group 
(table 2). Women with artificial menopause were Significantly more often current 
smokers, while women with bilateral oophorectomy were more often fanner smokers 
than the WOOlen in the reference group. 
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Table 1 
Age·adjusted baseline characteristics of 2713 naturally postmenopausal women, by categories of 
age at menopause. 
Age at menopause < 40 40-44 45-49 50-54 
n~52 n~253 n~717 n~ 1439 
Mean (Sf) 
Age (yr) 72.9 (10.5)' 72.6 (8.9)' 71.2 (9.6) 70.3 (9.7) 
Mean (SO)' 
Syst. blood pressure (mmHg) 147.8 (3.0) 141.8 (1.4) 140.4 (0.8) 140.6 (0.6) 
Diast. blood pressure (mmHg) 77.6 (1.6) 73A (0 .7) 72.9 (OA) 72.9 (0.3) 
Body Mass Index 27.6 (0.6) 26A (0.3) 26.8 (0.2) 26.8 (0.1) 
Total cholesterol (mmolll) 6.85 (0.17) 6.88 (0.08) 6.79 (0.05) 6.80 (0.05) 
HDL cholesterol (mmolm lA6 (0.05) 1.38 (0.02) 1.43 (0.01) 1.44 (0.01) 
Glucose (mmol/l) 6.60 (0.37) 6.85 (0.17) 6.80 (0.10) 6.93 (0.07) 
Diabetes (%) 8.7 (3.8) 10.9 (1.8) 10.0 (1.1) 10.6 (0.8) 
Current smokers (%) 41.6 (6.2)' 28.9 (2.8)' 27.1 (1.7)' 21.5 (1.2) 
Pack-years (n)' 33.3 (3.5) 28.5 (2.5) 28.2 (1.5) 25.4 (1.1) 
Former smokers (%) 45.9 (6.7)' 36.2 (3.0) 31.0 (1.8) 30.9 (1.3) 
Pack-years (n)' 16.4 (4.2) 14.1 (2.1) 18.1 (1.3) 16.0 (0.9) 
Alcohol drinkers (%) 79 (7.3) 71 (3.3) 71 (1.9) 74 (1.3) 
Alcohol (g/wk)' 6.3 (2.0) 9.0 (0.9) 8.3 (0.5) 8.3 (0.4) 
Parous ('Yo) 76 (5.4) 71 (2.5) 73 '(1.6) 75 (1.1) 
Education 15.9 (4.8) 18-1 (2.2) 20.1 (1.4) 18.1 (1.0) 
(% higher ed/university) 
Values are means or percentages with standard errors. Syst. "" systolic. Diast. ... diastolic. 
* adjusted for age 
t among smokers 
:t among former smokers 
§ among drinkers 
, compared to reference group, p < 0.05 
Natural Menopause 
~ 55 
(reference) 
n~252 
70.3 (8.6) 
142.3 (1.4) 
74.1 (0.7) 
27.2 (0.3) 
6.78 (0.08) 
1.42 (0.02) 
6.70 (0.17) 
9.7 (1.8) 
18.8 (2.7) 
24.5 (2.8) 
27.9 (2.9) 
13.8 (2.2) 
73 (3.0) 
7.8 (0.9) 
78 (2.5) 
18.6 (2.2) 
Table 3 shows the odds ratios for atherosclerosis for women with early menopause, 
compared to women in the reference group. Plaques in the carotid artery were present 
in 60.5 percent of women. Women with menopause before age 40 compared to 
women in the reference group had a more than two and a half times increased r1sk of 
carotid atherosclerosis, after adjustment for age, smoking, number of pack-years 
smoked, body mass index, alcohol intake, hormone use and education. PAD was pres-
ent in 20.2 percent of women. 
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Table 2 
Age·adjusted baseline characteristics of women after artificial menopause at or before age 45, 
and a reference group of women with natural menopause at or after age SO, by type of 
menopause. 
+ -H 
>- >- >- >->-
E E E E E g 8_ § 9 0 di ~ ~ Ulj ~ n::I ~ 0) ~ '" 0 ~ 0 ~ 
*>- 2:!~L *-a~ ~= 0->--I g I § g ~ g I 
n~ 146 n~72 n~60 
Mean (SO) 
Age (yr) 65.2 (7.0) 65.4 (7.4) 69.6 (8.1) 
Age at menopause (yr) 41.2 (3.2) 41.1 (3.5) 40.2 (4.3) 
Mean (SO)' 
Systolic blood pressure (mmHg) 137.9 (1.8) 133.9 (2.5) 137.6 (2.8) 
Diastolic blood pressure (mmHg) 72.7 (1.0) 70.5 (1.4) 72.0 (1.5) 
Body Mass Index 27.0 (0.3) 26.9 (0.5) 27.0 (0.5) 
T alai choleslerol (010101/1) 7.0 (0.09) 7.0 (0.13) 6.9 (0.14) 
HDL-choleslerol (mmolili 1.40 (0.03) 1.42 (0.04) 1.41 (0.04) 
Glucose (01010111) 6.8 (0.21) 7.4 (0.31) 7.1 (0.3) 
Diabetes (c/c) 9.8 (2.4) 13.1 (3.5) 16.9 (3.8) 
Current smokers ('-'Ie) 30 (4.0)' 28 (5.5) 37 (6.2)' 
Pack-years (n)' 31.5 (2.8) 37.1 (3.9)' 25.3 (4.2) 
Former smokers ('-'Ie) 38 (4.3) 32 (6.1) 44 (6.8)' 
Pack-years (n)t 15.9 (2.9) 10.6 (4.3) 16.1 (4.5) 
Alcohol drinkers ('-'Ie) 75 (3.9) 68 (5.5) 76 (6.3) 
Alcohol (g/wk)' 7.8(1.1) 8.0 (1.6) 9.5 (1.8) 
Parous (OM 81 (3.3) 75 (4.7) 77 (5.2) 
Education ('-'Ie higher ed.luniversity) 21 (3.2) 26 (4.6) 14 (4.6) 
Values are means or percentages with standard errors. ± = with or without. 
* adjusted for age 
t among smokers 
:t- among former smokers 
§ among drinkers 
, compared to reference group, p < 0.05 
'" U c 
l" "-
'" ~ 
- 0 
'" ~ 
"''''' 
n ~ 1691 
70.9 (9.4) 
53.3 (2.0) 
139.2 (0.6) 
72.9 (0.3) 
26.9 (0.1) 
6.8 (0.04) 
1.43 (0.01) 
6.8 (0.08) 
10.0 (0.8) 
22 (1.3) 
24.4 (1.2) 
32 (1.4) 
16.2{1.1) 
75 (1.4) 
8.5 (0.4) 
78 (1.1) 
21 (1.1) 
To maintain adequate numbers of events in all categories, the two categories with 
earliest menopause were combined for the analyses on PAD and myocardial infarction. 
The adjusted odds ratio for PAD increased gradually with earlier menopatlse to 1.67 
(1.02 - 2.74) in women with menopause before age 45. The magnittlde of the 
association increased with increasing severity of PAD with odds ratios 1. 28 (0.67 -
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Table 3 
Odds ratios for atherosclerosis according to categories of age at natural menopause. 
Age at meno- No. of cases! OR' (95% CI) ORt (95% CI) pause (yr) subjects 
Carotid atherosclerosis 
;::.: 55 86/166 reference reference 
50 - 54 567/928 1.56 0.11 ;2.19) 1.55 (1.10; 2.19) 
45 - 49 250/436 1.23 (0.85; 1.77) 1.14 (0.79 ; 1.66) 
40 - 44 1161165 2.13 (1.35; 3.38) 2.00 (1.25; 3.21) 
< 40 28/36 3.32 (1.39; 7.93) 2.75 (1.13; 6.67) 
P for trend p~o.01 p~0.04 
Peripheral arter;al disease 
~ 55 32/228 reference reference 
50 - 54 239/1290 1.37 (0.91 ; 2.08) 1.32 (0.86; 2.01) 
45 -49 144/645 1.62 (1.05; 2.51) 1.46 (0.94; 2.28) 
< 45 741269 1.93 (1.19; 3.13) 1.67 (1.02 ; 2.74) 
P for trend p<O.Ol p ~0.02 
Aortic calcifications 
;::.. 55 60/204 reference reference 
50 - 54 438/1143 1.58 (1.13; 2.21) 1.50 (1.06; 2.12) 
45 - 49 228/559 1.62 (1.13; 2.33) 1.46 (1.01;2.11) 
40 - 44 88/196 1.76 (1.14; 2.71) 1.56 (1.00; 2.43) 
< 40 22/36 3.95 (1.82; 8.58) 3.24 (1.47; 7.13) 
P for trend p~O.03 p~0.18 
Atherosclerosis score - moderate 
;::: 55 45/117 reference reference 
50 - 54 288/591 1.66 (1.10 ; 2.52) 1.60 (1.05; 2.45) 
45 - 49 134/260 1.83 (1.16; 2.89) 1.71 (1.07; 2.73) 
< 45 67/109 2.58 (1.49; 4.47) 2.41 (1.37; 4.23) 
P for trend p < 0.002 P < 0.01 
Atherosclerosis score - severe 
~ 55 15/87 1 reference reference 
50 - 54 119/422 2.33 (1.18; 4.63) 2.29 (1.08; 4.85) 
45 - 49 61/187 2.94 (1.40 ; 6.14) 2.93 (1.31; 6.59) 
< 45 41/83 5.21 (2.27; 11.9) 5.30 (2.12; 13.2) 
P for trend p < 0.0001 P < 0.0002 
Myocardial infarction 
~ 55 14/240 reference reference 
50 - 54 117/1335 1.55 (0.87; 2.76) 1.60 (0.89; 2.86) 
45 - 49 75/671 1. 91 (1.05 ; 3.48) 1.91 0.05; 3.49) 
< 45 39/275 2.40 (1.26 ; 4.57) 2.49 0.30 ; 4.76) 
P (or trend p~0.003 p~O.Ol 
OR denotes odds ratio. CI denotes confidence interval. * Values are adjusted for age. t Values are 
adjusted for age, smoking (never/past/current [pack-years of smoking for past and current smokers)), body 
mass index (3 categories), alcohol intake (4 categories), short term hormone replacement therapy (yes/no) 
and education (4 categories). Numbers do not always add up to totals due to missing values. 
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Table 4 
Odds ratios for atherosclerosis in women with artificial menopause at or before age 45 compared 
to women with natural menopause at or after age 50. 
no. of no.of OR' 95 % CI OR' 95 % CI 
events subjects 
Carotid atherosclerosis 
Spontaneous:?: 50 655 1096 reference reference 
hyst. ,,45 51 104 0.84 (0.56; 1.28) 0.81 (0.53; 1.24) 
hyst. + unilat. ooph. :s; 45 22 50 0.69 (0.38; 1.25) 0.66 (0.36 ; 1.23) 
hyst. + bilat. ooph." 45 28 42 1.47 (0.75; 2.89) 1.38 (0.69; 2.76) 
Peripheral arterial disease 
Spontaneous;:: 50 276 1522 reference reference 
hyst. ,,45 25 134 1.67 (1.04; 2.70) 1.61 (0.99; 2.62) 
hyst. + unilat. ooph. :s; 45 12 65 1.58 (0.81 ; 3.10) 1.38 (0.68; 2.79) 
hyst. + bilat. ooph." 45 14 56 1.82 (0.97; 3.44) 1.97 (1.02; 3.80) 
Aortic calcificatiollS 
Spontaneous;:: 50 495 1341 reference reference 
hyst. "45 37 125 0.94 (0.62 ; 1.43) 0.87 (0.57; 1.34) 
hyst. + unilat. ooph.:s; 45 22 66 1.13 (0.65; 1.94) 1.04 (0.59; 1.84) 
hyst. + bilat. ooph." 45 29 51 3.37 (1.64 ; 6.94) 2.14 (1.17; 3.92) 
Atherosclerosis score - moderate 
Spontaneous;:: 50 333 707 reference reference 
hyst. ,,45 31 75 0.87 (0.53; 1.42) 0.85 (0.52; 1.42) 
hyst. + ullilat. Doph. :s; 45 15 35 0.97 (0.48; 1.95) 0.87 (0.42 ; 1.79) 
hyst. + bilat. ooph." 45 15 29 1.24 (0.59 ; 2.64) 1.26 (0.58; 2.75) 
Atherosclerosis score - severe 
Spontaneous;:: 50 135 509 reference reference 
hyst. s 45 11 55 1.11 (0.52; 2.35) 1.12 (0.94; 2.56) 
hyst. + unilat. ooph.:s; 45 5 25 0.96 (0.31 ; 2.97) 1.04 (0.31; 3.46) 
hyst. + bilat. ooph." 45 9 23 2.38 (0.91 ; 6.21) 2.28 (0.72; 7.28) 
OR denotes odds ratio. CI denotes confjdence interval. *Values are adjusted for age. t Values are adjust-
ed for age, smoking (never/past/current [pack-years of smoking for past and current smokers] ), body mass 
index (3 categories), alcohol intake (4 categories), short term hormone replacement therapy (yes/no) and 
education (4 categories). Numbers do not always add up to totals due to missing values. 
2.44) for moderate and 2.11 (1.05 - 4.22) for severe PAD, after adjustment for 
confounders. AOltic atherosclerosis was present in 39.0 percent of women. \X'omen 
with m.enopause before age 40 had a more than threefold increased risk of a011ic 
atherosclerosis after adjustment for age and confounders. 
ll1e atherosclerosis scores showed that early menopause « age 40) was asso-
ciated with a nearly two and a half times increased risk for moderate and a more than 5 
times increased risk of severe atherosclerosis. Menopause before age 45 was associated 
with a two and a half times increased risk of myocardial infarction. 
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Analyses were repeated in women over 70 years of age. In these analyses, the 
magnihlde of the odds ratlos associated with early menopause remained elevated, al-
though somewhat decreased, and most estimates lost significance as a result of small 
numbers. 1he odds ratios in women over 70 years of age were 1. 56 (0.45 - 5.35) for 
carotid plaques, 1.76 (0.95 - 3.25) for PAD, 1.68 (0.87 - 3.22) for aOltic atherosclerosis, 
1.81 (0.30 - 11.0) for the moderate and 7.91 (2.48 - 25.3) for the severe atherosclerosis 
score. 'I11e risk of myocardial infarction could not be examined in age strata because of 
small numbers. 
Artificial Menopause 
Table 4 shows odds ratios of atherosclerosis in women with early altificial menopause, 
at or before age 45, compared to women with a natural menopause at or after age 50 
(reference group). Early bilateral oophorectomy was associated with an increased risk 
of atherosclerosis in the peripheral alteries, in the aorta and the atherosclerosis score 
while early hysterectomy and unilateral oophorectomy were not. The risk of PAD was 
also increased in women with early hysterectomy alone, but not in women with early 
hysterectonlY with unilateral oophorectomy. Risk of myocardial infarction was in-
creased for WOIuen with early bilateral oophorectOIuy compared to the reference 
group, while this was not seen for women with early hysterectomy with or without 
unilateral oophorectomy. The estimate for bilateral oophorectomy, based on 7 cases, 
did not reach statistical Significance (odds ratio 1.62 (0.69 - 3.75)). Additional adjust-
ment for diabetes or systolic blood pressure did not change the results. 
Repeating analyses with only women whose gynecologic operations were classi-
fied as definite left the point estimates for the odds ratios for aortic atherosclerosis 
(odds ratio 2.26 (0.90 - 5.73)), PAD (odds ratio 1.47 (0.50 - 4.29), the moderate athero-
sclerosis score (odds ratio 0.84 (0.26 - 2.73)), the severe atherosclerosis score 3.68 
(0.81 - 16.7) and myocardial infarction (odds ratio 1.83 (0.51 - 6.57)) with bilateral 
oophorectomy viItually unchanged. The odds ratio for carotid atherosclerosis remained 
non-significant (0.54 (0.20 - 1.46)). Also, odds ratios for hysterectomy with and without 
unilateral oophorectomy remained unchanged. 
Analysis in never smokers 
In never-smokers only (550/0 of women), the association between early natural meno-
pause and the risk of carotid atherosclerosis was unchanged. TIle association between 
PAD and natural menopause decreased, losing statistical significance, while the asso-
ciation between risk of aortic atherosclerosis and natural menopause disappeared 
(table 5). The results for the atherosclerosis scoreS and myocardial infarction were 
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Table 5 
Odds ratios for atherosclerosis and myocardial infarction according to categories of age at 
natural menopause, in all women and in never smokers, adjusted for age and confounders. 
Age at meno- No. of OR' No. of OR' 
cases! (95% CI) cases! Never (95% CI) pause (yr) 
subjects All women subjects smokers 
Carotid atherosclerosis 
~ 55 86/166 reference 49/99 reference 
50 - 54 567/928 1.55 (1.10; 2.19) 320/529 1.67 (1.05 ; 2.66) 
45 - 49 250/436 1.14 (0.79; 1.66) 125/233 1.01 (0.60; 1.66) 
< 45 144/201 2.11 (1.34; 3.30) 77/101 2.81 (1.48; 5.36) 
p for trend p~0.46 p~0.77 
Peripheral arterial disease 
~ 55 32/228 reference 22/139 reference 
50 - 54 239/1290 1.32 (0.86; 2.01) 130/714 1.14 (0.68; 1.93) 
45 - 49 144/645 1.46 (0.94; 2.28) 78/345 1.25 (0.72; 2.18) 
< 45 74/269 1.67 (1.02; 2.74) 35/132 1.48 (0.79; 2.79) 
p_ for trend p~0.02 p~0.50 
Aortic calcifications 
~ 55 60/204 reference 38/123 reference 
50 - 54 438/1143 1.50 (1.06;2.12) 226/617 1.04 (0.68; 1.51) 
45 - 49 228/559 1.45 (1.00; 2.10) 113/283 1.07 (0.68; 1.91) 
< 45 110/232 1.74 (1.14; 2.67) 52/107 1.10 (0.61; 1.96) 
p for trend p~0.09 p~0.61 
Atherosclerosis score - moderate 
~ 55 45/117 1 reference 27/72 reference 
50 - 54 288/591 1.60 (1.05; 2.45) 166/341 1.87 (1.08; 3.24) 
45 - 49 134/260 1.71 (1.07; 2.73) 64/135 1.59 (0.86; 2.93) 
< 45 67/109 2.41 (1.37; 4.23) 31/53 2.34 (1.09; 5.04) 
P for trend p < 0.01 p~ 0.13 
Atherosclerosis score - severe 
~ 55 15/87 reference 7/52 1 reference 
50 - 54 119/422 2.29 (1.08 ; 4.85) 56/231 2.19 (0.81 ; 5.91) 
45 - 49 61/187 2.93 (1.31; 6.59) 30/101 2.81 (0.96; 8.19) 
< 45 41/83 5.30 (2.12; 13.2) 26/46 6.63 (2.08; 21.1) 
p for trend p < 0.0002 p< 0.0001 
Myocardial infarction 
~ 55 14/240 reference 10/148 reference 
50 - 54 117/1335 1.60 (0.89; 2.86) 62/743 1.26 (0.62 ; 2.54) 
45 - 49 75/671 1.91 (1.05; 3.49) 46/362 1.80 (0.87; 3.72) 
< 45 39/275 2.49 (1.30; 4.76) 20/130 2.22 (0.98; 5.01) 
P for trend p~O.Ol p~O.Q1 
OR denotes odds ratio. CI denotes confidence interval. * Values are adjusted for age, smoking (never/past! 
current (pack-years of smoking for past and current smokers] ), body mass index (3 categories), alcohol 
intake (4 categories), short term hormone replacement therapy (yes/no) and education (4 categories). 
Numbers do not always add up to totals due to missing values. 
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essentially the same as those in the whole population. 11,e risk est~llates for the asso-
ciations with artificial menopause in never-smokers only estimates remained compara-
ble to those in the whole population) although most estimates lost significance, due to 
the smaller number of subjects in these analyses. Odds ratios associated with bIlateral 
oophorectomy in never smokers were 1.82 (0.58 - 5.67) for carotid plaques, 2.57 (0.94 
- 7.04) for PAD, 3.03 (1.16 - 7.89) for aOI1ic atherosclerosis, 0.88 (0.23 - 3.35) and 3.59 
(0.74 - 17.4) for the moderate and severe atherosclerosis score respectively, and 2.06 
(0.57 - 7.43) for myocardial infarction. Estin1ates for never smokers with hysterectomy 
with or without bilateral oophorectomy were unchanged. 
DISCUSSION 
OUf study showed that women who experience an early natural menopause have in-
creased rIsks of atherosclerosis at several sites. Also a histOlY of early bilateral oopho-
rectomy) but not early hysterectomy with or without unilateral oophorectomy, was as-
sociated with an increased rIsk of atherosclerosis. When restricting the analysis to 
never smokers only, the association of early natural menopause with the increased risk 
of aortic atherosclerosis disappeared, but not that of bilateral oophorectomy. The asso-
ciation with peripheral 31terial disease weakened) but also this association remained 
elevated with bilateral oophorectomy. The associations of early natural and attificial 
menopause with the atherosclerosis scores remained essentially the same in never 
smokers as in the whole population. Associations were also found between early 
menopause and myocardial infarction. 11,e Increased risks persisted into older age. 
\Vomen experiencing early menopause may differ In several characteristics from 
women experiencing a later menopause. Smoking, socio~economic status, alcohol in-
take and EMI may possibly confound the association between menopause and athero-
sclerosis. In this study, age at menopause and confounders were assessed in women 
who were already postmenopausal. 11,is will not have affected the measurement of 
socio-economic status (highest attaIned level of education), which remains relatively 
stable over time. BMI, alcohol intake and smoking may have changed over time, and it 
could be that some residual confounding has remained after adjustment for these 
factors. For alcohol and BMI we do not expect this to have a large effect on our results, 
because these factors have relatively weak associations with atherosclerosIs and cardio-
vascular disease. 
In palticular, cigarette smoking is likely to be a serious confounder. Smoking is 
strongly related to early menopause and increases the risk of atherosclerosis. Apalt 
from adjustment for smoking) associations were re~examined in never smokers only, in 
order to rigorously exclude residual confounding by smoking. 11,e risk of aortic ath-
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erosclerosis with early natural menopause viItually disappeared, and the association 
for atherosclerosis in the peripheral arteries decreased, loosing statistical significance. 
111is could indicate residual confounding by smoking, but as smoking has been found 
to reduce endogenous estrogen levels, we cannot exclude the possibility of effect 
modifkation. 'rtle associations of early natural menopause with carotid atherosclerosis, 
with the overall atherosclerosis scores and with nlyocardial infarction remained vittu-
ally unchanged among never smokers. FUlthermore, associations between altificiai 
menopause and all measures of atherosclerosis remained unchanged in never smokers, 
although as a result of small numbers in these analyses, statistical significance was lost 
in ail analyses, except for aOltic atherosclerosis. In a recently published report form the 
Nurses' Health Study, the association between younger age at menopause and higher 
risk of coronalY heart disease was found to be present among current and past SlllOk-
ers, but not among never smokers, which suggests residual confounding by smoking.27 
However, this obselvation was based on only nine cases of coronary heart disease in 
never smokers with menopause before age 45. Confidence intervals of the risk esti-
mates were wide, and thus this finding does not exclude the possibility of an associa-
tion. The largest study to date studying the association between early menopause and 
cardiovascular disease mortality did not make a distinction between never smokers and 
past smokers, and thus residual confounding in this study cannot be excluded.9 In our 
study, the association of early nahlral menopause with myocardial infarction remained 
borderline statistically significant. 
Age at natural menopause was self-reported. Misclassification is likely to be inde-
pendent of atherosclerosis and coronalY heart disease, and therefore, if present, caused 
underestimation of the effect. The distribution of age at menopause in our Shldy was in 
accordance with two leading studies on age at menopause in the Netherlands.28,291n 
these studies 7 percent of women reached menopause before age 45 and 10 percent 
after age 55. The mean age at menopause in our study population was slightly lower 
than the mean age at menopause in 111e Netherlands, which is usually seen when as-
sessing age at menopause retrospectively. Early 01' late menopause, being special 
events, are recalled better than 'average' menopause.30 
Misclassification of bilateral oophorectomy can obscure the hue associations. In 
this study, self-repOlted gynecological operations were verified with patient recordsl 
minimising errors in classification. Repeating analyses with only women whose gyne-
cologic operations were classified as definite did not change the results. 
In our study atherosclerosis was measured at three sites. Ultrasonographical as-
sessment of carotid plaques, measurement of the AAl, and radiographical asseSSlllent 
of aortic atherosclerosis have all been shown to be accurate non-invasive methods of 
measurIng atherosclerosis. A series of Shldies has demonstrated their associations with 
cardiovascular risk factors, atherosclerosis at other sites of the vessel bed l and cardio-
vascular morbidity and mortality.20,23,31-38 Myocardial infarction was self-reported or 
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from ECG evidence and checked with GP records.24 Only seven of the repOlted myo-
cardIal infarctions had occurred before menopause. Although we can not know at what 
age silent infarctions have occurred, only a velY small percentage is expected to have 
occurred before menopause. 
Most information on menopause and atherosclerosis has been obtained from 
autopsy studies. In two out of three autopsy studies, women who had a bilateral 
oophorectomy had an exceSs of coronalY atherosclerosis, which approached that of 
men, compared to women with intact ovaries.39-41 Parrish et al. found that excessive 
coronary atherosclerosis became apparent only 14.4 years after oophorectomy.40 In 
female cynomolgus monkeys atherosclerosis was increased in oophorectomised com-
pared to intact females after a period of 30 months on an atherogenic diet.42 More re-
cently, studies have been performed on the association of menopause with non-inva-
sively measured atherosclerosis. In one study, postmenopausal women had four to five 
times the odds of carotid plaque compared to premenopausal women, but no adjust~ 
ment was made for age.43 Other studies showed no differences in carotid plaques and 
intima~media thickness between pre- and postmenopausal women after adjustment for 
agep,18 In the Atherosclerosis Risk in Conununities Study no overall effect of meno-
pause on carotid intima-media thickness was found 16, however, women in the ARIC 
study were relatively young « 55 years of age). An Increased rIsk of radiographically 
assessed aortic atherosclerosis was shown in one study comparing postmenopausal to 
prernenopausal women.44 
Evidence on the association between menopause and coronalY healt disease is 
conflicting. One reason for this could be that different studies have adjusted for age 
and smoking with valying efficacy, which could have lead to biased estimates.27 An-
other problem is that a change in cardiovascular disease due to menopause will not be 
seen until 10 or 20 years later, by which time the effects of menopause are difficult to 
dIstinguish from the effects of ageing. Flllthermore, studies on associations with early 
natural menopause have mostly been performed in women who developed healt dis-
ease at young age « 50 and < 55 years of age), which indicates that the postmenopau-
sal period in these studies was shOlt.8,12,45,46 Our study population consisted of 
women between 55 and 106 years old, which allowed assessment of the associations in 
women long after rnenopause. Although the effect of altificial menopause on athero-
sclerosis could not be studied in age strata due to small numbers) we found that the 
effect of natural menopause on atherosclerosis remained present in women over age 
70. 
Several studies have reported the risk of cardIovascular disease to be increased in 
women after hysterectomy independently of oophorectomy. It has been hypothesised 
that hysterectomy increases risk of cardiovascular disease by compromising blood flow 
to the ovaries affecting their function, or through a hormonal or other secretory func-
tion of the utems.47-52 Our study showed that the increased risk of atherosclerosis was 
so 
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restricted to women with early bilateral oophorectomy, implying ovarian function is 
the key factor in the association. '!1,e finding of an increased risk of PAD after hyster-
ectomy alone could be a true association but also Illay be a chance finding. 
If menopause mediates the risk of cardiovascular disease through increased ath-
erogenesis statting after cessation of ovarian function, this may have implications for 
the practice of treaunent with HRT. Because the presently available dlugs for HRT are 
not suitable for long-term use due to an increased risk of breast-and endometrial can-
cer, it has been suggested that treatment with HRT could be delayed until the age at 
which cardiovascular disease and osteoporotic fractures frequently occur. Our study, 
however, suggests that early estrogen deprivation has a long-term effect and that pre-
vention might be indicated in an early phase. The extent to which HRT in the early 
postmenopausal phase may delay the onset or progression of atherosclerosis needs to 
be determined, in clinical trials adequately designed to study atherosclerosis as well as 
clinical endpoints. 
The results of this population-based study demonstrate that early menopause, 
both natural and by bilateral oophorectomy, is associated with increased levels of ath-
erosclerosis in several vessel beds, and 'with myocardial infarction. \\Tomen with early 
menopause remain at increased risk of atherosclerosis many years after menopause. 
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Abstract 
Objective - To evaluate the effect of ever use of hormone replacement therapy on the presence 
of peripheral arterial disease in women 55 to 80 years of age. 
Design - Cross-sectional analysis in population based cohort study. 
Setting - A community based cohort study in a suburban area of Rotterdam, The Netherlands 
(the Rotterdam Study). 
Subjects - 2196 naturally menopausal women aged 55 to 80 years. 
Outcome measures - Peripheral arterial disease defined as an ankle/arm systolic blood pressure 
index < 0.9. 
Results - Ever llse of hormone replacement therapy for one year or longer was associated with a 
52% decreased risk of peripheral arterial disease (odds ratio (OR) 0.48 (95% confidence interval 
(CI) 0.24 - 0.85)), while no association was found for use during shorter than 1 year (OR 0.97 (95 
% CI 0.58 - 1.63), after adjustment for age, smoking and socio-economic status. Additional ad-
justment for body mass index, age at menopause, total cholesterol and high-density lipoprotein 
(HDL) cholesterol, alcohol intake or frequency of visits to health care facilities did not change 
these results. 
Conclusions - The findings of this population~based study suggest that ever use of hormone re-
placement therapy is associated with a decreased risk of peripheral arterial disease in postmeno-
pausal women. 
I 58 
Hormone replacement therapy and peripheral arterial disease I 
INTRODUCTION 
Peripheral alterial disease is a growing clinicai and public health issue in elderly 
women. Prevalence rates have been estimated to range frarn 6 to 25% in women over 
55 years of age, and increase sharply with age. With the relatively large expected in-
crease in the number of elderly women compared to elderly men, women will repre-
sent the majority of patients with peripheral arterial disease in the next centulY. Several 
studies have demonstrated that patients with peripheral arterial disease, with or with-
out complaints of intermittent claudication, are at an increased risk of cardiovascular 
morbidity and mOltality compared to people without peripheral arterial disease. l 
Evidence from observational studies suggests that hormone replacement therapy 
(HRT) reduces morbidity and mOl1ality from cardiovascular disease in postmenopausal 
women.2,3 Recently, a randomised trial in women with coronary healt disease showed 
no effect of hormone replacement therapy on the incidence of coronary heatt disease 
after 4 years of treatment (the Heart and Estrogen/Progestin Replacement Study 
(HERS)).4 However, an increased risk of coronat)' healt disease events was found in 
the I-IRT group in the first year of the trial, and the risk decreased in subsequent years. 
111is might be explained by an inm1ediate prothrombotic, proanythmic or proischemic 
effect of treatment, which is gradually outweighed by a beneficial effect on the pro-
gression of atherosclerosis. Thus, a protective effect of this treatment may be present 
on the development of atherosclerotic disease, but data are scarce. 
We investigated the association between ever use of HRT and the presence of 
atherosclerosis in the peripheral arteries by measuring the ankle/arm systolic blood 
pressure index (AAI), in 2196 naturally postmenopausal women, aged 55 to 80 years of 
age, pal1icipating in the Rotterdam Study. 
METHODS 
The Rotterdam study is a prospective population-based follow-up study in 7983 sub-
jects aged 55 and over that aims to assess the occurrence of chronic diseases in an 
ageing population, and to clarify their detenninants. 5 During the first smvey, from 1990 
to 1993, all palticipants were intelviewed at home by a trained research assistant, and 
visited the study centre for clinical examination. A second visit to the study centre has 
taken place in 1993-1994. The study was approved by the Medical Ethical Committee 
of Erasmus University, and informed consent was given by al1 participants. 
Intelview information included rnedlcal history, current m~dlcation) smoking hab-
its, alcohol intake, highest attained level of education and age at last menstruation. At 
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the study centre height and weight were measured. Semm total cholesJerol and HDL-
cholesterol values were assessed by an automated enzymatic procedure. Random and 
postload serum glucose levels were assessed after an oral glucose tolerance test. 
11,e presence of peripheral arterial disease was assessed at baseline. Systolic 
blood pressure was calculated as the mean of two consecutive measurements at the 
right brachial altelY while the patient was in a sitting position. A single systolic blood 
pressure reading was taken both at the left and the right posterior tibial anelY as de-
scribed previously.6 The ratio of the systolic blood pressure at the ankle to the systolic 
blood pressure at the aml (AAI) was calculated for each leg. Peripheral arterial disease 
was considered present when the AA1 was lower than 0.9 on at least one side. 
In the baseline intelview (1990-1993) questions on ever use of female hormones 
for menopausal complaints and duration of use were asked. More information on use 
of female hormones was collected by a questionnaire in the fIrst follow-up visit to the 
study centre in 1993-1994, on average 2.2 years after baseline. In this questionnaire 
information on medication for menopausal complaints, medication after an operation 
of the womb/ovaries and specific information on type and brand of medication, dura-
tion of lise, recent use and dle use of progestins was col1ected. Infomlation from both 
the first and the second visit to the study centre was used for classiflcation of subjects. 
At baseline, 571 women reponed the use of female hormones for menopausal com-
plaints. Twenty-six women reported ever use of female hormones in the first follow-up 
visit to the study centre, while they had not reponed this in the baseline intelview. 
11,ese women were classifled as probable users. Additionally, 95 women reporting the 
use of medication for menopausal complaints in the follow-up visit's questionnaire, but 
who were not sure what type of medication this had been, and who had not reported 
use of female honnones in the baseline interview were classified as possible users. 
\Vomen reporting the use of only vaginal creams or ovules were classified as non-us-
ers. Thus, 692 (18 %) of women were classified as ever users of female hormones. Sev-
enty-four of these WOlnen repOlting to have continued use of female hormones in the 
period between the baseline and the follow-up visit were classifled as recent users. 
As data on use of HRT were obtained both in the fIrst and the second follow-up 
round, for this study only women participating in the second follow-up round 3784 
(78%) were considered. Women were excluded who repolted to have reached meno-
pause by surgelY or radIation of the womb/ovaries (n=719) or who were older than 80 
(n=496). l1lUs remained 2569 women. The AAl was not detemlined In 349 of these 
women (13.6 %). Eight women with an AAI > 1.5 were excluded as this AAI usually 
reflects alterial rigidity preventing arterial compression, which leads to spuriously high 
ankle blood pressure values. Information on use of HRT was missing in 8 women. 
l1ms remained 2196 women for analyses. 
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Statistical analysis 
Analysis of covariance adjusted for age was used to compare continuous variables 
between groups. Smokers Were categorised as current, past or never smokers and ad-
ditional adjustment was made for the number of pack-years (the number of years of 
smoking multiplied by the number of cigarettes smoked daily, divided by twenty). 
Analyses were stratified for shott-term « 1 year) and long-term hormone use C" 1 
year). For further stratification numbers Were inadequate. Logistic regression analysis 
was used to calculate relative risks of peripheral arterial disease for ever-users com-
pared to never-users. All OR's are presented with 95% confidence intelvals (CI). The 
odds ratios derived from logistic regression analyses were used as an approximation of 
relative risk. Reported P-values are two-sided. Analyses were performed using BMDP 
software (BMDP Statistical Software, Inc). 
RESULTS 
Of the 2196 women in the study population 351 reported ever use of HRT (16.2%). 
Duration of use ranged from 1 month to more than 15 years. ThiIty-two women (9% of 
users) repOlted use of progestins, additional to the use of estrogens. Thilty-one women 
(9% of users) were recent users. 
Age was comparable in the three study groups (Table I). Ever users of female 
hormones had a lower systolic blood pressure l were more often past smokers, and had 
a higher frequency of visits to health care facilities in the last month than never users. 
Both short-tenn and long-term users were more often past smokers. 
Mean AAI was 1.08 (SD 0.19), and 284 women had an AAI < 0.9 (12.9%, 95%CI 
11.5-14.3). Age, systolic blood pressure, total-cholesterol, glucose levels, the percent-
age of current smokers, and among smokers the nurnber of pack-years of smoking, 
were all Significantly higher in women with peripheral alterial disease (Table 2). 
Of the 351 ever users 34 had peripheral alterial disease, compared to 247 out of 
1837 of the never users. Logistic regression analysiS, with adjustment for age showed 
that, overall, ever users had a 30 % lower risk of peripheral alterial disease (Table 3). 
\"'{'hile use for a period shOlter than one year was not associated with a protective ef-
fect, use during 1 year or more was associated with a statistically significant 47% re-
duction of risk. Adjustment for smoking, number of pack-years smoked and level of 
education reduced the risk to 52%. Additional adjustment for body mass index, alcohol 
intake, age at menopause, levels of total and HDL-cholesterol, or the number of visits 
to health care facilities in the last month did not change the risk estinlates. When re-
peating the analyses after exclusion of women repolting recent use of female hor-
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mones, to assess the effect in past users only, a similar association was found (OR 0.39 
(95%CI 0.20 - 0.80). Also, excluding women classified as probable or possible users, 
did not change our results (OR 0.42 (95%CI 0.20 - 0.88)). In 31 recent users 3 women 
had perIpheral a1terial disease (9%), in the 32 users of progestins additional to estro-
gens, 3 women had peripheral alterial disease (9%). 
Table 1 
Age-adjusted baseline characteristics of short-term, long-term and never users of hormone 
replacement therapy among women with natural menopause, aged 55 - 80. Values are 
means or proportions with standard errors. 
Characteristics 
Age (years) 
Time since menopause (years) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Antihypertensive medication (%) 
Body mass index (kg/m') 
Total Cholesterol (mmol!!) 
HDL-Cholesterol (mmol/I) 
Glucose (mmol/I) 
Diabetes Mellitus' (%) 
Current smoker (%) 
Pack-years for current smokers (n) 
Past smoker (%) 
Pack-years for past smokers (n) 
Alcohol drinker (%) 
Visited General Practitioner in last month (%) 
Visited specialist in last month (%) 
Higher education' (% highest category) 
Income (Euro/month) 
.. compared to never users, p < 0.05 
t compared to never users, p < 0.01 
Never use 
(n ~ 1845) 
66.9 (0.15) 
17.0 (0.1) 
138.5 (0.5) 
73.3 (0.3) 
29.1 (1.0) 
26.7 (0.1) 
6.91 (0.02) 
1.45 (0.01) 
6.69 (0.06) 
B.5 (0.6) 
29.4 (1.2) 
27.0 (0.01) 
35.8 (1.2) 
17.4 (0.9) 
74 (1.0) 
3B (1.1) 
19 (0.9) 
21.9 (0.9) 
1276 (13.6) 
+- long term users compared to short term users, p < 0.05 
Short-term use Long-term use 
Use < 1 year Use ~ 1 year 
(n~157) (n ~169) 
66.5 (0.51) 67.3 (0.50) 
16.6 (0.3) 17.8 (0.3)* 
135.7 (1.6) 135.5 (1.6) 
73.1 (0.9) 72.9 (0.9) 
27.6 (2.4) 26.3 (3.4) 
26.5 (0.3) 26.2 (0.3) 
6.B3 (0.09) 6.95 (0.09) 
1.46 (0.03) 1.52 (0.03)* 
6.49 (0.19) 6.61 (0.19) 
6.2 (2.1) 7.4 (2.1) 
24.2 (4.2) 32.0 (4.3) 
32.3 (3.4) 28.0 (3.0) 
37.6 (4.1)* 46.0 (4.1)* 
20.8 (2.7)* 18.7 (2.5) 
75 0.6) 74 (3.5) 
45 (3.8) 43 (3.7) 
24 (3.0) 28 (3.0)t 
25.9 (3.2) 27.6 (3.2) 
1303 (45.4) 1221 (40.8) 
§ Diabetes was defined as a random or post/oad glucose levels of > 11.0 mmolll or current use of 
antidiabetic drugs. 
, Educational level was divided into four categories. 
Numbers do not add up to totals due to 25 missing values on duration of use. 
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Table 2 
Age-adjusted cardiovascular risk indicators in subjects with an AAI < 0.9 or an AAI ~ 0.9, 
among women with natural menopause, aged 55 - 80. Values are means or proportions with 
standard errors (SE). 
Cardiovascular risk indicators 
Age (years) 
Time since menopause (years) 
Systol ic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Body mass index (kglm') 
Total Cholesterol (mmol/l) 
HDL-Cholesterol (mmol/l) 
Glucose (mmolll) 
Diabetes Mellitus1 (%) 
Current smoker (%) 
Pack-years for cllrrent smokers (n) 
Past smoker (%) 
Pack-years for past smokers (n) 
Alcohol drinker (%) 
Higher education' (% high) 
Income (Euro/month) 
Intermittent claudication (% present) 
History of myocardial infarction ('-Yo present) 
History of angina pectoris (% present) 
History of stroke (% present) 
Carotid artery intima-media thickness (~m) 
Carotid artery plaques (% present) 
* p < 0.05 
tp<O.D1 
* p < 0.001 
§ p < 0.0001 
MI;, 0.9 
1912 
66.3 (0.15) 
16.7 (0.1) 
136.7 (0.5) 
73.2 (0.3) 
26.7 (0.1) 
6.88 (0.02) 
1.47 (0.01) 
6.57 (0.06) 
7.6 (0.6) 
26.3 (1.2) 
27.1 (1.0) 
35.9 (1.2) 
16.7 (0.8) 
76.0 (1.0) 
23.8 (1.0) 
1276 (13.6) 
0.32 (0.2) 
5.9 (0.6) 
5.6 (0.5) 
1.9 (0.4) 
73.3 (0.4) 
52.7 (1.3) 
AAI < 0.9 
284 
69.1 (0.40)' 
17.5 (0.3)' 
144.2 (1.2)' 
74.2 (0.7) 
26.4 (0.2) 
7.14 (0.07)' 
1.43 (0.02) 
7.03 (0.15)' 
10.8 (1.6) 
44.3 (3.1)' 
30.3 (2.0) 
41.2 (3.4) 
23.6 (2.3)' 
68.3 (0.03)* 
21.0 (2.5) 
1235 (31.7) 
4.6 (0.6)' 
9.6 (1.5)' 
7.4 (1.4) 
7.3 (1.0)' 
78.4 (1.0)' 
63.4 (3.4)' 
, Diabetes was defined as a random or postload glucose levels of> 11.0 mmolll or current use of 
antidiabetic drugs. 
# Educational level was divided into four categories. 
Numbers do not add up to totals due to 25 missing values on duration of use. 
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Table 3 
Relative risk of peripheral arterial disease associated with use of hormone replacement 
therapy a~·l1ong postmenopausal women with natural menopause, aged 55 M 80. 
Age-adjusted 
HRT No. of No. of Relative Risk* 
cases subjects (95% Confidence 
Interval) 
Never users 247 1837 1.00 reference 
Short term users 20 157 0.97 (0.60; 1.60) 
« 1 year) 
Long term users 13 169 0.53 (0.30; 0.93) 
(;> 1 year) 
All users 34 351 0.70 (0.48; 1.02) 
* adjusted for age using the logistic regression model. 
t adjusted for age, smoking and education using the logistic regression model. 
Numbers do not add up to totals due to 25 missing values on duration of use. 
DISCUSSION 
Multivariate-adj usted 
Relative Risk' 
(95% Confidence 
Interval) 
1.00 reference 
0.97 (0.58; 1.63) 
0.48 (0.24; 0.85) 
0.65 (0.44; 0.98) 
OUf results show a lower risk of atherosclerosis in the peripheral arteries in ever users 
of HRT compared to never users. 
Before interpreting these results several issues need to be addressed. In a study of 
elderly subjects there is the possibility of selection bias. Women had to survive until at 
least age 55 to be in our study. If women who never used female hormones Illore fre-
quently died of atherosclerotic complications before the start of our study, this may 
have led to an underestimation of the effect. The AAI gives a good indication of 
atherosclerosis in the lower lin1bs, assessing the adequacy of blood flow through the 
peripheral alteries.7,8 It has been shown to be associated with preclinical carotid ath-
erosclerosis and predicts cardiovascular mOltallty in elderly women and men. I ,9 11,e 
mean value of the AAI in this population was 1.08. 'l1,e prevalence of peripheral alte-
rial disease was 12.9 %. 11,is is comparable to values reported in other studies6 ,7,10-14 
Several studiesl5,16 have demonstrated that estrogen users are healthier than 
never users, even prior to use of replacement therapy. nlis supports the hypothesis 
that part of the apparent benefit associated with HRT is due to pre-existing characteris-
tics of the users. We cannot exclude the possibility that part (or the whole) of our 
findings is based on this selection bias. In our study we dealt with the issue of con-
founding in the following ways. We stratified for duration of homlOne use, and found 
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that in women who had used female hormones for a period shorter than a year, al-
though they were alike long-term users with respect to the presence of several socio-
economic and risk factors, no association was found with the presence of peripheral 
alterial disease. 111is reduces, but not fully excludes, the probability of selection bias. 
FUl1hennore, we adjusted for known risk factors. We measured the current status of 
risk factors, while the exposure to hormone use had largely taken place in the past. 
Socio-economic status (level of education), is a major confounder, but remains rela-
tively stable over time. The frequency of visits to health care facilities (possibly repre-
senting health conscious behaviour now and in the past) differed between ever and 
never users of HRT, but adjustment did not change our results. Smoking habits might 
have changed over time, but mlsclassification of smoking habits would have given an 
underestimation of the effect, because users were more frequently smokers. EMI and 
alcohol intake may undergo changes with age, and it could be that some residual con-
founding has remained after adjustment. We do not expect the latter to have a large 
effect on our results, however, because of the relatively weak associations of these 
factors with peripheral arterial disease, especially in women. 17,l8 
Assessment of use of hormone replacement therapy by intelview might have led 
to misclassification. Goodman et a1. showed a moderate to substantial agreement be-
tween users and physicians on ever/never use of estrogens, and no differential m1s-
classification with disease status of the subject in women up to 74 years of age. l9 The 
reported frequency and duration of use was similar to the those in studies in peri-
menopausal women in The Netherlands, where 12% of women between 45 and 65 
used HRT and 50 % of women discontinued use within one year.20-22 The most fre-
quently prescribed hormone therapy in the studied period was unopposed estrogen 
therapy in a dose of 0.625 mg daily.23 Progestins were added in 0.6% of prescriptions 
in 1970, gradually increaing to 11% of prescriptions in 1986. Our obselvation of 9% 
agrees with this. 
The finding that HRT inhibits development of atherosclerosis in the coronalY ar-
teries and aorta has been repOlted in several animal studies. 24,25 In women, two out of 
three angiography studies showed a lower degree of coronary atherosclerosis in HRT 
users compared to never users. 26-28 Another study, using ultrasonographic examina-
tion, found lower degrees of atherosclerosis of the carotid arteries, aorta, and iliac 
at1eries in 40 users of combined replacement therapy compared to never users.29 Most 
studies, however, focussed on comparing current users with never users. The effect of 
past use of female hormones was studied in the Cardiovascular Health Study (CHS), 
which showed no Significant differences in IMT between past users and never users. 30 
No tests were presented for differences in AAl between past and never users. The CHS-
finding that current users had a Significantly lower measure of IMT than never users 
could not be confirmed in the Atherosclerosis Risk In Communities (ARIC) study.31 In 
our study the number of recent users was small, but exclusion of recent users from the 
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analysis showed that prevalence of peripheral 31terial disease was lower in past users 
compared to never users. Thus, our results suggest that the advantage in levels of ath-
erosclerosis for women who have used HRT remains present after discontinuation of 
therapy. 
Only one large randomised placebo·controlled trial on the effects of HRT has 
been conducted. This trial in women with diagnosed cardiovascular disease showed no 
favourable effect of HRT on the prevention of incident coronary heart disease after 4 
years of follow.up4 This might indicate that bias in observational studies is larger than 
thought until now. On the other hand, in the trial an increased risk for coronalY heart 
disease events was found in the HRT group in the first year of the trial, while risk de· 
creased in subsequent years. 111i5 time-trend can be explained by an immediate pro-
thrombotic, proanythmic or proischemic effect of treatment that is gradually out-
weighed by a beneficial effect on the progression of atherosclerosis. 11ms, the results 
of the HERS trial do not exclude the possibility that HRT might inhibit the development 
of atherosclerosis. FUlthennore, in HERS, the effect of opposed estrogen was studied, 
while in our study mainly unopposed estrogen was used. Progestins have been shown 
to have unfavourable effects on several determinants of cardiovascular disease, which 
may have contributed to the absence of a positive trial result. 32 
As the number of elderly women increases in western society, peripheral arterial 
disease is likely to become an increasing problem. 11,e results of this study suggest that 
the use of HRT after menopause might protect against the development of peripheral 
arterial disease later in life. Confirmation of these findings should be provided by ran· 
domised trials including peripheral 3lterial disease as an outcome lneasure. 
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Abstract 
Background and purpose - Observational data suggest that hormone replacement therapy {HRTI 
reduces morbidity and mortality from cardiovascular disease in healthy postmenopausal women. 
The mechanisms underlying this protection are not entirely dear, but may include inhibition of 
the atherosclerotic process. 
Methods - We studied the association between ever use of hormone replacement therapy and 
intima-media thickness (lMT) of the common carotid artery in 1103 naturally menopausal women 
aged 55 to 80 years, in the Rotterdam Study, a community based cohort study in a suburban area 
of Rotterdam, The Netherlands. Mean and maximum IMT of the common carotid artery were 
measured non-invasivcly with B-mode ultrasound. 
Results - Ever use of hormone replacement therapy for one year or more was associated with a 
decreased mean and maximum IMT compared to never users «mean IMT 71.9 pm (standard er-
ror (SE) 1.0) versus 74.2 11m (SE O. 4), p~0.03), maximum IMT 95.2 11m (SE 1.5) versus 98.3 pm 
(SE 0.6), p= 0.04)), after adjustment for age, smoking, educational level, systolic blood pressure 
and body mass index. No association was found for use less than one year «mean IMT 73.9 pm 
(SE 1.3) versuS 74.2 pm (SE 0.4), p~0.69), maximum IMT 99.0 11m (SE 1.9) versus 98.31101 (SE 
0.6), P = 0.75)). Additional adjustment for diabetes, frequency of visits to health care facilities or 
total cholesterol and high density lipoprotein (HDl) cholesterol did not change these results. 
Conclusions - The findings of this population based study show that ever use of hormone re-
placement therapy is associated with a decreased intima-media thickness in the common carotid 
artery in elderly women. 
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INTRODUCTION 
Observational data suggest that hormone replacement therapy (HRT) reduces morbid-
ity and mortality from cardiovascular disease in postmenopausal women. 1-3 The 
mechanisms underlying this protection are not entirely clear. Poshllated mechanisms 
for a beneficial effect include changes in lipid levels, in haemostatic variables, in blood 
viscosity, direct effects on the arterial wall and inhibition of the atherosclerotic process. 
Recently, however, a randomised trial on the effects of honnone replacement therapy 
in women with coronary heart disease showed no effect on the overall risk of coronary 
heart disease, after 4 years of treatment (the Heart and Estrogen/Progestin Replacement 
Study (HERS)).4 However, an increased risk of coronalY heart disease events was 
found in the HRT group in the first year of the trial, and the risk decreased in subse-
quent years. This might be explained by an immediate prothrombotic, proarrythmic or 
proischemic effect of treatment, which is gradually outweighed by a beneficial effect 
on the progression of atherosclerosis. The results of HERS are thus suppOltive of the 
possibility that HRT inhibits the development of atherosclerotic disease. It is therefore 
important to assess whether favourable effects of hormone replacement therapy on 
atherosclerosis are indeed present. Data on the effects of use of hormone replacement 
therapy on atherosclerosis are conflicting.5,6 \,'e investigated the association between 
ever use of HRT and the presence of atherosclerosis in the carotid artelY, by measuring 
common carotid intima-media thickness in 1103 naturally postmenopausal women, 
palticipating in the Rotterdam Study. 
METHODS 
The Rotterdam Study 
The Rotterdam Shldy is a prospective population-based follow-up sUldy that aims at 
assessing the occurrence of chronic diseases in an ageing population, and to clarify 
their determinants. The study focuses on cardiovascular, neurogeriatric, ophthalmo-
logic and locomotor diseases, and has been described in more detail elsewhere.7 In 
brief, all residents aged 55 and over of a defined district in Rotterdam were invited to 
participate. A total of 7983 men and women (78% of those eligible) entered the study. 
During the first sUlvey, from 1990 to 1993, all participants 'were intelviewecl at home by 
a trained research assistant. The participants subsequently visited the study centre for a 
clinical examination. A second visit to the shldy centre took place in 1993-1994. The 
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study was approved by the Medical Ethical Committee of ErasnHlS University, and in-
formed consent was given by all palticipants. 
Measu rements 
Interview information was obtained by a trained research assistant. Data included 
medical history, current medication, smoking habits, alcohol intake, highest attained 
level of education and age at last menstruation. Menopause was defined as cessation of 
menses for 1 year Of more. At the study centre height and weight were measured. 
Blood pressure was measured twice with a random zero sphygmomanometer with the 
subject in sitting position, and averaged. SelUm total cholesterol values were assessed 
by an automated enzymatic procedure in a non-fasting blood sample. Serum HDL-
cholesterol was measured after precipitation of the non-HDL fraction with phospho-
tungstate-magnesiunl. Random and post -load serum glucose levels were assessed after 
an oral glucose tolerance test. 
Measurement of intima-media thickness 
To measure carotid intima-media thickness, ultrasonography of the left and right corn-
mon carotid artery was performed with a 7.5 MHz linear array transducer (AlL Ultra-
J'dark IV). On a longitudinal 2-dimensional ultrasound unage of the carotid artery, the 
anterior (near) and posterior (far) wall of the carotid attery are displayed as two bright 
white lines separated by a hypo-echogenic space. The distance of the leading edge of 
the first bright line of the far wall (lumen-intima interface) and the leading edge of the 
second bright line (media-adventitia interface) indicates the intima-media thickness. 
For the near wall, the distance between the trailing edge of the first bright line to the 
trailing edge of the second bright line at the near wall provides the best estimate of the 
near wall intima-media thickness.8 ,9 Following the ultrasound protocoPO, a careful 
search was performed for all interfaces of the near and far wall of the distal common 
carotid altery. \\/hen an optimallQngitudinal unage was obtained, it was frozen on the 
R wave of the electrocardiogram and stored on videotape. This procedure was re-
peated three times for both sides. The actual measurements of intima-media thickness 
were performed off-line. From the videotape, the frozen linages were digitised and 
displayed on the screen of a personal computer using additional dedicated software. 
This procedure has been described in detail previously.l1 'Vith a cursor the interfaces 
of the atterial segments were marked over a length of 10 mm. The beginning of the 
dilatation of the distal common carotid altery selved as a reference point for the sta11 of 
the measurement. The average of the intuna-media thickness of each of the three fro-
zen images was calculated. For each individual an intima-media thickness was deter-
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mined as the average of near and far wall measurements of the left and right artery. 
The readers of the ultrasound images from videotape were unaware of the exposure 
staniS of the subject. Reproducibility of intima-media thickness measurements was 
studied among eighty subjects who undenvent a second ultrasound scan of both ca-
rotid alteries within three months of the first scan. Measurements were shown to be 
highly reproducible,s Off-line the carotid artery was evaluated from tapes for the pres-
ence (yes/no) of atherosclerotic lesions on both the near and the far wall of the arter-
ies. Plaques were defined as a focal widening relative to adjacent segments) with pro-
trusion into the lumen either composed of only calcified deposits or a combination of 
calcification and non-calcified material. The cornman and internal carotid altelY and 
the carotid bifurcation were both on-line and off-line evaluated for the presence or ab-
sence of atherosclerotic lesions. In the analyses) carotid plaque was defined as the 
presence of plaques at the near or far wall at one or more sites. The size of the lesions 
was not quantified. A reproducibility study among 166 subjects on the assessment of 
plaques in the carotid bifurcation revealed a kappa of 0.65 for the right carotid altery) 
indicating moderate agreement. 12 
Assessment of use of hormone replacement therapy 
During the baseline interview (1990-1993) questions on ever use of female hormones 
for menopausal complaints and duration of use were asked. More information on use 
of female hormones was collected by a questionnaire in the first follow-up visit to the 
study centre in 1993-1994) on average 2.2 years after baseline. In this questionnaire) 
information on medication for menopausal complaints} medication after an operation 
of the womb/ovaries) specific information brand and type of fernale hormones) dura-
tion of use) recent use and the use of progestins was collected. 
Information froln both the first and the second visit to the snIdy centre was used 
for classification of subjects. At baseline) 571 women reported the use of female hor-
mones for menopausal complaints. Twenty-six women reported ever use of female 
hormones in the first follow-up visit to the study centre) while they had not reported 
this in the baseline interview. These women were classified as probable users. Addi-
tionally) 95 women reporting the use of medication for menopausal complaints in the 
follow-up visit's questionnaire) but who were not sure what type of medication this 
had been) and who had not reported use of female hormones in the baseline interview 
were classified as possible users. \':lomen reporting the use of only vaginal creams or 
ovules were classified as non-users of female hormones. Thus) 692 wornen were clas-
sified as ever users of female hormones at the follow-up visit. Seventy-four of these 
women reponed to have continued use of female hormones in the period between the 
baseline and the follow-up visit. As we cannot be sure whether these women were cur-
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rent users at the time of 1M'!' measurement at baseline, these women were classified a::; 
recent users. 
Population for analysis 
In the Rotterdam Study, 4853 postmenopausal women participated. As data on use of 
HRT were obtained both in the first"and the second follow-up round, only women par-
ticipating in the second follow-up round were analysed in this study (n=3784). \\famen 
were excluded who repOlteci to have reached menopause by surgcty (n=677) or radia-
tion of the womb or ovaries (0=42) and women who were older than 80 (n=558), as 
the lise of hormone replacement therapy in older women was rare. FUlthennore, 55 
women had no data on the use of HRT. After excluding women who fulfilled one or 
more of these exclusion criteria, 2401 women remained for analysis. Intima-media 
thickness was determined in the first 1103 of these women only. Compared to women 
with data on INIT women without data were slightly younger, had a significantly higher 
systolic and diastolic blood pressure, were Significantly less often past smokers, and 
were less often former smokers. No differences were found in other cardiovascular risk 
factors. 
Statistical analysis 
Analysis of covariance was used to compare characteristics of HRT -users and non-us-
ers, adjusted for present age. Age-adjusted linear regression analysis was used to assess 
the association between risk factors and Ji\'IT. Multivariate analysis of covariance was 
used to assess the association between the use of HRT and JMT. Multivariate analyses 
included smoking status (current, past and never), number of pack-years for current 
and past smokers (the number of years of smoking multiplied by the number of ciga-
rettes smoked daily), educational level On four categories: primaly education, lower 
general education/lower vocational education, intermediate vocational education, and 
higher education/university), systolic blood pressure and body mass index (EMI). A 
distinction was made between short-term use (up to one year) and long-term use (one 
year or rnore), because a large group of women had reported sh0l1-term use and no 
effect on development of atherosclerosis was expected from this. Additional analyses 
were performed adjusting for diabetes (defined as a random or post-load glucose level 
of> 11.0 mmolll or current use of anti-diabetic dlUgS), frequency of visits to health 
care facilities in the last month and levels of total cholesterol and HOL-cholesterol. To 
assess the effect of past use, the analysis was repeated excluding recent users. The 
analysis 'vas repeated after exclusion of probable and possible users. All reported P-
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values are two-sided. Analyses were performed using BMDP software (BMDP Statistical 
Software, Inc). 
RESULTS 
At baseline no differences were seen between ever users and never user of HRT in age, 
educational level and income (table 1). Long-term llsers had a significantly lower BMI, 
and were Illore often current smokers although this comparison did not reach statistical 
significance (p~O.lJ). Short-term users had a slightly higher diastolic blood pressure 
Table 1 
Age-adjusted baseline characteristics of short-term! long-term and never users of female 
hormones among women with natural menopause! aged 55 to 80. Values are means or 
proportions with standard errors. 
Never use Short term use Long-term use 
Characteristics Use < 1 year Use ~ 1 year 
(n ~ 875) (n ~ 79) (n ~ 136) 
Age (years) 67.9 (0.23) 66.5 (0.71) 67.1 (0.56) 
Time since menopause (years) 18.6 (0.2) 18.1 (0.5) 19.4 (0.4) 
Systolic blood pressure (mmHg) 137.1 (0.6) 138.3 (2.2) 136.9 (1.9) 
Diastolic blood pressure (mmHg) 71.9 (0.4) 74.2 (1.2) 72.3 (0.9) 
Body mass index (kglm') 27.0 (0.1) 26.7 (0.5) 26.0 (O.4)'§ 
Total Cholesterol (mmolll) 6.96 (0.04) 6.81 (0.14) 6.98 (0.10) 
H DL-Cholesterol (mmol/l) 1.45 (0.01) 1.47 (0.04) 1.48 (0.03) 
Diabetes (%) 8.0 (0.9) 9.1 (0.3) 8.5 (2.3) 
Current smoker (%) 29.6 (1.8) 23.3 (5.9) 37.8 (4.6) 
Packyears for smokers (n) 28.4 (1.4) 38.9 (5.3) 28.0 (3.0) 
Former smoker (%) 37.6 (1.8) 35.9 (5.9) 45.3 (4.5) 
Packyears for past smokers (n) 17.6 (1.3) 25.8 (4.4) 16.9 (3.0) 
Alcohol drinker (%) 72 (1.6) 75 (5.2) 75 (3.9) 
Visited GP in last month (%) 40 (1.7) 53 (5.5)' 45 (4.2)§ 
Visited specialist in last month (%) 19 (1.3) 26 (5.4) 26 (3.4)'§ 
Higher education (% highest category) 20.5 (1.3) 21.3 (4.5) 26.1 (3.4) 
Income (euro/month) 1192 (18.5) 1279 (61.0) 1147 (46.9) 
* compared to never users, p < 0.05, t compared to never users, p < 0.01, * long term users compared 
to short term users, p < 0.05, § ever users compared to never users, p < 0.05. Numbers do not add up to 
totals due to 13 missing values on duration of use. 
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(p=0,07) and more pack~years of smoking (p=O,06 for current and p=O,OS for past 
smokers) than never users. In comparison to never users sh011-tenn users rcpOlted sig-
nificantly more visits to the GP} while long-term users reported more visits to medical 
specialists in the last month. 
Of the 1103 women in this study, 228 repOIted a histOIY of use of HRT (20,7')1,), Of 
these 13 did not report duration of hormone usc. Duration of lise ranged from 1 month 
to more than 15 years. Seventy-nine women (36.7%) reported use for a period up to 
one year, 6s (31.6%) 1 to 4 years and 68 (31.6%) more than 5 years, Twenty~one 
women (9% of all users) reported to have used HRT in the period between the first and 
second visit. Twenty women (9% of all users) reported a histOlY of use of progestins, 
additional to the use of estrogens. 
Mean IMT in our study group was 72,6 Jim (standard deviation 13,5) and ranged 
from 43,0 Jim to 145,S Jim, Table 2 shows age~adjusted associations between cardio~ 
vascular risk indicators and Ii'vIT. Age, systolic blood pressure, total- and HDL choles-
terol levels, diabetes and current smoking were all independently and significantly as-
sociated with IMT. The association of Bj\rfI with IIvlT did not reach statistical signifi-
cance (95% CI -0,02; 0,31, p=O,OS), 
Table 2 
Age-adjusted regression coefficients for association between cardiovascular risk factors and 
intima-media thickness. 11 is the increase of IMT in ,.Hn per unit increase in the cardio-
vascular risk factor. 
Characteristic p 95 % confidence interval 
Age (years) 0,87 (0.77; 0,79) 
Systolic blood pressure (mmHg) 0,12 (0,08; 0,15) 
Diastolic blood pressure (mmHg) -0,05 (-0,12; 0,0]) 
Baby mass index (kg/m') 0,15 (-0,02; 0,3]) 
Total Cholesterol (mmol/I) 0,81 (0.71 ; 0,92) 
HDL-Cholesterol (mmol/l) ~2,41 (-4,33 ; -0,49) 
Diabetes (yes/no) 4,05 (1,54; 6,57) 
Current smoker (yes/no) 2,97 (1.10 ; 4,85) 
Former smoker (yes/no) 0,85 (-0.73; 2,42) 
Alcohol drinker (yes/no) -0.43 (-1.20; 0,34) 
Visited GP in last month (yes/no) 1.93 (0,51 ; 3,35) 
Visited specialist in last month (yes/no) -0,04 (-1.77 ; 1.69) 
Higher education (highest category) ~o, 13 (~1.03 ; 0.78) 
Income (per 100 euro) -0,046 (-0,185; 0,093) 
HDl = high density lipoprotein. GP = general practitioner. 
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Analysis of covariance showed that users of HRT had a mean age-adjusted IlvlT of 
73.0 Jim compared to a mean IMT of 74.3 Jim in non-users (p~0.13, table 3). Stratifica-
tion for duration of use, however, showed that while use shorter than one year was not 
associated with a reduction of 1M'!', use during 1 year or more was associated with a 
statistically significant reduction of IMT. Analysis adjusted for smoking, for number of 
packyears smoked, level of education, systolic blood pressure and BlvII did not change 
these results. Additional adjustments for diabetes, frequency of visits to a GP or to a 
medical specialist in last month or total cholesterol and high density lipoprotein cho-
lesterol did not change the risk estimates. No associations were found with duration of 
use in women who had used one year or more. 
The numbers of recent users and users of combined estrogen-progestin therapy 
were small. Comparison of mean U\'IT in the 21 recent users with never users after ad-
justment for age and confounders showed a decrease in IMT (69.6 Jim (SE 2.5) versus 
74.1 Jim (SE 0.4), p ~ 0.08). 
\';rhen repeating the analyses excluding women reporting recent use of female 
hormones, in order to assess the effect in past users only, similar association were 
found for past users versus never users for mean UvIT (71.9 Jim (SE 1.3) versus 74.3 Jim 
(SE 0.4), p ~ 0.07) and for maximum IMT (94.0 Jim (SE 1.9) versus 98.4 Jim (SE 0.6), p 
= 0.03). Also when repeating the analysis after exclusion of women who were classi-
fied as probable and possible users (121 wOluen), similar associations were found for 
both mean and maximum IMT. 
Table 3 
Intima-media thickness in women with and without a history of hormone use. Values are 
means or proportions with standard errors. 
Never 
Short-term Long-term 
Ever users 
Characteristic users 
lIsers 
p' < lyr 
users 
~ 1 year p' All p' 
(n ~ 984) (n ~ 79) (n ~ 136) (n ~ 228) 
CCA IMT mean 74.3 (0.4) 73.9 (1.3) 0.72 72.2 (1.0) 0.05 73.0 (0.78) 0.13 
(~m)' 
adjusted full' 74.2 (0.4) 73.9 (1.3) 0.69 71.9 (1.0) 0.03 72.8 (0.78) 0.10 
CCA IMT maximum 98.3 (0.6) 99.0 (1.9) 0.76 95.6 (1.5) 0.09 97.0 (1.14) 0.32 
(Illll) , 
adjusted full' 98.3 (0.6) 99.0 (1.9) 0.75 95.2 (1.5) 0.04 96.8 (1.14) 0.23 
CCA = common carotid artery. IMT = intima-media thickness. * Adjusted for age, t Adjusted for age, 
smoking, education, sbp and BM!. :f: p-va[ue for comparison to never lIsers. Numbers do not sum up to 
totals due to missing values on duration of hormone use. 
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Carotid plaques were measured in 1887 of the 2401 women eligible for this study 
(79%). Plaques were found present in 48 0,1) of ever users and 53 % of never users after 
adjustment for age and confounders (p~0.15). 
DISCUSSION 
\"'{le found a lower level of I!vIT in the COIllmon carotid artery in women who had llsed 
HRT for one year or longer) compared to never users. Use of HRT for a period shoner 
than one year was not associated with a decreased 1MT. 
Before interpreting these results several issues need to be addressed. In this study 
of elderly women there is the possibility of selection bias. \'lomen had to sUivive until 
at least age 55 to be in our study. In case a protective effect of HRT is present, and 
women who had never used female hormones had died of, or not responded because, 
of atherosclerotic complications before the start of our study, this may have lead to an 
underestimation of the effect. 
Several studies demonstrated that estrogen users are healthier than never users, 
even prior to use of replacement therapy, which SUppOlts the hypothesis that part of 
the apparent benefit associated with HRT is due to pre-existing characteristics of the 
users. 13,14 \'?omen who take hormones are a self-selected group and m.ay have 
healthier life-styles with fewer risk factors than women who do not. Also, compliant 
women who stay on estrogen represent a minority of all women who are ever pre-
scribed estrogen, and these women may differ frOll.l the less compliant women. \Y./e 
cannot exclude the possibility that part (or the whole) of our findings is based on this 
selection bias. In this study we have dealt with the issue of confounding in the follow-
ing ways. \Ve stratified for duration of hormone use, and found that short-term users 
were similar to long-term users with respect to the presence of several socio-economic 
and risk factors, like income, frequency of visits to GP or medical specialist in last 
month, alcohol consumption and total and HDL-cholesterol levels. Among women 
who had used female hormones for a period shOlter than a year no association was 
present with IMT. This diminishes, but not fully excludes, the probability of selection 
bias. Furthermore, we adjusted for known risk factors. \Ve measured the current status 
of risk factors, while the exposure to honnone use had largely taken place in the past. 
Socia-economic status (level of education) may be a major confounder, but remains 
relatively stable over time. The frequency of visits to health care facilities (possibly rep-
resenting health conscious behavior now and in the past) differed between ever and 
never users of HRT, but adjustment did not change our results. Smoking habits might 
have changed over time, but misclassification of smoking habits would have given an 
underestimation of the effect, because users were more frequently smokers. BM1 and 
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alcohol intake may undergo changes with age, and it could be that some residual con-
founding has remained after adjustment. \\le do not expect this to have a large effect 
on our results, however, because of the relatively weak associations of these factors 
with IMT. 
Use of hormone replacement thera py was assessed by interview. This might have 
led, to a certain extent, to misclassification. Greendale et a1. demonstrated that a single 
self-repmt question is adequate to asceltain ever-use of postmenopausal estrogen use 
in women up to 64 years of age. 15 Another study showed moderate to substantial 
agreement between users and physicians on ever/never use of estrogens, and no dif-
ferential misclassification with disease status of the subject in women up to 74 years of 
age. 16 The reported frequency and duration of use of HRT seemed to be similar to the 
those in studies in perimenopausal women in The Netherlands, where 12%) of women 
between 45 and 65 used HRT and 50 % of women discontinued use within one 
year. 17-19 
According to data from the Institute of Medical Statistics, (an institution repm1ing 
yearly updates on prescriptions per indication) the most frequently prescribed hor-
mone therapy in the studied period was unopposed estrogen therapy in a dose of 
0.625 mg daily. Besides conjugated equine estrogens, also oestradiol preparations were 
prescribed. Progestins were added in 0.6<% of prescriptions in 1970, gradually increas-
ing to 11 %) of prescriptions in 1986. Our observation of 9% agrees with this and with 
that of others. 18 
Increased UdT of the common carotid artery has been shown to be associated 
with risk factors for atherosclerosis 20-22, with atherosclerosis in other locations 9,12 and 
with cardiovascular disease. 23 ,24 Thus, HvIT can be used as an indicator for generalised 
atherosclerosis. Ultrasonographic measurements of IIvrr have been shown to be highly 
reproducible.8,25 
The finding that HilT inhibits development of atherosclerosis in the coronal), ar-
teries and ao11a has been reported in several animal studies. 26-31 Studies with angio-
graphic endpoints showed a lower degree of coronal), atherosclerosis in HRT users 
compared to nonusers.32-34 Detection bias could have been introduced, however, if 
wOIllen on estrogen were selected for an angiogram on the basis of less severe symp-
toms in cornparison with non-users. Results from population based studies have been 
conflicting. In the Cardiovascular Health study, carotid H...tT and stenosis in elderly 
women using estrogen and progestin were similar to those of women using estrogens 
alone, and both groups had a lower I.MT of the internal and common carotid artery 
compared to never users,35 Another large population-based study in women under age 
55 (the Atherosclerosis Risk In Conununities study, ARIC), however, did not find an 
association between HRT and n.,·IT.5 In two small cross-sectional studies a lower IMT 
was found on ultrasonographic examination of the carotid arteries36 and in the aOlta 
and iliac a11eries37 in users of combined replacement therapy compared to nonusers. 
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Results from the Asymptomatic Carotid Atherosclerosis Progression Study (ACAPS) 
among 186 postmenopausal women sugge:;ted that hormone replacernent therapy rnay 
halt progression of atherosclerosis, as measured by carotid intima-media thickncss.38 
Most studies focussed on current lIsers. The effect of past use of female hormones 
was studied in an earlier repOlt fro111 the Cardiovascular Health Study, which showed 
that differences in mean carotid wall thickness were greater between current and past 
users than between past and never users.6 Maximum wall thickness did not differ be-
tween past and never users, In our study the number of recent users was small) but 
excluding recent users from the analysis clearly demonstrated the association in past 
users. POSSibly, this difference in findings can be explained by the longer period since 
hormone use among women in the Cardiovascular Health Study, as these women were 
older than the women in our study population. 
Although some studies have found an effect of duration of use of female hor-
mones on atherosclerosis 41,42,43, several large population based studies 6 39 40, did not 
find this association. This may be explained as a reflection of unreliability of data on 
duration. On the other hand, the observations of a stronger protective effect of HRT in 
current than in past users, and a diminishing of the protective effect after cessation of 
therapy, suggest that other mechanisms than the inhibition of atherosclerosis are also 
active. Our results suggest use of HRT for one year or more decreases the development 
of atherosclerosis, but no effect of duration of use was found. 
Only one randomized trial on the effects of HRT on cardiovascular disease has 
been conducted (Heart Estrogen/Progestin Replacement Study (HERS». This trial in 
women with diagnosed cardiovascular disease showed no favorable effect of HRT on 
incident COrOI1<ll), hean disease after 4.1 years of follow-up.4 This result indicates that 
bias in observational studies lllay be larger than thought until now. On the other hand) 
in the trial an increased risk for corona!)' heart disease events was found in the HRT 
group compared to the placebo group in the first year of the trial, but decreased in 
subsequent years. This time-trend should be interpreted with caution, but might be 
explained as being attributable to an immediate prothrombotic, proarrythmic or pro-
ischemic effect of treatment, that is gradually outweighed by a beneficial effect on the 
progression of atherosclerosis. Thus, the results of the HERS-trial do not exclude the 
possibility that HRT might inhibit the development of atherosclerosis. The immediate 
effects of hormone replacement therapy lllentioned above might be expected to be of 
more importance in women with previous cardiovascular disease. FUlthennore, in the 
HERS trial the effects of opposed estrogen were compared to placebo, while in our 
study mainly unopposed estrogen was used. The effects of different kinds of progestins 
on development of atherosclerosis remain unclear. 44-46 
Our results suggest that past use of hormone replacement therapy is associated 
with a favorable atherogenic status. Further understanding of the effects of hormone 
replacement therapy on atherogenesis can be obtained only in randomized trials, ade-
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quately designed to take the distinct effects of hormone replacement therapy on the 
ShOlt- and the longer tcnn into account. 
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4.1 The effect of hormone 
replacement therapy on 
changes in arterial 
distensibility and compliance 
I Chapter 4.1 
Abstract 
A single centre randomised placebo-controlled trial was performed to assess the two-year effects 
of hormone replacement therapy compared to placebo on mechanical arterial properties in 99 
peri menopausal women recruited from the general population. The trial was double-blind with 
respect to a sequential combined regimen of oral 17~-oestradiol and desogestrel (17flb-D) and 
the placebo group and open with respect to combination of conjugated equine oestrogens and 
norgestrel (CEE-N). At baseline, distensibility and compliance of the common carotid artery was 
measured non-invasively with B-mode ultrasound and a vessel wall movement detector system, 
and the distensibility coefficient (DC) and compliance coefficient (CC) were calculated. Meas-
urements were repeated after 6 and 24 months. Changes in DC and CC in treatment groups were 
compared to placebo. After 24 months, changes for 17f3E2-D compared to placebo were -1.4 x 
10~' / kPa (95% CI-4.4 ; 1.7, p~0.391 for DC and 0.26 mm' / kPa (95% CI -0.01 ; 0.53, p~0.071 
for cc. Changes for CEE-N compared to placebo were 0.4 x 10·' / kPa (95% CI (-1.0 ; 1.9, 
p~0.791 and 0.11 mil)' / kPa (95% CI .-0.14; 0.37, p~ 0.401. For systolic blood pressure, dia~ 
stolic blood pressure and arterial lumen diameter no changes were found. In this study no signifi-
cant differences in changes in distensibility and compliance were found between perimenopausal 
women using 17r3E2-D or CEE-N and women using placebo after 6 and 24 months. 
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INTRODUCTION 
Epidemiological studies have shO'wn a lower risk of coronary heart disease among 
postmenopausal users of oestrogen supplements compared to non-users.1-3 Postulated 
mechanisms for a beneficial effect include changes in lipid and haemostatic variables 
and direct effects on the arterial wall. In experimental studies in animals oestrogens 
had direct vasodilatol), effects4-7 and were shown to affect the structure and mechani-
cal properties of large arteries.8-10 Improved endothelial function has been shown after 
hormone replacement therapy (HRT) in animal studiesll , in postmenopausal women 12-
14 and after oestrogen use in transse}"'l.lal men. 15,16 Also, HRT has been suggested to 
decrease the pulsatility index, a measure reflecting decreased peripheral vascular re-
sistanceJ7-20 Data on effects of HRT on distensibility and compliance of large arteries 
in humans are scarce. In a recent study oestrogen users had a higher arterial distensi-
bility than non-users while oestrogen-progestin users had a lower arterial distensibility, 
and systernic al1eriai compliance was higher in both oestrogen and oestrogen-progestin 
users compared to nOll-users.21 In another study HRT-users had a more favorable 
augmentation index, a measure of pulsatile vascular afterload, than non-users, while 
there was no difference in Pulse \,'ave Velocity (P\VV), a measure of alterial stiffness. 22 
Both studies, however, were observational. Rajkumar et ai. showed women using HRT 
did not only have better systemic alterial compliance than non-users, but withdrawal of 
therapy, in a small group of women, resulted in a significant deCI'ease of compliance.23 
To our knowledge no randoI11ised studies have been performed to date on effects of 
HRT on distensibility and compliance of large alteries. 
The present study was conducted to assess the long-term effect of Liseta®, a 24-
day active, 28-day sequential combined regimen of oral 17f3-oestradiol and desogestrel, 
and Prempak@, a combination of conjugated oestrogens and norgestrel on several car-
diovascular risk factors (Bak, 1998, unpublished results) and structural and dynamic 
alterial characteristics of the carotid artery. Here we present the results of the effects of 
HRT on sL-..:: months and two-year change in arterial distensibility and compliance in 
comparison to placebo in perimenopausal women. 
METHODS 
Study population and methods 
TI,e design of the study was randomised, double-blind with respect to 17flE,-D and 
placebo groups and open with respect to CEE-N. The study was conducted in one 
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centre and included 121 peri menopausal women. Palticipants were recruited from the 
general population in the town of Zoetermeer (The Netherlands), They completed a 
questionnaire on menopause and gynaecological issues that was sent to all women 
between 40 and 60 years of age. \,'omen who were eligible based on the questionnaire 
and interested in participating in a hormone replacement study were invited for the 
screening procedure. The study was performed from October 1992 to July 1995. The 
study was approved by the J\-IedicaJ Ethics Committee of Erasmus University, and writ-
ten consent was obtained from all participants. 
Subject selection was based on the following criteria: age between 40 and 60 
years; not hysterectomised; climacteric symptoms (hot flushes and/or outbreaks of 
sweating), body weight between 80% and 130% of the ideal bod)' weight (Metropolitan 
Life Insurance Company Tables for \'<'omen, 1983). 'I11e main exclusion criteria were: 
absence of spontaneous vaginal bleeding for more than 5 years; use of sex-steroids 
currently or within the last two months or ethinyl-oestradiol or injectable sex steroids 
within the last six months or hormone implants at any time previously; histOlY or pres-
ence of any malignant disorder; histol1' or presence of cardiovascular or cerebrovas-
cular disease or thromboembolism / thromboSiS; history or presence of hepatic or renal 
disease, uncontrolled hypertension (systolic blood pressure> 170 nunHg and/or dia-
stolic blood pressure> 105 mmHg); significant hyperlipiclaemia (fasting total choles-
terol > 9.5 mmol/I and/or fasling triglycerides > 2.5 mmol//). A celvical smear and a 
mammography were done unless results were available dated less than one and two 
years previously, respectively. 
17PE,-D and placebo tablets were supplied in identical looking push-through-
strips, CEE-N was supplied in the original, commercially available, strips. The compo-
sition of the three study drugs was as follows, Each strip of 17PEr D contained 12 tab-
lets with 1.5 mg 17p-oestradiol (micronised), 12 tablets with 1.5 mg 17p-oestradiol (mi-
cronised) + 0.15 mg desogestrel (Liseta®; NV Organon), and 4 placebo tablets. Placebo 
was 17PEr D matched and contained 28 placebo tablets. Each strip of CEE-N contained 
28 tablets with 0.625 mg conjugated oestrogens and 12 tablets with 0.15 mg norgestrel 
(Prempak®; Novo Nordisk). Subjects in the 17PEr D or 17pE,-D-matched placebo 
groups took one tablet per day, on a continuous basis. Subjects treated with CEE-N 
took one tablet per day /i·OJll da)' 1 to 16 and two tablets per day from day 17 to 28, for 
each cycle. Tablets were taken after breakfast. Sex steroids other than the study medi-
cation, hydantoins, barbihlrates, primidone, carbamazepine, rifampicin, griseofulvin, 
ancllipid lowering agents were not allowed during the study. 
Randomisation to treatment with 17PE2-D, CEE-N, or placebo was performed in a 
ratio of 3:2:2 using a computerised allocation algorithm. The treatment allocation of 
3:2:2 was chosen to assure the gain of sufficient infonnation on the relatively new 
combination 17pE,-D. The design was double-blind with respect to 17PEr D and pla-
cebo groups, and open with respect to CEE-N. The first pa11 of the study comprised sLx 
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consecutive cycles of 28 days, after which the blind was broken and the trial was con-
tinued as an open trial for another 18 months for the 17PE,-D and CEE-N groups. As in 
studies of HRT blinding is difficult to maintain throughout the study, because of the 
clear effects on menstrual cycle (participants were asked to complete a bleeding diary), 
the ultrasound technician was blinded for the intervention groups. All palticipants, in-
cluding those in the placebo group, were invited for a final ultrasound examination 18 
months after the blind was broken. Alterial characteristics were measured non-inva-
sively at day of randomisation, and at cycle 6 and 24 .. Measurements were performed 
on day 21 ± 2 of the cycle for the 17PE,-D group and on 25 ± 2 for the CEE-N group. 
At baseline, information was obtained about smoking. Body weight and body 
height were measured and body mass index was calculated. Fasting blood samples 
were obtained between 8.00 and 10.00 a.m. Cholesterol and triglycerides were assayed 
enzymatically with a Hitachi 747 automated analyser with kits from Boeringher Mann-
heim (Germany). J-IDL-cholesterol ,vas measured after precipitation with phos-
phowolfram/phosphotungstic acid and 2 11111101 of manganese chloride per litre. The 
LDL-cholesterol concentration was calculated with the Friedewald f0f1uula. 24 
Measurement of arterial distensibility and compliance 
The vessel wall motion of the right COIlUHon carotid altery was measured by means of 
a Duplex scanner (ATL Ultramark IV, operating frequency 7.5 MHz) connected to a 
vessel wall movement detector system (\,{/TS).25 'I11e details of this technique have 
been described elsewhere. 26-28 Briefly, this system enables the transcutaneous assess-
ment of the displacement of the arterial walls during the cardiac cycle and, hence, the 
time-dependent changes in alterial diameter relative to its diastolic diameter at the start 
of the cardiac cycle. Subjects were instructed to refrain from smoking and from taking 
coffee, tea, alcohol or pain-medication on the day of mea:::;urernent, and from taking 
alcohol on the day before. Subjects were placed in supine position, with the head tilted 
slightly to the contra-lateral side for the measurements in the carotid artery. A region at 
1.5 em proximal to the origin of the bulb of the carotid altery was identified using B-
mode ultrasonography. Based on the B-mode recording an lvI-line perpendicular to the 
altery was selected, and the received radio frequency signals were recorded over five 
cardiac cycles and digitally :::;tored. The displacement of the alterial walls \vas obtained 
by processing the radio frequency signals originating from two :::;elected sample vol-
umes positioned over the anterior and posterior walls. The successive values of the 
end-diastolic diameter (Dd), the absolute :::;troke change in diameter during sy:::;tole 
("'0), and the relative stroke change in diameter (("'O)/Od) were computed from the 
recording during five cardiac cycles (Figure 1). Blood pressure was measured with a 
Dinamap automatic blood pressure recorder (Critikon, Inc, Tampa, Florida, USA), and 
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Figure 1 
Example of distensibility measurement. The upper figure shows movements of the anterior (ant) 
and posterior wall (pos), the lower line the change in lumen diameter resulting from these 
movements (distensibility). Below the figure the calculated change in lumen dialllater (dist in 11), 
end-diastolic lumen diameter (diam in mm) and relative distension (dist in %) are shown. 
read 4 times at the right upper ann during the measurement session. The mean was 
taken as the subjects reading. Pulse pressure (pP) was defined as systolic blood pres-
sure (SBP) minus diastolic blood pressure (DBP). The alterial wall distensibility coeffi-
cient (DC) and compliance coefficient (CC) were calculated according to the following 
equations29; 
DC ~ (2"'D!D) I "'P 
CC ~ (nD x "'D) I 2"'P) 
\Vith this system a wall displacement of a few micrometers can be resolved26, and D! 
"'D, "'DID, DC and CC can be assessed reliably.28 TI,e al1erial wall properties, as de-
termined in this way, are defined as the relative and the absolute change in arterial 
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cross-sectional diameter (distensibility) and alterial volume compliance for a change in 
pressure. They reflect a combination of passive elastic properties and active compo-
nents induced by smooth muscle cells. All measurements were done by a single per-
former, who was blinded for the treatment group. A reproducibility study was per-
formed in which 15 participants undelwent a second exarnination within one month 
from the initial examination of the right carotid altelY. The coefficients of variation for 
distension and lunlen diameter were 8.5% and 1.2%), respectively. 
Data analysis 
In total 121 perimenopausal women were randomised. Baseline distensibility meas-
urements were not performed in 22 subjects for logistic reasons, who were distributed 
randomly over the treatment groups. The following results are based on the 99 subjects 
with baseline assessment. FOIty-four subjects received 17PEr D, 29 CEE-N and 26 pla-
cebo (randomisation code 3:2:2). Data are presented by treatment group. The individ-
ual changes in common carotid altery DC and CC from baseline to cycle 6 and to cycle 
24 were calculated. Analyses for the changes in the first 6 months were performed us-
ing those subjects of whom information on distensibility at baseline and at 6 cycles 
(n=61) were present. Analyses for changes over 24 months were performed using 
those subjects for whom data at baseline and at 24 cycles (n=48) were present. For this 
analysis, two dummy variables were constructed: the first with placebo (value 0), 
17PEr D (value 0) and CEE-N (value 1) and the second with placebo (value 0), 17i3ErD 
(value 1) and CEE-N (value 0). A linear regression analyses with change in DC and CC 
as dependent variables and the two dummy variables as independent variables were 
used to study whether the change in DC and CC from baseline in the treatment groups 
differed among treatment groups. Results are presented as mean differences in change 
in DC and CC relative to the placebo group with 95%l confidence intelvals. Analyses 
were performed \vith and without adjustment for values of baseline measurements, and 
analyses with adjustment for baseline are presented. In a similar way analyses were 
performed to study whether change in lumen diameter, systolic and diastolic blood 
pressure and pulse pressure from baseline differed across the treatment groups. All 
analyses Were performed using SAS software (SAS Statistical Software, Inc). 
The sample size calculations for the present trial showed that with 44 subjects in 
the 17PEr D group a standard deviation of the distensibility coefficient of 7.1, a two-
sided a of 0.05 and a power of 0.80, a difference in change of distensibility coefficient 
of 4.9 x 10·'/kPa between the treated and placebo group could be detected after 24 
months. For the compliance coefficient, with a standard deviation of 0.37, a difference 
in change of 0.27 mm' ! kPa between the treated and the placebo groups could be de-
tected after 24 months. 
Table 3 
Change in blood pressure, distensibility and compliance after 6 months and 24 months in 3 treatment groups. 
17 ~oestradiol + Desogestrel 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Distensibility Coeffident (10-3 / kPa) 
Compliance Coefficient (mm' I kPa) 
Conjugated equine estrogens + 
Norgestrel 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Distensibility Coefficient (l 0-3 / kPa) 
Compliance Coefficient (mm 2 / kPa) 
difference 
6 months 
n ~ 61 
95% CI for the 
difference p 
(n =24 versus placebo (n = 20) 
3.33 (-0.3 - 7.0) 0.43 
-2.73 (-6.4 - 1.0) 0.31 
-0.08 (-3.0 - 2.8) 0.56 
-0.003 (-0.12 - 0.11) 0.97 
(n = 17 versus placebo (n = 20) 
1.59 
-2.15 
0.96 
-0.003 
(-2.3 - 5.5) 
(-6.2 - 1.9) 
(-2.2 - 4.2) 
(-0.14-0.13) 
0.08 
0.15 
0.96 
0.96 
24 months 
n ~ 48 
difference 95% cr for the difference p 
1.13 
-1.16 
-1.37 
0.26 
n=13versusn=18 
(-5.5 - 7.7) 0.74 
(-6.7 - 4.4) 0.68 
(-4.4 - 1.7) 0.39 
(-0.01 - 0.53) 0.07 
n = 17 versus n= 18 
-2.25 (-8.3 - 3.8) 0.48 
0.05 
0.41 
0.11 
(-1.3 - 1.4) 0.98 
(-1.0-1.9) 0.79 
(-0.14-0.37) 0.40 
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ADVERSE EVENTS 
The total number of subjects that discontinued drug treatment after 6 months was 23; 
11 (21%) in the 171lE,-D group, 8 (23.5%) in the CEE-N group, 4 (11.4%) in the placebo 
group. After cycle 6, 5 women decided not to enter the second part of the study: 4 
(10%) in the 171lE,-D group, and 1 (4%) in the CEE-N group. Between cycle 6 and cy-
cle 24, 20 (45%) women in the 171lE,-D group and 19 (56%) in the CEE-N group com-
pleted the study. Of the women that had been randomised to the placebo group, 22 
out of 35 who completed the 6 months were willing to visit the research centre for the 
cycle 24 visit. During the study, the occurrence of unacceptable adverse events was the 
main reason for withdrawal. The number of evaluable subjects at baseline, 6 and 24 
months was 44,24 and 13 for the 171lE,-D group, 29, 17 and 17 for the CEE-N group 
and 26, 20 and 18 for the placebo group. Ninety-sLx women had at least one adverse 
experience in this period: 42 in the 171lE,-D group (80.8%), 29 in the CEE-N group 
(85.5%) and 25 in the placebo group (71.4%). The type and severity of the adverse ex-
periences recorded were consistent with those sometimes seen with this type of ther-
apy, such as headache, depressive feelings, abdominal pain and nausea. During treat-
ment, four of the adverse experiences recorded were classified as serious but probably 
not drug-related (one myocardial infarction in the placebo group, and cases of epilep-
tic seizure, syncope and unspecified uterine disorder in the 17!lET D group). 
DISCUSSION 
In the present study in perimenopausal women, no significant differences in change in 
alterial distensibility of the common carotid artel), could be demonstrated between 
women using 171lE,-D or CEE-N and women using placebo after 6 and 24 months. Also 
changes in systolic and diastolic blood pressure and lumen diameter did not differ sig-
nificantly between intelvention and placebo groups. In our study no significant differ-
ences were found between the effects of 171lE,-D and CEE-N. 
Before interpreting these data, some issues need to be addressed. Participants 
were healthy subjects from the general population. Compliance to study medication, as 
assessed by tablet count and diary-checks, was satisfactOl), in all three groups with a 
mean compliance rate of luore than 97%. 111e double-blind design with respect to 
171lE,-D and placebo intelvention was difficult to maintain throughout the study, be-
cause the clear effects on menstrual cycle (pat1icipants were asked to complete a 
bleeding dial),) and climacteric symptoms could not be ignored. However, the ultra~ 
sound technician was blinded for the intelvention group. The percentage of women 
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who had withdrawn from the study or had missing data on distensibility (52 q11) was 
comparable in the 17pEr D and the CEE-N groups. Theoretically, the drop-out rate may 
have influenced the effectiveness of the randomisation process, Le. resulting in incorn-
parability in prognosis of the three groups. However, women who completed the study 
had similar levels of baseline cardiovascular risk factors and distensibility and compli-
ance compared to women who had withdrawn. A high drop-out rate does have an 
unfavourable effect on the precision of the estimates of change in distensibility and 
compliance, which decreases the ability to observe differences across groups. After 6 
months of study the blind was broken and the trial continued for 18 months as an open 
trial. The fact that) in contrast to the placebo group) the treatment groups were subject 
to intensive follow~up from cycle 6 to 24) cannot explain our results) as it would) if 
anything, have resulted in a more health-conscious behaviour of the treatment group, 
and thus can be expected only to have increased a possible difference between the 
treated and placebo groups. 
\Ve measured distension in the carotid altery and adjusted for pulse pressure 
measured in the brachial altelY. \Ve assume that pulse pressure measured in the bra-
chial altery is representative for pulse pressure in the carotiei altery. In dogs) it has 
been demonstrated that pulse pressure in the brachial allel), is linearly related to blood 
pressure in the carotid altery over a wide range of blood pressures.27 It is known that 
the arterial pressure-waves undergo transformation in the alterial tree and therefore the 
pulse pressure is higher in the brachial artery than in the more central vessels.30 \'(lith 
increasing age and alteriai stiffness) however) this difference between central and pe-
ripheral pulse pressure decreases. If, in line with the decreasing difference seen with 
age and arterial stiffness) the overestimation of pulse pressure is less in untreated 
women, the DC would be overestimated in this group, and a true difference in disten-
sibility between the groups would only be larger than the difference obselved in our 
study. Although it has been demonstrated that DC and CC do not differ in the different 
phases of the menstrual cycle, in spite of distinct changes in endogenous oestrogen 
levels31 , all measurements were performed on a defined day in the second phase of 
the cycle) to exclude incomparability due to differences in treatment phase. 
A body of evidence on favourable effects of oestrogen on the vascular system is 
available from animal and observational studies) as well as in a limited number of ran-
dOlnised studies. Our randomised study, however) did not show an effect of HRT on 
carotid al1CI)' dbtensibility and compliance in a group of 99 perimenopausal women. 
Favourable effects of oestrogen on vasodilatOlY responses have been shown in animal 
experiments) but these findings are based mainly on oestrogen administration and not 
on oestrogen-progestin combinations.4-7,11 The effects of progestins on vascular prop-
elties are not well understood.32,33 In a recent study Register et a1. demonstrated that 
oestrogen alone, but not in combination with medroxyprogesterone acetate inhibit 
potentially detrimental aortic connective tissue alterations in ovariectomised monkeys 
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on lipid lowering therapy.34 In a randomised cross-over trial Luckas et a!. showed that 
the addition of progestagen to oestrogen replacement therapy partly antagonises the 
favourable effect of oestrogen on pulsatility index in the peripheral alteries in post-
menopausal women. Other studies have found similar antagonistic effects of progestins 
in uterine alteries in oophorectomised ewes and women3S-37, and in the carotid arter-
ies in women.38 Possibly, addition of progestagens to oestrogen replacernent therapy 
in our shlely might have attenuated oestrogen-mediated changes in vascular properties. 
Furthermore, the difference between our findings and the positive findings in obselva-
tional studies could be explained by the better vascular condition of HRT users in these 
studies might be, in part, due to the selection of healthy women for use of HRT.3,39 
Another explanation for the apparent difference between our findings and that of other 
studies could be the different endpoints used. Studies have used pulsatilit)' index (pe-
ripheral vascular flow), flow-mediated dilatation (endothelial function), systemic alte-
rial compliance (compliance over the total aneriai system), and augmentation index 
(reflecting both arterial stiffness and peripheral pressure wave reflections), which 
probably reflect essentially different arterial properties. The two studies examining lo-
cal carotid artelY distensibility as in our study, found no differences in DC between 
HRT-users and non-users40 and no change of DC with the menstmal cycle.31 It is not 
established whether changes in alterial distensibility are the result of short term-effects 
or of structural changes in the arterial wall. Sholt-term effects on arterial distensibility 
have been shown as a response to treatment with calcium antagonists.41 Also structural 
changes may underly a decrease in arterial distensibility. In vitro investigations as well 
as animal studies showed that oestrogens decrease collagen production and decrease 
the elastin/collagen ratio.8-10 Possibly, these struchlral changes need more time to de-
velop than the two years of this intelvention trial. In a recent study, a difference in alte-
rial distensibility was shown between premenopausal women and postmenopausal 
women who were on average 5.4 years after menopause. 25 
The lack of change in blood pressure with HRT in our study is in agreement with 
a large bod)' of literature showing that HRT is not associated with changes in blood 
pressure. The finding of an increased s),stolic blood pressure in the 17PEr D group af-
ter 6 but not after 24 months, which was not statistically significant after adjustment for 
baseline values, could be a true transient effect of the treatment, specific for 17J3ET D, 
but considering the literature, probably should be seen as a chance finding. 
In the present shldy all women had climacteric complaints and were predomi-
nantly pcrimenopausal. Although in women with symptoms oestradiol levels are de-
creased compared to premenopausal women42, the endogenous oestradiol production 
in these women will probably influence the effects of HRT. Because symptomatic 
women are the target population for HRT, the vast majority of HRT in the Netherlands 
is prescribed for the indication menopausal complaints43, it is of interest and of practi-
cal impol1ance to know the effects of HRT on cardiovascular risk factors in this popu-
99 
I Chapter 4.1 
latLon. However, it is not perimenopallsal women, but postmenopausal women in 
whom prevention of coronary hean disease is of most imp0l1ance. \V'e have to be 
careful to c},.'1rapolate our findings from this relatively young population to the use in 
older, postmenopausal women. Possibly, when studying postnlenopausal women, with 
low endogenous estrogen levels, the contrast between the placebo and the intelven~ 
tion groups would have been larger, and an effect Blight have been present. The weH-
known beneficial effects of HRT on total-cholesterol, LDL-cholesterol, HDL-cholesterol 
and the HDL-c/LDL-c ratio in our study (unpublished results) were all present and in 
the same direction as those in studies in postmenopausal women44 , although the mag-
niulde of the effect might have been larger in the postmenopausal women. 
Up to date, no information is available as to what increase in alterial distensibility 
or compliance is clinically relevant. Sample size calculations showed the trial could 
have detected changes of 4.9 1O-3/kPa in DC and of 0.27 mm'/kPa in cc. We detected 
a mean change in DC of 0.4 1O-3/kPa in the CEE-N group relative to the mean change 
in the placebo group, and of 0.11 mm'/kPa in CC. In the 17PE,-D we detected a mean 
change of -1.4 IO-J/kPa in DC and 0.26 nun'/kPa in cc. 'I1,is suggests there are no ef-
fects of treatment on distensibility, but we cannot exclude the possibility that in a larger 
study or in a study of longer duration, the effects of 17PE,-D would have reached sta-
tistical significance. This trial is the first mndornised study of HRT on local carotid ar-
telY distensibility and compliance. 
\Vhether loss of distensibility or compliance are early markers for asymptomatic 
atherosclerotic changes is still a matter of debate.45-49 Decreased distensibility is unfa-
vourably associated with age50,51 and with several cardiovascular risk factors, like 
cholesterol52 and hypeltension.53,54 Loss of distensibility in elastic arteries has been 
shown to be associated with an increased risk of cardiovascular disease in cross-sec-
tional studies.55,56 Longitudinal data on the effect of decreased distensibility on cardio-
vascular morbidity or mOltality are, however, still awaited. 
To conclude, in the present study in healthy perimenopausaJ women from a gen-
eral population, no significant changes in arterial distensibility and compliance could 
be demonstrated for women using 17p-oestradiol plus desogestrel or conjugated 
equine aestrogens plus nargestrel during twa years of observation. 
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Abstract 
Objectives - To assess the two-year effects of a combined regimen of oral 17~-e5tradiol and 
desogestrel (17PE-D), and a sequential combination of conjugated equine estrogens and norges-
trel (CEE-N) on common carotid intima-media thickness and end-diastolic lumen diameter in 
comparison to placebo in peri menopausal women. 
Methods - The study was a single center, randomized, group-comparative, double-blind study 
with respect to the 17PE-D and placebo groups and open with respect to CEE-N. After cycle 6, 
the blind was broken and the trial was continued as an open trial for another 18 months for the 
active study arms. The study included 121 peri menopausal women recruited from the general 
population. Common carotid intima-media thickness and end-diastolic lumen diameter were 
measured at baseline and cycle 24 with B-mode ultrasonography. 
Results - At cycle 24 small changes in intima-media thickness and lumen diameter were obser-
ved. Relative to placebo changes in intima-media thickness were -0.009 mm [95% CI -0.045; 
0.027J for 17pE-D and -0.016 mm [95% CI -0.055; 0.024J for CEE-N. For end-diastolic lumen 
diameter the changes were -0.091 mill [95% CI -0.236; 0.055J and -0.125 111111 [95% CI -0.820; 
0.032J for 17PE-D and CEE-N, respectively. 
Conclusions - In this study among perimenopallsal women a significant effect of 17f3E-D and 
CEE-N on common carotid intima-media thickness and lumen diameter could not be demon-
strated. Although the sample size of the present trial is too limited to provide definite conclu-
Sions, the direction of the effect is in agreement with evidence from earlier studies on the effects 
of hormone replacement therapy in postmenopausal women. 
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INTRODUCTION 
It is widely believed that ovarian estrogen production is responsible for the lesser de-
gree of atherosclerosis and cardiovascular risk in premenopausal women compared to 
men and postmenopausal women. In a recent Dutch study, each year of delayed natu-
ral menopause represented a 2% decrease in the annual hazard of cardiovascular 
death. 1 If ovarian estrogen production is responsible for protecting the atteries in pre-
menopausal women) then peri- and postmenopausal women could possibly benefit 
from estrogen replacement therapy. In support of this view, results from observational 
studies demonstrated that estrogen replacement therapy is associated with a 40-50% 
reduction in coronat)' hea11 disease risk in postmenopausal women. 2,3 Posnllated 
mechanisms for a beneficial effect include favorable changes in cardiovascular risk 
factors 2,3.4, favorable effects on endothelial fUl1ction5,6, and favorable effects on ath-
erosclerosis.7,8,9 
In the Netherlands, hormone replacement therapy is most commonly used by 
women with climacteric corn plaints like hot flushes, vaginal dl)'neSS and disturbances 
in menstruation pattern. \Vomen with climacteric complaints have lower endogenous 
estrogen levels compared to women without these complaints. In a Dutch study on 
determinants of first prescription of hormone replacement therapy perimenopausal 
women aged 45 to 50 were most likely to start using this therapy and they did not use 
it for a very long period of time.l° In populations at large, atherosclerosis can be stud-
ied non-invasively by measurement of intima-media thickness of superficial alteries 
with B-mode uitrasound. ll ,12,13,14 Increased carotid intima-media thickness has been 
associated with unfavorable levels of cardiovascular risk factors, prevalent cardiovas-
cular disease, atherosclerosis elsewhere in the arterial systemll,12,13,15,16,17 and with 
risk of future myocardial infarction and stroke.18,19 There is a growing belief that ca-
rotid intima-media thickness can be regarded as an indicator of generalized atheroscle-
rosis, and may be used as an intermediate endpoint or proAl' endpoint in observational 
studies and trials as a suitable alternative for cardiovascular morbidity and mortality.20 
Data on non-invasively assessed intima-media thickness and hormone replacement 
therapy are limited. Unopposed estrogen replacement therapy (without progestins) 
was in one large cross-sectional study in elderly postrnenopausal women inversely re-
lated to carotid intima-media thickness9, but this finding could not be confirmed in an-
other large cross-sectional study among middle-aged postmenopausal women.21 In a 
recent study among postmenopausal women indices of arterial function in long-term 
hormone replacement therapy users 'were compared with age matched controls. 22 In-
tuna media thickness was significantly lower in the hormone replacement therapy us-
ers. In a lipid intervention study, estrogen replacement therapy was shown to be re-
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lated with a reduction of progression of carotid intima-media thickness among post-
menopausal WD1uen who did not use lipid lowering agents.8 Data from intervention 
studies on the effect of hormone replacement therapy on progression of atherosclerosis 
are currently lacking, as well as data from studies in perirnenopausai women. 
The present study was primarily conducted to assess the effect of hormone re-
placement therapy in perimcnopausal warnen on several cardiovascular risk indicators 
(Bak AAA, Witteman JCM, Planellas J, VanderBom JG, Coelingh Bennink HJT, Grabbee 
DE. Effects of hormone replacement therapy on fibrillol,1ic activity and coagulation 
inhibitors in perimenopausal women. 1998. Submitted)) whereas structural and dy-
namic arterial characteristics of the carotid artcIY were also measured. Here we present 
the results of the effects of 17PE-D, a 24 clay active tablet, 28-day sequential combined 
regimen of oral 17~-estradiol and desogestrel (Org32818; LisetaR) and CEE-N, a se-
quential combination of conjugated equine estrogens and norgestrel (Prempak-CR), on 
two-year change in common carotid intima-media thickness and end-diastolic hllnen-
diameter in cOlnparison to placebo in perimenopausal women. 
MATERIALS AND METHODS 
Population 
The design of the study was randomized, grolip-comparative, double-blind the first six 
months with respect to 17PE-D and placebo groups and open with respect to CEE-N . 
The study was conducted in one center and included 121 perimenopausal women. 
Paliicipants were recruited from the general population in the town of Zoetenneer 
(The Netherlands). They completed a questionnaire on menopause and gynecological 
issues that was sent to all women between 40 and 60 years of age. \\;fomen who were 
eligible based on the questionnaire and interested in paliicipating in a hormone re-
placement sUldy were invited for the screening procedure. Subject selection was based 
on the following criteria: age between 40 and 60 years; not hysterectomized; climac-
teric symptoms (hot flushes and/or outbreaks of sweating); and body weight between 
80% ancl 130% of the ideal body weight (Metropolitan Life Insurance Company Tables 
for \~lomeIl, 1983). The main exclusion criteria were: absence of spontaneous vaginal 
bleeding for more than 5 years; use of sex-steroids currently or within the last two 
months or ethinylestradioI . or injectables within the last six months or hormone im-
plants at any time previously; history or presence of any malignant disorder; history or 
presence of cardiovascular or cerebrovascular disease or thrombo-embolism / throm-
bosis; histOIY or presence of hepatic or renal disease, uncontrolled hypellension (sys-
tolic blood pressure> 170 mmHg and/or diastolic blood pressure> 105 nunHg) and 
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significant hyperlipidaemia (fasting total cholesterol> 9.5 nunolll and/or fasting tri-
glycerides> 2.5 mll101/l). A cervical smear and a mammography were done to exclude 
any cervical or breast-pathology unless results were available dated less than one and 
two years previously, respectively. 
The study was performed from October 1992 to July 1995. The study was ap-
proved by the .Medical Ethics Committee of the Medical School, Erasmus University 
Rotterdam, and written consent was obtained from all participants. 
Design 
17PE-D and placebo tablets were supplied in identical looking push-through-strips. 
CEE-N was supplied in the original, commercially available, strips. The composition of 
the three study drugs was as follows. Each strip of 17pE-D contained 12 tablets with 1.5 
mg l7p-estradiol (micronized), 12 tablets with 1.5 mg 17p-estradiol (micronized)+ 0.15 
nig desogestrel, and 4 placebo tablets. Placebo was 17PE-D matched and contained 28 
placebo tablets. Each strip of CEE-N contained 28 tablets with 0.625 mg conjugated 
estrogens and 12 tablets with 0.15 mg norgestrel. Subjects in the 17PE-D or 17PE-D -
matched placebo groups took one tablet per day, on a continuous basis. Subjects 
treated with CEE-N took one tablet per day from day 1 to 16 and two tablets per day 
from day 17 to 28, for each cycle. Tablets were taken after breakfast. Sex steroids other 
than the sUldy medication, hydantoins, barbiturates, priInidone, carbamazepine, rifam-
picin, griseofulvin, and lipid lowering agents were not allowed during the sUldy. 
Randomization to treatment with 17~E-D, CEE-N, or placebo was performed in a 
ratio of 3:2:2 using a computerized allocation algOrithm. The first part of the study 
comprised six consecutive cycles of 28 days, after which the blind was broken and the 
trial was continued as an open trial for another 18 months for the 17PE-D and CEE-N 
groups. All pal1icipants, including those in the placebo group, were invited for a final 
ultrasound examination at 24 months (cycle 24). Arterial characteristics Were measured 
non-invasively at day of randomization and after 24 months (cycle 24). 
At baseline, information was obtained about smoking. Body weight and body 
height were measured and body mass index was calculated. Blood pressure was meas-
tIred twice, separated by a pulse count, at the right upper ann in sitting position using 
a Hawksley random-zero sphygmomanometer. Fasting blood samples were obtained 
between 8.00 and 10.00 a.m. Cholesterol and triglycerides were assayed enzymatically 
with a Hitachi 747 automated analyzer with kits from Boeringher Mannheim. HDL-
cholesterol was measured after precipitation with phosphowolfram/phosphotungstic 
acid and 2 mmol of manganese chloride per liter. The LDL-cholesterol concentration 
was calculated with the Friedewald fonnula. 23 
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Figure 1 
A characteristic longitudinal ultrasound image of the distal coml11on carotid artery, on which 
the interfaces are marked over a length of 10 111111. 
Measurement of arterial characteristics: Intima-media thickness 
To measure carotid intima-media thickness, ultrasonography of the right common ca-
rotid aJtelY and carotid bifurcation was performed with a 7.5 l\1Hz linear array trans-
ducer (An UltraMark IV). On a longitudinal 2-dimensional ultrasound image of the 
carotid artery, the anterior (near) and posterior (far) wall of the carotid artery are dis-
played as two bright 'white lines separated by a hypo-echogenic space. The distance of 
the leading edge of the first bright line of the far wall (lumen-intima interface) and the 
leading edge of the second bright line (media-adventitia interface) indicates the intima-
media thickness. For the near wall, the distance between the trailing edge of the first 
bright line to the trailing edge of the second bright line at the near wall provides the 
best estimate of the near wall intima-media thickness. The distance between the lead-
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ing edge of the second bright line (intima-lumen interface) on the near wall and the 
lumen-intima interface at the far wall reflects the lumen diameter (figure 1). 
Following the ultrasound protocoI 14,16,18, a careful search was performed for all 
interfaces of the near and far wall of the distal common carotid artelY. \Vhen an opti-
mal longitudinal image was obtained, it was frozen on the R wave of the electrocardio-
gram and stored on video tape. This procedure was repeated three times. The actual 
measurements of intima-media thickness were performed off-line. From the videotape, 
the frozen images were digitized and displayed on the screen of a personal computer 
using additional dedicated software. This procedure has been described in detail pre-
viously.24 In short, with a cursor the interfaces of the distal common carotid artery 
were marked over a length of 10 mm. The beginning of the dilatation of the distal 
conU11on carotid altery served as a reference point for the stalt of the measurement. 
The average of the intima-media thickness and lumen diameter of each of the three 
frozen images was calculated. For each individual a common carotid intima-media 
thickness was determined as the average of near and far wall measurements of the 
right artety. The reader of the ultrasound images from videotape was unaware of the 
intelvention status of the subject. Results from a reproducibility study of intima-media 
thickness measurements have been published elsewhere.25 
Data analysis 
Data are presented by treatment group. Analyses were performed using those subjects 
of which information on intima-media thickness at baseline and 24 cycles was present. 
In this analysis the individual change in C01111110n carotid intima-media thickness at cy-
cle 24 from baseline was calculated. Two dummy variables were constructed: the first 
dummy with placebo (value 0), 17PE-D (value 1) and CEE-N (value 0); and the second 
dummy with placebo (value 0) 17PE-D (value 0) and CEE-N (value 1). A linear regres-
sion analysis with change in intima-media thickness as dependent variable and the two 
dummy variables as independent variable was used to study whether the change in 
intima-media thickness from baseline differed across the treatment groups. Results are 
presented as mean differences in change in intima-media thickness with corresponding 
95%) confidence interval. Analyses were performed with and without adjustment for 
values of baseline intima-media thickness. Since the findings in both analyses were 
similar, only results of the first approach is presented. In a similar way analyses were 
performed to study whether change in lurnen diameter from baseline differed across 
the treatment groups. 
The a priori sample size calculation for the present trial showed that with 52 sub-
jects in the 17PE-D group, a standard deviation of measurement of progression of in-
tima-media thickness of 0.07 mm, a two-sided alpha of 0.05 and a power of 80%, a 
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two-year difference in progression rate between 17PE-D and placebo of 0.047 nun 
could be detected. 
RESULTS 
One hundred and twenty one perirnenopausal subjects were randomized. Fifty two 
subjects received 17PE-D, 34 CEE-N and 35 placebo. TI,e general characteristics of the 
study groups are presented in table 1. Most cardiovascular risk factors were well bal-
anced between the three groups and at baseline there were no rnajcr differences in 
common carotid intima media thickness and end-diastolic lumen diameter between the 
three study groups. Current smoking was more conUllon in the CEE-N group compared 
to the 17PE-D and the placebo group (table I). Mean time since last menstIuation was 
3 months (range 1 -11) in the perimenopausal women, and was similar in the three 
study groups, Thirteen of the 121 women were postrnenopausal, defined as cessation 
of menses for more than one year. 
The baseline characteristics of women who completed 24 cycles and of whom 
ultrasound data were available were compared to women who withdraw or had miss-
ing ultrasound data (table 2). No statistically significant differences in cardiovascular 
risk factors were found between these two groups of women. 
Table 1 
General characteristics of the study population. 
17PE-D CEE-N Placebo 
(n ~ 52) (n~34) (n ~35) 
Age (years) 46.9 (4.0) 47.5 (3.9) 47.2 (4.1) 
Body Mass Index (kglm') 23.4 (2.8) 23.9 (2.9) 23.7 (2.9) 
Systolic blood pressure (mmHg) 111.8 (12.4) 112.5 (14.8) 115.9 (15.6) 
Diastolic blood pressure (mmHg) 73.3 (8.1) 73.4 (9.7) 74.6 (10.8) 
Total Cholesterol (01010111) 5.7 (1.0) 5.8 (0.9) 5.9 (0.9) 
LDL Cholesterol (mmolll) 3.7 (0.9) 3.8 (0.8) 3.9 (0.8) 
HDL Cholesterol (010101/1) 1.5 (0.3) 1.4 (0.3) 1.5 (0.3) 
Current Smoking 13.5% 32.4% 20.0% 
Intima media thickness (mm) 0.62 (0.077) 0.62 (0.077) 0.62 (0.077) 
Lumen diameter (mm) 5.62 (0.50) 5.65 (0.44) 5.78 (0.64) 
Values are proportions or means with standard deviation in parentheses. 
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After 6 cycles) 5 women decided not to enter the second palt of the study: 4 (10%) 
in the 17~E-D group and 1 (4%) in the CEE-N group. Between cycle 6 and cycle 24, 8 
women (22%) in the 17~E-D group and 4 (16%) in the CEE-N group discontinued 
medication. Twenty-nine (56%) women in the 17PE-D group and 21 (62%) in the CEE-
N group completed the study. Of the women that had been randomized to the placebo 
group) 22 out of 31 who completed the sL"'( months were willing to visit the research 
center for the cycle 24 visit. From the subjects who completed the study ultrasound 
data were available for 24 women in the 17PE-D group; 17 women in the CEE-N group 
and 21 subjects in the placebo group. 
Change in intima-media thickness 
The mean change of intima media thickness was an increase of 0.0088 mm (SD 0.058) 
in the placebo-group; a decrease of 0.0071 nun (SD 0.062) in the CEE-N group and a 
decrease of 0.0014 mm (SD 0.064) in the 17PE-D group. Results of comparison of the 
effects of 17pE-D) CEE-N and placebo on change in intima-media thickness are given 
in"table 3. The results are adjusted for baseline value of intima-media thickness. Rela-
tive to placebo changes in intima-media thickness were -0.009 [95% CI -0.045; 0.027) 
for 17PE-D and -0.016 [95% CI -0.055; 0.024) for CEE-N . 
Table 2 
Baseline characteristics of women who completed the study and of whom ultrasound-data 
are available and those who had wHhdrawn or had missing ultrasound data. 
withdrawn or missing data completed study and 
ultrasound measurements 
17PE-D CEE-N Placebo 17PE-D CEE-N Placebo 
Number 28 17 14 24 17 21 
Age (years) 47.7 47.1 48.8 46.0 47.9 46.1 
Body mass index (kg/m') 23.0 24.2 23.3 23.9 23.7 24.0 
Systolic pressure (mmHg) 114 113 11 7 109 112 115 
Diastolic pressure (mmHg) 75 75 75 71 72 74 
Total cholesterol (0101011/) 5.6 5.8 6.1 5.7 5.8 5.8 
LDL (mmolll) 3.64 3.71 4.05 3.66 3.85 3.83 
HDL (mmoll/) 1.51 1.42 1.46 1.55 1.32 1.45 
Current smoking 7% 35% 7% 21% 29% 29% 
Intima media thickness (mOl) 0.632 0.635 0.630 0.602 0.610 0.612 
Lumen diameter (0101) 5.70 5.74 5.65 5.59 5.57 5.86 
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Table 3 
Difference in change in intima-media thickness (lMT, in mm) and end diastolic lumen 
diameter (in mm) between active treatment groups and placebo at cycle 24, adjusted for 
baseline-value of intima media thickness or lumen diameter, respectively. 
Change in IMT 
Change in lumen 
diameter 
17PE-D vs placebo 
-0.009 (-0.045; 0.027) 
-0.091 (-0.236; 0.055) 
CEE-N vs placebo 
-0.016 (-0.055; 0.024) 
-0.125 (-0.282; 0.032) 
17PE-D + CEE-N 
vs placebo 
-0.012 (-0.044; 0.020) 
-0.105 (-0.235; 0.025) 
Values are linear regression coefficients with 95% confidence intervals in parentheses. 
Change in end-diastolic lumen diameter 
TI,e mean change of end-diastolic lumen diameter was an increase of 0.0897 mm (SD 
0.229) in the placebo-group; a decrease of 0.0063 nUll (SD 0.261) in the CEE-N group 
and an increase of 0.0259 nUll (SD 0.243) in the 1711E-D group. Results of the compari-
son of the effects of 1711E-D, CEE-N and placebo on change in end-diastolic lumen di-
ameter are given in table 3. The results are adjusted for baseline value of lumen di-
ameter. The changes were -0.091null [950;;, CI -0.236; 0.055J in the 1711E-D group and -
0.125 mm [95%CI -0.282; 0.032J in the CEE-N group compared to placebo. 
Adverse events 
During the first 6 cycles the number of subjects that discontinued drug treatment was 
23; 11 (21.2%) in the 1711E-D group, 8 (23.5%) in tbe CEE-N group and 4 (11.4%) in the 
placebo group. Ninety-sLx women had at least one adverse experience during this pe-
riod: 42 subjects in the 1711E-D group (80.8%), 29 in the CEE-N group (85.3%) and 25 in 
tbe placebo group (71.4%). 
During the study, the occurrence of unacceptable adverse experiences was the 
main reason for withdrawal from the study. The type and severity of the adverse expe-
riences obselved were consistent with those sometimes seen with this type of therapy, 
such as headache, depreSSive feelings, abdominal pain and nausea. 
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DISCUSSION 
In the present study among perimenopausal women a significant effect on change in 
intima-media thickness and end-diastolic lumen diameter of 17PE-D and CEE-N com-
pared to placebo could not be demonstrated. Although the estimates of the effects 
were in a favorable direction, Le. reduced progression of intima-media thickness and 
smaller end-diastolic lumen diameter, the 95% confidence limits were wide. 
Before interpreting the data, some issues need to be addressed. The percentage of 
women that withdrew at cycle 6 (19°;<)) is not unusual for this type of study. However, 
at the end of the study it was possible to evaluate only 52% of the randomized women, 
because of subsequent withdrawal in the hormone-treated groups, loss to follow up in 
the placebo-group and missing ultrasound data in all three groups. Compliance, as as-
sessed by tablet count and dialY checks, was satisfactOlY in all three' groups with a 
mean compliance rate of more than 97% in the first 6 cycles. The dropout rate may 
have affected the randomization process, Le., resulting in incomparability in prognosis 
of the three groups. \Vomen who completed the study had on average lower, although 
not statistical significant, levels of baseline cardiovascular risk factors and intima-media 
thickness than women who had withdrawn. This may have resulted in a lower progres-
sion rate of intima-media thickness in all three treatment groups. Also, the mean levels 
of some cardiovascular risk factors in women who had withdrawn in the placebo 
group were slightly higher than those in women who had withdrawn in one of the two 
active treatment groups. Furthermore, a high withdrawal rate has an unfavorable effect 
on the precision of the estimates on change in intima-media thickness and lumen di~ 
ameter and consequently on the ability to obselve differences across groups. Secondly, 
in the study the blind was broken after 6 cycles and the trial continued for 18 cycles as 
an open trial. In contrast to the treatment group, the placebo-group was not subjected 
to follow-up between cycle 6 and cycle 24. Therefore possible differences in healthy 
behavior could lead to an overestimation of the effects of hormone replacement ther~ 
apy on intima media thickness. 
Observational studies have demonstrated that estrogen replacement therapy is 
associated with a 40-50% reduction in cardiovascular disease risk in postmenopausal 
women,2,3 Posntlated mechanisms for a beneficial effect include favorable changes in 
LDL and HDL levels, in carbohydrate metabolism27, in endothelial function5,6 and in 
haemostatic parameters. 28 Unopposed estrogen is not suitable for long-term lise due to 
the higher incidence of endometrial hyperplasia and endometrial cancer.29 Therefore} 
treatment with combined estrogen and progestin is usually given. It has been sug-
gested that the beneficial effect of estrogen is reduced by the addition of progestins. 
Recently the results were presented of the first trial on the effects of combined hor-
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rnone replacement therapy on cardiovascular endpoints (HERS),3o After four years of 
treatment the relative risk of cardiovascular disease in hormone replacenlent therapy 
users was one compared to non llSerSj although there was a trend in the last two years 
of the study of a decreasing risk in the active treatment group. This trial was conducted 
in postmenopausal women with coronary heart disease and therefore the results could 
not automatically be generalized to healthy women. 
Several obsclvational studies examined the relation between hormone replace-
ment therapy and intima media thickness. In a cross-sectional analysis the vessel wall 
characteristics of elderly women using estrogen and progestin were similar to those of 
women using estrogens alone. Both groups had a reduced intima-media thickness of 
the internal and common carotid artelY compared to never users.9 Results from the 
Asymptomatic Carotid Atherosclerosis Progression Study (ACAPS) among 186 post-
menopausal women suggested that hormone replacement therapy might decrease pro-
gression of atherosclerosis, as measured by carotid intima-media thickness.8 The inves-
tigators showed a reduction in the annual progression of carotid intima-media thick-
ness among hormone replacement therapy users compared to non-users. Until now, 
the studies evaluating the effects of hormone replacement therapy on intima media 
thickness all have an observational design in which the effect of "the healthy estrogen 
user" may have led to biased estimates. Most of these studies focus on postmenopausal 
women using hormone replacement therapy. In the Netherlands most hormone re-
placement therapy users are perimenopausal. Therefore it is of interest and of practical 
importance to evaluate the effects of hormone replacement therapy on intima media 
thickness in peri menopausal women in a controlled randomized trial. Although not 
statistically Significant, the estimates of the hormonal effect in the present trial are in 
agreement with the findings from most observational studies in postmenopausal 
women, despite of possible variable endogenous estrogen levels in perimenopausal 
women. 
Our finding that treatment may have a favorable effect on end-diastolic lumen di-
ameter, Le., a diameter reduction, is intriguing. In the present study, B-mode images 
are frozen on the R-wave of the ECG, thereby generating images of the carotid altery at 
end-diastole. As such, the size of the lumen diameter may be regarded as an indicator 
of arterial stiffness: the stiffer the artery, the larger the lumen diameter at end-diastole. 
In an earlier study we showed that a larger end-diastolic lumen diameter was associ-
ated with presence of isolated systolic hypertension 17) a condition predominantly char-
acterized by stiffness of the large arteries. The results of the present study are in 
agreement with the studies suggesting a beneficial role of combined hormone re-
placement therapy on alterial stiffness,32,33 
In conclUSion, in the present experimental study among perimenopausal women 
a significant effect of 17PE-D and CEE-N on common carotid intima-media thickness 
and lmnen diameter could not be demonstrated. Although the sample size of the pres-
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ent trial is too limited to provide definite conclusions, the direction of the obselved 
effects is in agreement with evidence from earlier studies on the effects of honnone 
replacement therapy in postmenopausal women. Therefore perimenopausal women 
possibly benefit from the effects of honnone replacement therapy on the intima media 
thickness in the carotid <lIter)' which could lead to a decrease in their cardiovascular 
disease risk. 
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General discussion I 
his thesis describes the effects of two specific detem1inants of cardiovascular 
disease in women in the general population. On the one hand it describes the 
associations of menopause and the decrease in estrogen levels that accompa-
nies it, with cardiovascular disease. On the other hand it examines the effects 
of replacement of estrogen. In this chapter the main findings of our and other studies 
will be summarised. The shortcomings and merits of the individual studies presented in 
this thesis have been discussed in the previous chapters, but several specific meth-
odological aspects of studies on this topic will be discussed. Possible clinical implica-
tions will be discussed. Finally, recommendations for future research will be made. 
BACKGROUND 
Cardiovascular diseases are the major cause of death in men and women alike. Based 
solely on the demographic evolution, it is predicted that the proportion of elderly peo-
ple in our country as well as in most \'?estern countries, will increase in the coming 
years. As the ageing of the population is more pronounced in women than in men, the 
absolute number of deaths from cardiovascular disease in women is bound to increase. 
Cardiovascular disease is generally considered a disease of men. One reason for this is 
the low incidence of the disease in women at young age. At older age, however, car-
diovascular disease also becomes the most important cause of mortality for women. In 
the 1950's it was suggested that estrogen is an impOltant mediator of a woman's risk of 
cardiovascular disease. It was noticed that coronalY heart disease is rare in young 
women and increases only after middle age, and that this might be ascribed to the de-
creaSing estrogen levels after menopause. An increased risk of coronalY heart disease 
was found in young women who had both ovaries removed. Although the assumption 
that the lower incidence of cardiovascular disease among older women is due to 
menopause is long and widely held) it is still debated.1-3 Data 011 the association be-
tween menopause and cardiovascular disease are conflicting. Several studies have 
shown an inverse association between age at natural menopause and risk of cardiovas-
cular disease 4-10, but others did not.1 1-15 This inconsistency might be the result of a 
methodological problem; a lag time of at least 10 years between menopause and the 
occurrence of coronalY healt disease in women makes the effect of rnenopause diffi-
cult to disentangle from that of age. 
Hormone replacement therapy might offer possibilities for prevention. On the 
other hand, it may increase the risk of endometrial hyperplasia and cancer16,17, breast 
cancer18, venous thromboembolic events19,20 and gallbladder disease,16,20 As coronalY 
hean disease is the most common and most deadly disease of women, any significant 
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reduction in coronary hean disease risk due to hormone replacement therapy would 
strongly affect the benefit-risk scale of this therapy. 
The first randomised trial of estrogen and heart disease was performed in the 
1960s, in men. Men with heart disease were prescribed 2.5 mg or 5 mg of conjugated 
estrogen daily, which is much higher than the dose commonly used in women today. 
The estrogen arm of the trial was stopped early as treated men were observed to have 
an increased rate of thromboembolic events, myocardial infarction and cancer (as well 
as gynecomastia and impotence). It is now thought that the high doses of estrogen may 
have been responsible for this effect, or that men and women might respond differ-
ently to estrogen therapy. Observational evidence from the last 20 years suggests that 
hormone replacement therapy reduces morbidity and 111011ality from cardiovascular 
disease in healthy postmenopausal women. It has been demonstrated that estrogen 
replacement therapy raises HOI. and lowers LDL cholesterol levels in men and women, 
and that estrogen therapy decreases diet-induced atherosclerosis in primates. Although, 
the mechanisms underlying the protective effect of estrogen are not fully known, these 
findings suggested that the correction of the low levels of estrogen after menopause 
might prevent disease. Only recently the nex't randomised trial with clinical outcomes 
was conducted, this time in women (the Heart and Estrogen/progestin Replacement 
Study, HERS 20). 
Insight in the associations between estrogens and cardiovascular disease in 
women might shed light on the aetiology of cardiovascular disease, and on possibilities 
for prevention and treatment. 
MENOPAUSE 
Main Findings 
Mellopause a1/d riskjactors jor cardiovascular disease 
The mechanisms through which menopause might exert its effect on the cardiovascular 
system remain largely unknown. Increased levels of serum total cholesterol after cessa-
tion of menses have been found in most studies on menopause and risk factors.21-33 
Inconsistent results, however, have been repOlted with respect to HDL-cholesterol 25-
27,29-31,34, apolipoproteins 24,25,29,33-35, blood pressure 2t-23,25,26,31,36-39, waist-to-hip 
ratio 40,41 and insulin. 42-44 \Vhen comparing cardiovascular risk factors between pre-
and postmenopausal women (see chapter 2.1) we found that total cholesterol, LDL 
cholesterol and a polipoprotein B are the primaly cardiovascular risk factors affected by 
Illenopause. No differences between pre- and postmenopausal wornen were found in 
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high density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein Ai, blood glu-
cose, insulin, body mass index, waist-to-hip ratio, and systolic and diastolic blood pres-
sure. Because increased cholesterol levels were established soon after cessation of 
menses, preventive measures aimed at reduction of cholesterol in women might best 
be initiated in early menopause. lv1any other risk factors are thought to relate to meno-
pausal status. Haemostatic factors, homocysteine metabolism, endothelial function, 
glucose metabolism and inflammatolY markers all seenl to playa role in atherosclerosis 
and cardiovascular disease. Data on relations to menopause are sparse, however, and 
their specific role in atherogenesis after menopause needs to be investigated. 
Besides effects on risk factors, recent studies have increasingly emphasised the 
direct beneficial effects of estrogens on the alterial wall. Although several studies have 
shown that estrogen replacement has beneficial effects on arterial characteristics, the 
effect of endogenous estrogen on the vascular system is still unknown. Few studies 
have addressed the effects of endogenous estrogens and nahual menopause on the 
dynamic characteristics of the arterial system. Although no changes in distensibility 
were found during the menstrual cycle45, going through menopause has been shown 
to negatively affect the elastic propelties of the aortic root in hypertensive women.46 
\Y,fe studied the relation between nahlfal menopause and arterial distensibility in the 
common carotid altery, comparing pre- and postmenopausal women. The results of 
our study suggest that the distensibility of the common carotid altery is negatively af-
fected by natural menopause in healthy women (chapter 2.2). \';rhether loss of disten-
sibility is an early marker for asymptomatic atherosclerotic changes or whether it re-
flects other stnlctural changes of the alterial wall is still a matter of debate.47-50 Loss of 
distensibility in elastic alteries has been shown to be associated with an increased risk 
of cardiovascular disease in cross-sectional studies.51.52 If abnormal alterial characteris-
tics occur before clinical manifestation of disease are apparent, this could be important 
for identifying patients at risk. Longihldinal data on the effect of decreased distensibil-
ity on cardiovascular morbidity or mOitality are, however, still awaited. 
Mellopause alld atiJerosclerosis 
A change in incidence in coronaty heart disease will not be seen iHunediately after 
menopause but probably only 10 to 20 years later, by which time the effects of meno-
pause are difficult to distinguish from the effects of ageing. As one of the main mecha-
nisms through which menopause is thought to exert its effect on the cardiovascular 
system is the inhibition of the atherosclerotic process, and atherosclerosis is present 
long before symptomatic coronary heart disease develops, studying the association 
with atherosclerosis might be a sensible approach to study the role of menopause. In 
chapter 2.3 we studied the effect of age at menopause on development of non-inva-
sively measured atherosclerosis. Our study population consisted of women between 55 
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and 106 years old, which allowed assessment of the associations in women long after 
menopause. Age at natural menopause was significantly and inversely related to the 
risk of atherosclerosis in different vessel beds and with myocardial infarction. Analyses 
were repeated after stratification for smoking habits. Although risk of early natural 
menopause with aortic atherosclerosis disappeared in women who had never smoked, 
and risk of peripheral alteriai disease decreased, loosing statistical significance, the as-
sociations of early artificial menopause with these two measures of atherosclerosis re-
mained. Also the association between early natural menopause and the other measures 
of atherosclerosis remained among never smokers. These result.s suggest an association 
is present between a decrease in estrogen levels and atherosclerosis, independent of 
smoking. Early bilateral oophorectomy, but not hysterectomy alone or hysterectorny 
with unilateral oophorectomy, was associated with an increased risk of atherosclerosis 
at different vessel beds and with myocardial infarction. Several studies have found the 
risk of cardiovascular disease to be increased in women after hysterectomy independ-
ently of oophorectomy. It has been hypothesised that hysterectomy increases risk of 
cardiovascular disease by compromising blood flow to thc ovaries affecting their func-
tion, or through a hormonal or other secretory function of the uterus. 53-58 The results 
from our study, where self-reported gynecological operations were verified with pa-
tient records, thus rninimising errors in classification, imply ovarian function is the key 
factor. nle results support the hypothesis that endogenous estrogens protect women 
from developing atherosclerosis, and that increased atherogenesis might be one 
mechanism mediating the observed epidemiological link between menopause and car-
diovascular disease. The results further suggest that the moment of cessation of ovarian 
estrogen production may have consequences for the cardiovascular system well into 
high age. The extent to which hormone replacement therapy in the early postmeno-
pausal phase may postpone or delay the development of atherosclerosis needs to be 
determined. 
Mellopause and cardiovascular disease 
Mean age at menopause seems to have remained constant over the last 100 years. If no 
cohort effect is present for age at menopausc, we should be able to use vital statistics 
to see whether an increase in coronary heart disease incidence exists after menopause, 
A semi-logarithmic plot of coronalY heart disease mortality rates by age does not show 
an increased acceleration in women after the age of 50, that is, there is no inflection at 
the age of menopause (figure 1), This in contrast to the pattern in breast cancer, which 
is a strongly estrogen dependent disease, and which clearly decreases after meno-
pause. This argument is often used to argue that menopause does not affect the risk of 
coronalY heart disease, and that the increase in risk of coronary heart disease in 
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Semi-logarithmic plot of age-
specific death rates versus 
age, in women in 1962, USA 
(after R.E. Tracy, J Chron Dis 
1966) 
women after middle age is merely an effect of ageing. But perhaps, this approach is 
not justified for examining the effect of menopause. 
Firstly, an increased acceleration of coronaty heart disease mortality rates at or 
after the age of menopause implies that the relative risk associated with menopause 
continuously increases with age, which is not seen for any other coronary healt disease 
risk factor, including hypeltension and smoking. Secondly, since the acceleration of 
coronalY heart disease mOltality rates declines with age in men, it is not likely to find 
an increased acceleration in women, even when menopause elevates the risk. To 
iHustrate the effect of menopause under more realistic assumptions, we conducted a 
simulation study. \Ve used mOltality rates of UK men 2, the Framingham risk ['unction 
59 and estimates of relative risks at young ages from the MRFIT Study 60, to constluct a 
graph of coronalY heart disease mOltality rates in men in the first decile of the 
Framingham risk score to represent wornen premenopausal until the end of life. 111e 
CUIve was gently smoothed (figure 2). Based on estimates of the effect of age at 
menopause9, we assumed menopause to enhance coronary heart disease mOltality 
with 20, 60 and 100% at ages 50-54, 55-59 and 60-69 years, respectively, taking into 
account variation in menopausal age and a lag-time. \'{Ie assumed the menopause-
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The lower curve gives mortality rates in women staying premenopausal until the end of life. The 
upper curve gives mortality rates when an effect of menopause is imposed on the curve reflecting 
the life-long premenopausal state. 
related risk to decrease gradually thereafter until no excess risk at age 85-89. The upper 
curve in the figure represents the curve when an effect of menopause is imposed upon 
the curve reflecting the lifelong premenopausal state. The thus constructed curve does 
not show an inflection around the age of menopause and is comparable in shape to 
that of UK women. 2 Although we will probably never know the true effect of meno-
pause, and cannot be certain that our assumptions are correct, our data suggest that the 
observed coronary heart disease m011ality pattern in women in the population is not 
incompatible with an effect of menopause. 
Methodological considerations for studies on menopause 
Desigll 
In a cross-sectional sntdy, the exposure and outcome variables are measured at the 
same point in time. This generally complicates interpretation of study results in terms 
of a cause-effect relation, Our study in chapter 2.3, however, although exposure 
(menopause) and outcome (atherosclerosis and coronary healt disease) were meas-
ured at the same moment, is conceptually a follow-up study. Since we studied only 
postrnenopausal women, it is clear that menopause preceded the measurement of ath-
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erosclerosis. A hist01Y of coronaty heatt disease was verified using medical record from 
general practitioners and ECG diagnoses, and it was shown that 97% of detected in-
farctions had occurred after menopause.61 Although we cannot know when silent 
myocardial infarctions have occurred, only a very small percentage is thus expected to 
have occurred before menopause. \Vhereas a velY long follow-up time would have 
been necessalY to asses effects of menopause in a prospective follow-up study, this 
design, in which menopause was assessed in retrospect and data were verified with the 
general practitioners records, enabled us to study women long after menopause. A se-
lective survival which might have occurred if women with early menopause would 
have died more often of atherosclerotic complications before the start of our study, 
will, if anything, have given an underestimation of the effect. 
In studies on effects of menopause on cardiovascular disease several other meth-
ods can be used. One method is to follow women from premenopausal state, through 
menopause, into the postmenopausal phase. In this design it is necessalY to have a 
control group of premenopausal warnen of the same age, that does not become post-
menopausal during the study period. Such sUlClies in a restricted age range around the 
menopause will include mostly perimenopausal women, women with irregular menses 
and recent postmenopausal women, which reduces the contrast in estrogen status. 
\"'{lith this design either a long follow-up time or a large group of women is necessaly. 
Another method could be to compare pre and postmenopausal women. In this design 
inevitably an age-difference between the groups will endanger comparability. Snldies 
that include women in a broad age range may not be able to validly rerl.love the con-
founding effect of age. In our study, we examined the effects of natural menopause in 
a selected population in which the contrast in estrogen staniS between pre- and post-
menopausal women of the same age was maximised, which enabled us to efficiently 
study djfferences associated with menopausal status (chapter 2.1 and 2.2). 
E,poslIl'e assessmellt - Mellopallse 
The onset of menopause is defined as the age at which a woman's last menstruation 
takes place. In fact, however, menopause is not an acute event, but a process of about 
10 years in which the ovaries slO"wly decrease their function (a process called "shutting 
down")' The exact moment when menstruation ceases is the rnoment when estrogen 
levels decrease below the level necessary to stimulate the endometrium, and in epide-
miological studies it is this moment which is used as a proxy for onset of menopause. 
A difficulty in the assessment of age at menopause is that a menstruation can be taken 
as the last menstruation only in retrospect. Recalling this age can thus pose a problem. 
However, early or late menopause, being special events, are recalled better than 'aver-
age' menopause62 which reduces the risk of misclassification of e:A'tremes. 
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Misclassification of exposure can obscure a true association. Non-differential error 
can lead to a false negative finding (a type II error), Differential error may arise when 
women with more atherosclerosis would have reported bilateral oophorectomy more 
often than women with less atherosclerosis, which we do not assume to be likely. If 
this type of misclassification has occurred, this would have given an underestimation of 
the true effect. In our study (chapter 2.3), self-reported gynecological operations were 
verified with patient records, in order to minimise errors in classification. 
Outcome assessmellt- subclillical atherosclerosis 
Traditionally, epidemiologists have studied cardiovascular disease by examination of 
the relation between potential risk factors and the presence or occurrence of cardio-
vascular events. Yet, the use of the discrete event as a study outcome has two disad-
vantages. The first is that cardiovascular events result from a combination of processes, 
which makes understanding of the aetiology djfficult. The second is that the events 
reflect a near end-stage of the disease, which prohibits the study of risk factor effects at 
earlier stages of the disease. The study of determinants of underlying processes will 
enhance understanding of the aetiology. As atherosclerosis is present long before 
symptomatic coronary heatt disease develops, it is an interesting approach to study the 
role of menopause by studying its association with atherosclerosis. 
To study atherosclerosis non-invasively in asymptomatic, non-hospitalised sub-
jects it is necessary to rely on vessel beds other than the coronary and cerebral arteries. 
Atherosclerosis in these vessel beds needs to represent a generalised process, In this 
thesis aOltic calcification, carotid atherosclerosis and atherosclerosis in the alteries of 
the lower extremities were used as measures of atherosclerosis, and assumed to be a 
prox')' for generalised atherosclerosis. Radiographically assessed aortic atherosclerosis, 
ultrasonographically assessed carotid plaques and the ankle-arm systolic blood pres-
sure index have all been shown to be accurate non-invasive methods of measuring 
atherosclerosis. A series of studies have demonstrated their associations with cardio-
vascular risk factors) atherosclerosis at other sites of the vessel bed) and cardiovascular 
morbidity and m0!1aliry63-72 
Outcome assessmelli- Mecballical arterial properties 
Pathofysiologic changes in the blood vessels are associated with a wide variety of car-
diovascular events, but our ability to assess vascular function is limited. Imaging tech-
niques provide information regarding intirnal pathology, but they provide little infor-
mation about the functional propelties of the arterial wall. Recently several new meth-
ods have been developed to non-invasively assess mechanical propelties of arteries in 
humans, Various parameters are in use to characterise these propelties. Parameters 
conunonly used are distensibility and compliance) defined as the relative (~-diameter / 
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end-diastolic diameter) and absolute (A V) change in atterial volume for a change in 
pressure (L\P). Although with the use of these parameters valuable information can be 
obtained about changes in altery wall propelties, it should be realised that the methods 
presently in use still have their limitations. For calculation of altcrial distensibility, not 
only local distension of the artery, but also pulse pressure at the site of measurement is 
needed. This is approximated by pulse pressure measured in the brachial altely, as 
discussed in chapter 2.2. 
COl/folil/di1lg al/d mediati1lgfactors 
It has been suggested that early menopause can be seen as a marker for prernature 
ageing. If this were the case, ovarian failure and the development of cardiovascular 
disease could both be the result of the premature ageing process in these women, and 
not necessarily cause and effect. \Ve do not believe this is the case as the results of our 
studies in chapter 2.1 show that lipid levels differ between pre- and postmenopausal 
women, but do not increase with time since rnenopause (figure 2, chapter 2.1, page 
14). 'I11e hypothesis would also involve that other risk factors known to increase with 
ageing, like blood pressure and glucose levels, should have differed between pre- and 
postmenopausal women, which was not obselved in our study. 
Theoretically, other factors like socio-economic status, parity or genetic factors 
related to early menopause can confound or modify the studied associations. Although 
some of the mentioned confounders are known to increase lipid levels, the effects on 
cardiovascular disease of these factors repOited in the literature do not seem to be large 
enough to explain the difference found in our study. Knowledge on genetic factors in 
coronalY heart disease is limited. Evidence that genetic factors are related to age at 
menopause has been obselved previously in family and twin studies,73-75, but the 
genes involved remain ill defined. Until now, only a limited number of genes have 
been studied in the association with the onset of menopause,76,77 In a recent study, it 
was shown that a common allelic variation in the estrogen-receptor gene is associated 
with age at menopause as well as hysterectomy,78 This receptor also mediates the acti-
vation of the LDL-receptor in the liver. Possibly, the increase of cholesterol with meno-
pause is modified by polymorphisms in the estrogen receptor, or by other polymor-
phisms like the apolipoprotein-E gene. 
Cigarette smoking is likely to be a serious confounder. Smoking is strongly related 
to early menopause and increases the risk of atherosclerosis. As some misclassification 
in smoking habits is inevitable when using intelview data, adjustment for smoking 
might not suffice and residual confounding can only be excluded by examining asso-
ciations in never smokers only. In a recently published repOit form the Nurses' Health 
Study, the association between younger age at menopause and higher risk of coronary 
heart disease was found to be present among current and past smokers, but not among 
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never smokers, which suggests residual confounding by smoking,79 However) this ob-
servation was based on only a small number of cases, In our study in chapter 2.3 the 
risk of aonie atherosclerosis with early natural menopause virtually disappeared among 
never smokers oniy, and the association for atherosclerosis in the peripheral atteries 
decreased, loosing statistical significance. This could indeed indicate residual con-
founding by smoking, but as smoking has been found to reduce endogenous estrogen 
levels, one cannot exclude the possibility of effect modification. We found the associa-
tions of early natural menopause with carotid atherosclerosis and with two compound 
scores of atherosclerosis remained vittually unchanged among never smokers. Fur-
thennore, point estimates for the associations between al1ificial menopause and all 
measures of atherosclerosis remained unchanged in never smokers. Thus, our results 
do suggest the presence of an association between age at menopause and the risk of 
atherosclerosis, independent of smoking . 
. Many studies did not examine the associations by smoking status. Stratified analy-
sis in these and future studies would increase their validity. 
HORMONE REPLACEMENT THERAPY 
Main Findings 
Hormolle replacemellt tberapy alld atberosclerosis 
Obselvational evidence suggests that hormone replacement therapy reduces morbidity 
and mortality from cardiovascular disease in healthy postmenopausal women. 16.80,81 
The mechanisms underlying this protection are not entirely clear, but may include in-
hibition of the atherosclerotic process. \"'{fe investigated the association between ever 
use of hormone replacement therapy and the presence of atherosclerosis in the arteries 
of the lower e)"'1remities and in the carotid arteries in wornen from the Rotterdam Study. 
Although randolnised trials arc indispensable to determine to what extent the findings 
from observational studies are biased by confounding, our obselvational study in 
women aged 55 to 80, showed that the level of atherosclerosis was lower in past users 
compared to never users. This suggests that the advantage of women who have used 
hormone replacement therapy remains present after discontinuation of therapy. 
Obselvational studies have found hormone replacement therapy reduces cardio-
vascular morbidity and mOllality by as much as 40 %, Many studies have tried reducing 
selection bias by adjusting for confounding variables in the analyses, Many large stud-
ies, however, did not have information on important factors, like smoking, socio-eco-
nomic status or usc of other medication. Other shldies assumed to have reduced selcc-
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tion bias by restricting the study population, for example to a single socio-economic 
class (the Nurses Health Study). Still, in most studies selection bias can not be ex-
cluded. Only one large randomised trial has been conducted on the effect of hormone 
replacement therapy on cardiovascular disease in women (HERS). This was a secon-
dary prevention trial among 2763 postmenopausal women with known heart disease 
(and an intact uterus) who were randomly assigned to daily conjugated equine estro-
gen plus medroA'yprogesteron acetate therapy or placebo. The trial showed no favour-
able effect of hormone replacement therapy on the prevention of further cardiovascu-
lar disease after 4.1 years of follow-up, and an increased risk of gall-bladder disease 
ancl venous thromboembolic disease.2o nlese results might indicate that the bias in 
observational studies is larger than thought until now. On the other hand, in the trial an 
increased risk for coronary hean disease events was found in the first year of the trial, 
while risk decreased in subsequent years. This time-trend should be interpreted with 
caution, but can be explained as being attributable to an immediate prothrombotic, 
proarrythmic or pro ischemic effect of treatment that is gradually outweighed by a 
beneficial effect on the underlying progression of atherosclerosis. Thus, the results of 
the HERS-trial SUppOlt the hypothesis that hormone replacement therapy can affect the 
development of atherosclerosis. 
In the ROMEO trial (chapter 4.2) among perimenopausal women a significant ef-
fect on change in intima-media thickness and end-diastolic lumen diameter of 17f3-es-
tradiol plus desogestrel and conjugated equine estrogens plus norgestrel compared to 
placebo could not be demonstrated. Although the direction of the obselved effects was 
favourable, i.e. reduced progression of intima-media thickness and smaller end-dia-
stolic lumen diameter, the sample size of this trial was insufficient to provide definite 
conclusions. \,'hile it was expected that the measured anti-atherogenic effects of hor-
mone replacement therapy would be smaller in perimenopausal women than in post-
menopausal women, as endogenous estrogen production will reduce the contrast in 
estrogen levels between the treatment and the placebo group, the majority of honnone 
replacement therapy in The Netherlands is prescribed to perimenopausal women, and 
it is of impOltance to assess the effect of hormone replacement therapy in this group of 
women. Larger randomised trials, with measures of atherosclerosis as outcome rneas-
ure are needed to provide definitive evidence. 
Hormone replacemelll tiJeraj»), and mecbanical arterial pl'Opelties 
A difficulty in comparing our results with respect to mechanical alterial propelties with 
the results from other studies in the relatively new field of non-invasiveIy measured 
mechanical arterial properties is the variety of different endpoints that is being used to 
describe alterial propelties. Studies have shown favourable effects of estrogen therapy 
on pulsatility index (peripheral vascular flow). flow-mediated dilatation (endothelial 
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function), systemic arterial compliance (compliance over the total arterial system), and 
on augmentation index (reflecting both atterial stiffness and peripheral pressure wave 
reflections), which probably all reflect essentially different alterial propelties. Two 
studies examined the associations between estrogens and arterial distensibility by the 
same method as we used. One cross-sectional observational study did not find a differ-
ence in arterial distensibility between users and non-users of combined hormone re-
placement therapy, but a higher distensibility in users of estrogen replacement only82 
Another study 8howed no changes in arterial distensibility over the menstmal cycle. 
Our study is the first randomised trial of hormone replacement therapy on local disten-
sibility and compliance of the carotid altely. No significant changes in atterial distensi-
bility and compliance could be demonstrated for women using 17J3-estradiol plus 
desogestrel or conjugated equine estrogens plus norgestrel during two years of obser-
vation. This suggests there are no effects of treatment on distensibility, but as compli-
ance was lower in the treated group than in the placebo group, we cannot exclude the 
possibility that in a larger study or in a study of longer duration, the effects would have 
reached statistical significance. To date, no information is available as to what increase 
in alterial distensibility or compliance is clinically relevant, by what mechanisms estro-
gen can affect distensibility, and how long the exposure to estrogen is needed to 
achieve an effect. Longitudinal studies of the consequences of decreased arterial dis-
tensibility on coronary heart disease are awaited, and special attention is indicated to 
examine differences between men and women. 
Methodological considerations for studies on hormone replacement 
therapy 
Exposure assessmellt 
In Ollr study use of hormone replacement therapy was assessed by interview. This 
might have led, to a ce11ain c)..1ent, to misclassification. Greendale et a1. demonstrated 
that a single sclf-repOit question is adequate to asceltain ever-use of postmenopausal 
estrogen use in women up to 64 years of age.83 Another study showed moderate to 
substantial agreement between llsers and physicians on ever/never use of estrogens, 
and no differentialrnisclassification with disease status of the subject in women up to 
74 years of age.84 In the Rotterdam Study, we compared reported use of hormone re-
placement therapy with the general practitioners records in a random sample of 
women. These records did not provide a gold standard to which repOlted hormone use 
could be verified. \\lhen prescriptions for hormone replacement therapy are found in 
the medical record the use of hormone replacement therapy can be assumed. How-
ever, when no information is found, this could have been due to an inadequate regis-
tration system. The reported frequency and duration of use in our study was compara-
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ble to the those in studies in peri menopausal women in The Netherlands, where 12% 
of women between 45 and 65 use hormone replacement therapy and -50 % of women 
discontinue use within one year. 85-87 If differential misclassification were present, this 
could have biased the estimates. In the study of subclinical atherosclerosis, however, 
we do not assume this to be likely. 
Confounding 
HRT seems to improve women's risk factor profile and reduce risk of cardiovascular 
disease and mortality. Results from obselvational studies are strong, consistent and 
biologically plausible. Still, potential biases are large and most would be expected to 
spuriously enhance the obselved cardioprotective effect. Several studies demonstrated 
estrogen users are healthier than never users, even prior to use of replacement therapy 
88,89, which supports the hypothesis that part of the apparent benefit associated with 
HRT is due to pre-existing characteristics of the users. \V'omen who take hormones are 
a self-selected group and may have healthier life-styles with fewer risk factors than 
women who do not. Not only self-selection, but also selection of low risk women by 
prescribing physicians may playa role in this respect. Thirdly, compliant women who 
stay on estrogen represent a minority of all women who are ever prescribed estrogen, 
and these women may differ in several ways from less compliant women. \Ve cannot 
exclude the possibility that part (or the whole) of the findings is based on this self-se-
lection, doctors-selection or cornpliance bias. 
In order to evaluate possible bias in obselvational epidemiological studies, ideally, 
important characteristics are measured and adjusted for in analyses. Not all con-
founders may be known, however, or measurable. In our study we dealt with the issue 
of confounding in the following ways. Firstly, in the Rotterdam Shldy a large number of 
risk factors were measured, for which we adjusted in the analysis. As a result of our 
retrospective follow-up design) we used the current status of risk factors, while the ex-
posure to hormones had largely taken place in the past (chapter 2.3). Secondly, we 
stratified in the analyses for duration of use of HRT, and found that in women who had 
used female hormones for a period shorter than a year, altllOugh they were alike long-
term users with respect to the presence of several socia-economic and risk factors, no 
association was found with atherosclerosis. This increases the probability of a biologi-
cal mechanism and reduces the probability of selection bias, although it can not fully 
exclude it. Randomised trials are needed to provide definitive evidence. 
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MECHANISMS 
The mechanisms through which estrogens exert their effects on cardiovascular disease 
are diverse. Most attention has been directed to the effects of estrogen on lipid me-
tabolism. In the first place, estrogen causes induction (up-regulation) of LDL receptors 
in the liver, which increases catabolism of LDL-cholesterol, and lower LDL-cholesterol 
levels. Also, Iipoprotein(a) levels can be lowered by estrogens, possibly by the same 
mechanism, as lipoprotein(a) has a similar structure to LDL-cholesterol. Estrogen in-
creases catabolism of apo-lipoprotein B, and this results in a net reduction in circulat-
ing apolipoprotein B levels. Fmthermore, estrogen increases HDL-cholesterol, paltly by 
enhancement of HDL constituents - apolipoprotein A-I - and pal1ly by inhibition of 
the enzyme hepatic lipase, which degrades HDL-cholesterol. Oral administration of 
estrogens enhances triglyceride synthesis in the liver, possibly through induction of 
fatty-acid binding protein in the liver cell membrane by estrogens. Fmthennore oral 
estrogen increases production and immediate catabolisation of VLDL-cholesterol, 
which also results in increased triglyceride levels, as well as increased VLDL-levels.90 
Estrogens probably have other ways of inhibiting atherosclerosis. Effects, such as 
inhibition of platelet aggregation and inflanullatOlY cell attachment to the vessel wall, 
enhanced fibrinolytic activity, release of growth factors that stirnulate smooth muscle 
cell migration, inhibition of oxidative modification of LDL and HDL-cholesterol, reduc-
tion of blood viscosity, and calcium channel blocking properties may be beneficial.91 
Estrogen has been shown to have chronic and immediate vascular effects. The 
mechanisms of these vascular effects are not fully elucidated, but as discussed in 
chapter 2.2, estrogens might change the structure of the alterial wall by decreasing 
collagen production and the elastin/collagen ratio.91-93 Specific binding of estrogens to 
receptors in endothelial and vascular smooth muscle cells has been demonstrated in 
different vascular beds in animals and in humans.94 ,95 Fl..llthennore, estrogen may be 
related to the augmentation of nitric oxide release, which leads to a relaxation of the 
vessel waJI.96 
CLINICAL IMPLICATIONS 
Although evidence on the effects of menopause on coronaty heart disease is conflict-
ing, the results of our studies suggested that menopause affects risk factors for cardio-
vascular disease, mechanical alterial propelties, levels of atherosclerosis and the risk of 
myocardial infarction. The major risk factor affected by menopause is cholesterol 
(chapter 2.0. Because higher cholesterol levels are reached in the first years after 
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menopause, preventive measures aimed at reducing cholesterol levels might best be 
initiated immediately after menopause. Our study further suggests that early estrogen 
deprivation may have a long-term effect; increased risks of atherosclerosis remained 
detectable in women after age 70. To what extent hormone replacernent therapy can 
be used to delay the onset and progression of atherosclerosis and cardiovascular dis~ 
ease needs to be determined. 
The results from our studies showed that HRT users have lower levels of athero-
sclerosis and this advantage remains after discontinuation of therapy. However, this 
study remains obselvational. As mentioned, the HERS trial, a secondmy prevention 
trial, showed that HRT did not diminish the risk of recurrent cardiovascular events. 
Furthermore, in a recent obsetvational study it was shown that women with a history 
of coronary allery disease starting HRT after a myocardial infarction had an increased 
risk of hospitalisation for unstable angina compared to women who had never used 
HRT.97 l1lfombogenic properties of estrogens are likely to play a part in this. Until 
findings from large randomised trials confIrm the benefit of estrogen therapy for pre-
vention of cardiovascular disease, no definitive conclusions can be drawn on the use of 
HRT in primaly prevention. 
FUTURE RESEARCH 
Studies in the past have focussed on men for practical reasons) including the accessi~ 
bility of the working population, and their higher frequency of cardiovascular disease. 
However, coronalY heart disease is also the leading cause of death in women. Data for 
women are needed, not only to obtain direct evidence in women for their own benefit, 
but also because a better understanding of why men are at so much greater risk of 
coronary heart disease may lead to better methods of prevention and treatment for 
both sexes. In general, studies in women will benefit from the opportunity of non~in­
vasive measurement of atherosclerosis because accurate risk assessment will not be 
hampered by low rates of cardiovascular events. The non-invasive measurement of 
mechanical arterial properties will provide valuable methods to study the association of 
not only stnlctural but also functional rnechanical allerial properties with a number of 
disease processes. 
Knowledge on cardiovascular risk factors in women lags behind that in men. It is 
often assumed that the magnitude of effects of classical risk factors or their interactions 
are the same in men and women, but physiological differences between the sexes may 
increase risk factor levels or modify the effect of risk factors. Estrogens are associated 
with a diversity of factors influencing atherogenesis, like haemostatic and fibrinolytic 
factors, homocysteine metabolism, endothelial function and inflammatOlY factors, 
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which provide interesting fields of research. The roles of these factors and their rela-
tionship to other life-style factors) such as anti-oxidants, intake of specific fatty acids) or 
physical activity, their interactions with classical risk factors, such as blood pressure 
and lipids) and sex-hormone profiles need to be documented in women and in men 
separately. Insulin resistance has been put fOlward as a potentially impOltant risk fac-
tor. Diabetes mellitus is the only risk factors for which the relative effect is stronger in 
women than in men, and elucidating the reasons behind this may provide information 
about the causes of the female protection for cardiovascular disease. Insulin resistance 
has been found to cluster with elevated blood pressure and lipid abnormalities.98 Ab-
dominal obesity and increased levels of serum androgens in women have been sug-
gested to be associated with several of these risk factors, but the biological mechanisms 
underlying these associations need further investigation. 
In contrast to the extensive research on exogenous hormones, little is known on 
the relation between endogenous hormones with lipid levels and coronary healt dis-
ease. For LOL-cholesterol, premenopausal women have lower levels than men of the 
same age, but after age 50 the increase in LDL levels in women is greater. These sex-
differences might be due to the decrease of circulating hormone levels with meno-
pause, and may explain the sex-differences in coronalY heal1 disease. \",\lhether the lev-
els of estrone and estradiol that establish after menopause are associated to the devel-
oprnent of atherosclerosis is not yet known. Since both exogenous and endogenous 
estrogens may be impOltant determinants of coronalY healt disease risk, information 
about the serum sex hormone levels to lipid levels, other risk factors, atherosclerosis 
and coronalY heart disease would enhance our understanding of the pathogenesis of 
coronalY heart disease in women. 
HRT has several limitations for disease prevention, like the resumption of men-
strual bleeding with estrogen therapy, breast tenderness, fluid retention and mood 
fluctuations with progestins, and a potentially increased risk of breast- and endometrial 
cancer, venous thromboembolic events and gaUbladder disease. Optimal disease pre-
vention therapy for postmenopausal women might be better realised by estrogen-like 
compounds that mimic the actions of estrogens on the bones and cardiovascular sys-
tem (including serum lipids), while at the same time minimising estrogenic effects on 
the breast and endometrial tissues. Selective estrogen receptor modulators (SEMIs) 
comprise a group of structurally diverse compounds which are distinguished from es-
trogens by their ability to interact with the estrogen receptor but to act either as a re-
ceptor agonist or antagonist depending on the target tissue and hormonal milieu. Ra-
loxifene, the most investigated SEfu\'I to date, has been shown to have estrogenic ef-
fects on bone and lipids, but estrogen antagonistic effects on breast and uterus.99 Al-
though Raloxifene was shown to decrease LDL-cholesterol, lipoprotein (n) and in-
creaSe HDLrcholesterol, a disadvantage of this medication is that it does not decrease, 
and possibly even increases, the incidence of hot flushes. IOO Large-scale clinical testing 
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currently in progress for raloxifene, and soon for other SERl\is, will have to evaluate 
the potential of this new group of drugs as a potential substitute for long-term female 
hormone replacernent therapy. 
The effects of progestins on vascular properties and on development of athero-
sclerosis are not yet well understood. The many different types of progestins in use, 
with their different androgenic qualities, have prevented clear conclusions on their ef-
fects. As estrogen therapy should always be combined with progestins to reduce the 
risk of endometrial carcinoma this field needs further investigation. 
Incidence of menopausal complaints is much lower in Asian countries than in the 
western world, as is the incidence of chronic and degenerative diseases.· DietaIY factors 
have been thought to be responsible for this. This dietalY hypothesis became more 
specific with the detection and identification of two groups of compounds of plant ori-
gin (lignans and isoflavonoids) with molecular weight and structure similar to those of 
steroids) the precursors of which are found especially in soy and unrefined grain prod-
ucts which are highly prevalent in the Asian diet. It has been proposed that these die-
talY phyto-estrogens (plant estrogens) might be modulators of the human hormonal 
system, and thus may affect the incidence of hormone-sensitive diseases, among which 
cardiovascular disease, without having the unfavourable side-effects known of estro-
gen therapy,IOl Studies have shown that phyto-estrogens bind to estrogen receptors, 
and show significant estrogenic effects in animals and humans.1°2 l11e lowering effect 
of soy intake on plasma-lipids has been well known, and it might be the high phyto-
estrogen concentration in so)' that, at least partially, is responsible for the favourable 
effects.1°3 However, also the plant proteins in themselves may affect lipid proteins. 
Most information on effects of phyto-estrogens in vivo is based on consumption of 
phyto-estrogen-rich diets and the causal relationship and the mechanisms of phyto-es-
trogen action in humans stiH remain to be demonstrated. The potential of phyto-estro-
gens, especially soy-intake, in prevention of cardiovascular disease provides interesting 
fields for fUIther research. 
As mentioneci before, genetic factors affecting age at menopause might playa role 
in modifVing the risk of cardiovascular disease. Evidence that genetic factors are related 
to age at menopause has been observed previously in family and twin studies,73-75 Yet, 
the genes involved remain ill defined. A promising line of study is the estrogen recep-
tor gene. In a recent study, the different polymorphisms of this gene were found to be 
associated with age at menopause as well as the risk of hysterectomy,78 This receptor 
also mediates the activation of the LDL-receptor in the liver, and it would be of interest 
to relate the polymorphism with cholesterol levels in women. 
Due to the problems of selection bias, inevitably the definitive proof on effects of 
HRT will have to come from large randomised trials. After the results of the PEPI-trial, 
which showed favourable effects of HRT compared to placebo on several cardiovas-
cular risk factors, the HERS trial was the first randomised study on cardiovascular 
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events, performed in women with existing coronalY healt disease. In primary preven-
tion, a large randomised trial is underway in the United States. The \\fomeo's Health 
Initiative (\'VHI) is a primm)' prevention trial among 27.500 postmenopausal warnen, In 
this trial, women with a uterus are being ranclomised to conjugated equine estrogens 
plus medroxyprogesteron acetate or placebo and women without a uterus are being 
randomised to conjugated equine estrogens or placebo. \'(famen will be fcHawed for 10 
years for cardiovascular events, osteoporotic fracnlres and cancer. Similarly, in the UK, 
the Medical Research Council has slatted the recruitment for the \\"'omen's International 
Study on long Duration Oestrogen after Menopause (W1SDOM), an international trial 
of 30,000 women. Results of these studies are not expected until 2006. Until tben a 
careful weighing of individual factors should provide the basis for counselling of peri~ 
and postmenopausal women considering long-term hormone replacement therapy, but 
general considerations for treatment of all asymptomatic women is not justified at pres-
ent. 
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Summary 
n this thesis, the association between estrogen, atherosclerosis and coronalY heart 
disease in women is described. The first patt of the thesis deals with the 
associations of menopause with risk factors for coronary heart disease, me-
chanical propelties of the large alteries, atherosclerosis and myocardial infarction. 
In the second part, in search of possibilities for prevention, the effects of honnone 
replacement therapy are addressed. 
The incidence of cardiovascular disease in women rises sharply after middle age. Al-
though results of large follow-up studies are inconsistent, menopause is thought to be 
a major determinant of this increase. The mechanism through which menopause might 
exelt its effect on the cardiovascular system is still unknown. Increased levels of serum 
total cholesterol after cessation of menses have been found in most studies on meno-
pause and risk factors. Inconsistent results, however, have been repOlted for HDL-
cholesterol, apolipoproteins, blood pressure, waist-to-hip ratio and insulin. A difficulty 
when studying difference::; between pre- and postmenopausal women is the high cor-
relation between menopausal stahls and age. Studies that included women in a broad 
age range may not be able to validly remove the confounding effect of age. Studies in a 
restricted age range around the menopause will include premenopausal women who 
have irregular menses and postmenopausal women who only recently passed meno-
pause, which reduces the contrast in estrogen status. 
Chaptet' 2.1 describes the relations between natural menopause and several athero-
genic factors in a highly selected population in which the contrast in estrogen status 
between pre- and postmenopausal women of the same age was maximised. Risk fac-
tors were compared in 93 premenopausal and 93 postmenopausal women who were 
matched on age (range 43-55 years). The women were selected from respondents to a 
mailed questionnaire about the menopause, which was sent to all wornen aged 40 to 
60 years, living in the Dutch town of Zoetenneer (n= 12,675j response 54 %). Post-
menopausal wornen who were at least three years after menopause or whose menses 
had stopped naturally before age 48 were age-matched with premenopausal women 
with regular menses and without menopausal complaints. Compared to premeno-
pausal \yomen, postmenopausal women had significantly increased levels of total 
cholesterol (10.0%, 95% confidence intelval 5.1 ; 14.0), low density lipoprotein (LDL) 
cholesterol (14.0%, 6.9 ; 19.9), and apolipoprotein B (8.2%, 0.6 ; 15.5). The difference 
was present within three years after onset of menopause and did not show a trend to-
wards an increase with the number of postmenopausal years. No differences were 
found in HDL-cholesterol, triglycerides, apolipoprotein AI, blood glucose, insulin, 
body mass index, waist-to-hip ratio, and systolic and diastolic blood pressure. The re-
sults of this study add to the evidence that total cholesterol, LOL cholesterol and apo-
lipoprotein B are the primary cardiovascular risk factors affected by menopause. 
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In chapter 2.2 distensibility of the common carotid al1elY, an indicator of arterial 
elasticity, was compared in pre- and postmenopausal women in the same study. Al-
though the beneficial effects that exogenous estrogens have on a11erial characteristics 
have been shown in several studies, the effect of endogenous esU-ogen on the vascular 
system is not known. Distensibility of the carotid artelY was measured non-invasively 
with B-mode ultrasound and a vessel wall movement detector system. Alterial distensi-
bili!)' is expressed as the change in atterial diameter (distension, .6.D) with the cardiac 
cycle, adjusted for lumen diameter, pulse pressure and mean arterial blood pressure. 
Compared to premenopausal women, postmenopausal women had significantly lower 
arterial distension (L\D 370.5 lun (SE 9.5) versus 397.3 lun (SE 9.6». These results sug-
gest that the distensibility of the C01111110n carotid attelY is unfavourably affected by 
natural menopause in presumed healthy women. 
In Chapter 2.3 associations of early natural and attificlal menopause with athero-
sclerosis and myocardial infarction were examined in 4,853 postmenopausal women 
aged 55 and over in the Rotterdam Study. Atherosclerosis was assessed in the aorta by 
detection of calcified plaques on lateral X-ray's of the abdomen, in the carotid alteries 
by ultrasonography, and in the peripheral alteries by measurement of the ankle-ann 
systolic blood pressure index. A histOlY of myocardial infarction was based on self-re-
ported information checked with GP or hospital records and/or on ECG evidence. \Y,Te 
found that age at natural menopause was Significantly and inversely related to the risk 
of atherosclerosis and that of myocardial infarction. After adjustment for confounders, 
odds ratios for women with menopause before age 40 compared to women with 
menopause after age 55 were 3.24 (95 percent confidence interval 1.47 - 7.13) for aor-
lie atherosclerosis, 2.75 (1.13 - 6.67) for carotid atherosclerosis, and for women with 
menopause before age 45 odds ralios were 1.67 (1.02 ; 2.74) for peripheral alterial dis-
ease, and 2.49 (1.30 - 5.74) for myocardial infarction. The associations were present 
both in women above and below age 70. Early bilateral oophorectomy, but not hyster-
ectomy with or without unilateral oophorectomy, was associated with an increased risk 
of atherosclerosis at all sites and with myocardial infarction. 
If endogenous estrogens protect women from developing atherosclerosis, substitution 
of exogenous estrogens might provide opporhlI1ities for prevention. Thus, in chapter 
3 of this thesis the extent to which honnone replacement therapy in the early post-
menopausal phase may postpone or delay the development of atherosclerosis was ex-
amined, The association of ever use of hormone replacement therapy with the pres-
ence of peripheral alterial disease, a major representative of atherosclerotic disease, 
was evaluated in chapter 3.1. A total of 2,196 naturally postmenopausal women aged 
55 to 80 years were studied in the Rotterdam Study. Peripheral mterial disease was de-
fined as an ankle/arm systolic blood pressure index < 0.9. Ever use of hormone re-
placement therapy for one year or more was associated with a 52% decreased risk of 
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peripheral arterial disease (Odds Ratio (OR) 0.48 (95% confidence intelval (CI) 0.24 ; 
0.85)), while no association was found for use during 1 year or sholter (OR 0.97 (95 % 
CI 0.58 j 1.63), after adjustment for age, smoking and socio-economic status. Additional 
adjustment for body mass index, age at menopause, total cholesterol and HDL-choles-
terol, alcohol intake or frequency of visits to health care facilities did not change these 
results. The results of this study suggest that the use of hormone replacement therapy 
after menopause might protect against the development of peripheral arterial disease 
later in life, 
In chapter 3.2, the association of hormone replacernent therapy with intima-me-
dia thickness of the common carotid artet)' was examined, l'vlean and maximal intima-
media thickness of the conunon carotid artery were measured in a total of 1,103 natu-
rally menopausal women aged 55 to 80 years in the Rotterdam Study. A histol)' of ever 
use of hormone replacement therapy longer than one year was associated with a lower 
intirna-media thickness (71.9 jJm in hormone users versus 74.2 JIm in nonusers, 
p~0.03)), while no association was found for use during 1 year or shorter (73.9 P111 in 
hormone users versus 74.2 JIm in nonusers (p=0.40», after adjustment for age, smok-
ing and socio-economic stanis. Additional adjustment for body mass index, age at 
menopause, alcohol intake or frequency of visits to health care facilities did not change 
these results. 
In chapter 4 of this thesis results from ROMEO, a randomised intelvention trial, are 
reported. The ROMEO trial is a single centre rand0111ised placebo-controlled trial, con-
ducted to assess the two-year effects of a sequential combined regimen of oral 17P-
estradiol plus desogestrel (17PEr D) and a combination of conjugated eqUine estrogens 
plus norgestrel (CEE-N), compared to placebo on several cardiovascular risk factors in 
perimenopausal women, Also, dynamic and structural alteriai characteristics of the 
common carotid altery were measured. In chapter 4.1, the results are presented from 
an analysiS on two dynamic alterial characteristics, distensibility and compliance. The 
ROMEO study included 121 perimenopausal women recruited from the general 
population. The trial was double-blind with respect to the 171l-estradiol plus deso-
gestrel and placebo groups and open with respect to conjugated eqUine estrogen plus 
norgestreJ. After six cycles, the blind was broken and the trial was continued as an 
open trial for another 18 months for the active study arms. At baseline distensibility and 
compliance of the common carotid artel), was measured non-invasively with B-mode 
ultrasound and a vessel wall movement detector system, and the distenSibility coeffi-
cient (DC) and compliance coefficient (CC) were calculated. lvleasurements were re-
peated after 6 and 24 months. Changes in DC and CC in treatment groups were com-
pared to placebo. After 24 months changes for 171l-estradiol plus desogestrel compared 
to placebo were -1.4 x 10-3 / kPa (95% CI -4.4 ; 1.7, p~0.39) for DC and 0.26 mm' / kPa 
(95% CI -0.01 ; 0.53, p~0.07) for cc. Changes for conjugated equine estrogens plus 
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norgestrel compared to placebo were 0.4 x 10-3 / kPa (95% CI (-1.0 ; 1.9, p=0.79) and 
0.11 mm' / kPa (95% CI -0.14 ; 0.37, p= 0.40). Also for systolic blood pressure, diastolic 
blood pressure and alteriallumen diameter no changes were found. 
In chapter 4.2 the effect of both treatments on intima-media thickness was de-
scribed. ConUllon carotid intima-media thickness and end-diastolic lumen diameter 
were measured at baseline and cycle 24 with B-mode ultrasonography. At cycle 24 
small changes in intima-media thickness and lumen diameter were observed. Relative 
to placebo changes in intima-media thickness were -0.016 mm (95% CI -0.055, 0.024) 
for 17p-estradiol plus desogestrel and -0.009 mm (95% CI -0.045,0.027) for conjugated 
equine estrogens plus norgestrel. For end-diastolic lumen diameter the changes were -
0.125 mm (95% CI -0.820, 0.032) and -0.091 nun (95% CI -0.236, 0.055) for 17P-
estradiol plus desogestrel and conjugated equine estrogens plus norgestrel, respec-
tively. 
\Vle concluded that in this study among perimenopausal women a significant ef-
feel of 17p-estradiol plus desogestre1 and conjugated equine estrogens plus norgestrel 
on common carotid intima-tnedia thickness and lumen diameter could not be dem-
onstrated. Although the duration of the present trial is too limited to provide definite 
conclusions, the direction of the effect is in agreement with evidence from earlier 
studies on the favourable effects of hormone replacement therapy in postmenopausal 
women. 
In chapter 5, the general discussion, the results described in this thesis and several 
methodological issues are discussed. \"XTe conclude that menopause has an unfavour-
able association with several cardiovascular risk factors, structural characteristics of the 
large alteries, on atherosclerosis and on coronalY hean disease. Hormone replacement 
therapy, which has been shown in earlier observational studies to be associated with a 
lower risk of coronary healt disease, was shown to protect women from development 
of atherosclerosis in the lo'wer e:X1:remities and in the common carotid artelY. This sug-
gests that the mechanisms underlying this protection include inhibition of the athero-
sclerotic process. Our analyses of a randomised, placebo-controlled study could not 
confirm the effect on hormone replacement therapy on atherosclerosis of the common 
carotid altety, but the duration of this study was small, and the favourable direction of 
the effect was in agreement with expectations. Until findings from large randomised 
trials confirm the benefit of estrogen therapy for prevention of cardiovascular disease 
no defjnite conclusions can be drawn, and hormone replacement therapy should not 
be routinely recommended for this purpose in clinical practice. 
[152 
I Samenvatting 

o 
Samenvatting I 
it proefschrift beschrijft de relatie tussen oestrogen en) atherosclerose en 
halt-en vaatziekten bij vrouwen. In het eerste dee! worden de gevolgen 
beschreven van de menopauze voor risicofactoren voor h31t- en vaatziek-
ten) voor de alterieie elasticiteit) vaal' de kans op atheroscIerose en voor het 
kriigen van een hartinfarct. Het tweede gedeelte van het proefschrift beschriift de 
effecten van hormoon substitutie therapie op arteriele elasticiteit en op atherosclerose. 
De incidentie van hart- en vaatziekten neemt snel toe bij vrouwen na de middelbare 
leeftijd. Hoewel de resultaten van verschillende grote follow-up onderzoeken hierover 
niet consistent zijn) lijkt de rnenopauze een determinant te zijn van deze toename. De 
mechanismen waardoor de menopauze het fisico op halt-en vaatziekten beihvloedt 
zijn nog niet geheel opgehelderd. De meeste studies vinden een toe name van totaal-
cholesterolspiegels na de menopauze) maar wisselende resultaten worden gevonden 
voor HDL-cholesterolspiegels) apolipoprotei'nen) bloeddtuk) middel-heupratio en insu-
linespiegels. Studies nam de effecten van menopauze worden bemoeilijkt door de 
sterke correlatie tussen menopauze en leeftijd. Studies die vrouwen binnen een brede 
leeftijdsgroep onderzoeken) kunnen niet goed corrigeren voor het effect van leeftijd op 
de te bestuderen variabelen. In studies onder vrouwen fond de menopauze zullen 
weer veel vrouwen deeinemen die reeds een onregelmatige cyclus hebben en post-
menopauzale vrouwen die pas de menopauze gepasseerd zi;n. Dit verzwakt het con-
trast in oestrogeenstatus tussen pre- en postmenopauzale vrouwen. 
IIoofdstuk 2.1 beschrijft de relaties tussen natuurlijke menopauze en verschillende 
atherogene factoren. In dit onderzoek is getracht het contrast in menopausale status te 
maximaliseren tussen pre- en postmenopauzale vrouwen van dezelfde leeftijd. Risico-
factoren werden vergeleken in 93 premenopauzale en 93 postmenopauzale vrouwen 
die op leeftiid gematcht waren (leeftiid 43 - 55 iaar). De vrouwen werden geselecteerd 
middels een vragenlijst over de menopauze die aan aBe vrouwen tussen de 40 en 60 
jaar in Zoetermeer werd verzonden (n= 12675, res pons 54%). Postmenopauzale vrou-
wen die ten minste voor hun 48e spontaan in de menopauze waren gekomen en vrou-
wen die al ten minste 3 jaar niet meer menstrueerden) werden gematcht met vrouwen 
van dezelfde leeftijd die nog regelmatig mensttueerden en nog geen overgangs-
klachten hadden. Vergeleken met premenopauzale vrouwen hadden postmenopauzale 
vrouwen significant verhoogde spiegels van totaal cholesterol (10.0%) 95% betrouw-
baarheidsintelval (BI) 5.1 ; 14.0), LDL-cholesterol (14.0%, 6.9 ; 19.9) en apolipoprote'ine 
B (8.2%, 0.6 ; 15.5). De hogere waarden in de postmenopauzale groep waren al aan-
wezig binnen 3 jam na de laatste menstruatie en namen niet toe met het aantal jaren na 
de menopauze. Er werden geen verschillen- gevonden in HDL-cholesterol) triglyce-
riden) apolipoprotei'ne AI) glucosespiegels, insulinespiegels) midde1-heupratio) body 
mass index en systolische en diastolische bloeddruk. De resultaten van deze studie 
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laten zien dat vooral totaal cholesterol, LDL cholesterol en apolipoprote'ine B be'invloed 
worden door de menopauze. 
In hoofdstuk 2.2 werd de distensibiliteit van de arteria carotis communis, een 
maat voor vaatwandelasticiteit, verge1eken tUssen pre- en postmenopauzale vrouwen 
in deze1fde studie. Hoewel eerder is aangetoond dat toegediende oestrogenen een 
gllnstig effect hebben op verschillende vaatwandeigenschappen, is niet bekend wat 
het effect is van het wegvallen van de eigen oestrogenen ten gevolge van de meno-
pallze. De distensibiliteit van de vaatwand werd gemeten door middel van echografie 
en een vaatwandbewegingsdetectiesysteem. Distensibiliteit werd uitgedmkt als de 
verandering in de diameter van het vat (distensie (D)) rnet de haltslag, gecorrigeerd 
voor de originele diameter van het vat, de polsdruk en de gemiddelde alteriele bloed-
druk. Vergeleken met premenopauzale vrouwen hadden postmenopauzale vrouwen 
een significant lagere distensie ((D 370.5 Jim (SE 9.5) versus 397.3 Jim (SE 9.6)). Deze 
resultaten geven aan dat de elasticiteit van de arteria carotis communis in gezonde 
vrouwen ongunstig wordt beYnvloed door de menopauze. 
In hoofdsnJk 2.3 worden de relaties onderzocht tllssen de leeftijd waarop de 
menopauze is ingetreden en het v66rkOlnen van atherosclerose en myocardinfarct in 
4853 postmenopallzale vrollwen van 55 jaar en ollder in het ERGO onderzoek. 
Atherosclerose werd gemeten op drie plaatsen. In de aOlta, door rniddel van detectie 
van gecalcificeerde plaques op dwarse rontgenfotds van de buik, in de arteria carotis 
door middel van echografie en in de arterien van de benen door meting van de enkel-
annindex. Een voorgeschiedenis van myocardinfarct werd vastgesteld op basis van zelf 
gerapporteerde gegevens en op ECG-informatie, geverifieerd met behulp van gege-
vens uit de huisaltsenstatus. \Vle vonden dat een vroege menopauze was geassocieerd 
met een verhoogd risko op atherosclerose en myocardinfarct. Na correctie voor ver-
storende factoren hadden vrouwen met menopauze voor hun 40ste een 3.2 maal ver-
hoogde kans op atherosclerose in de a0l1a (95% BI 1.47 ; 7.13), een 2.8 maal ver-
hoogde kans op atherosclerose in de carotiden (95%1 BI 1.13 ; 6.67), en voor vrouwen 
met een menopauze voor hun 45ste een 1.7 maal verhoogde kans op perifeer vaat-
lijden (95% CI 1.02 ; 2.74) en een 2.49 maal verhoogde kans op een myocardinfarct 
(95% BI 1.30 ; 5.74). Deze associaties werden gevonden in Vfouwen onder en vrouwen 
boven de 70 jaar. Een vroege bilaterale ovariectornie gaf een verhoging van de kans op 
atherosc1erose in de drie onderzochte locaties en op een m),ocardinfarct, terwiji een 
vroege hysterectomie, met of zonder unilaterale ovariectomie geen riskoverhoging gaf. 
Als het wegvallen van endogene oestrogenen het risko op atherosc1erose verhoogt, 
zou substitutie van oestrogenen (hormoon substitutie therapie) deze toename mogelijk 
kunnen uitstellen of venragen. In hoofdsnlli 3 van dit proefschrift worden de resulta-
ten beschreven van twee observationele studies naal' het verband tussen honnoon sub-
stitutie therapie en atherosc1erose. 
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Het effect van hormoon substitutie therapie in het verleden op de aanwezigheid 
van perifeer vaatlijden werd onderzocht in hoofdstuk 3.1. Binnen het ERGO onder-
zoek werden 2196 vrouwen met een natulIrlijke menopauze tussen de 55 en 80 jaar 
bestudeerd. Perifeer vaatlijden werd gedefinieerd als een enkel-armindex Jager dan 0.9. 
Hormoon substitutie therapie in het verleden gedurende meer dan 1 jaar was geasso-
cieerd met eell 50% verlaagde kans op perifeer vaatlijden (odds ratio 0.48, 95% BI 0.24 
; 0.85), telwijl geen verband werd gevonden bij gebruik van ho1'moon substitlltie thera-
pie gedurende een periode kOlter dan een jaar (odds ratio 0.97, 95% BI 0.58 ; 1.63). 
Deze associaties waren onafhankelijk van leeftijd, Loken of sociaal-economische status. 
AanvllIlende correcties voor body mass index, leeftijd van menopauze, totaal choles-
terol en HOL cholesterol) alcoholgebruik of het aantal bezoeken aan voorzieningen in 
de gezondheidszorg (een rnaat voor medische consumptie) veranderden de resultaten 
niet. De resultaten van deze studie suggereren dat het gebruik van honnoon substitutie 
therapie lla de menopauze mogelijk beschenning biedt tegen perifeer vaatlijden ap 
latere leeftijd. 
In hoofdstul{ 3.2 ,vordt de associatie van hormoon substitutie therapie op de 
vaatwanddikte (de intima-media dikte) van de aneria carotis onderzocht. De gemid-
delde en de maximale wanddikte van de atteria carotis communis werden echografisch 
gemeten in 1103 natuurlijk postmenopauzale vrouwen tussen de 55 en 80 jaar in het 
ERGO onderzoek. Gebruik van honnoon substitutie therapie in het verleden gedu-
rende langer dan een jaar was geassocieerd met een dunnere vaatwand (71.9 PIll in 
gebruiksters versus 74.2 Ji111 in vrouwen die nooit hormoon substitutie therapie hadden 
gebruikt, p ~ 0.03). Gebruik gedurellde eell periade kaner dan een jaar was Iliet geas-
socieerd met een verandering in wanddikte (73.9 .um in gebruiksters versus 74.2 pm in 
vrouwen die noait gebruikt hadden (p""0.40)), na correctie voor leeftijd) roken) systoli-
sche bloeddruk) body mass index en sociaal-economische status. Additionele correcties 
voor diabetes) het aantal bezoeken aan voorzieningen in de gezondheidszorg, totaal 
cholesterol en HDL-cholesterol veranderden deze resultaten niet. 
In hoofdstuk 4 van dit proefschrift worden de resultaten van de ROMEO studie, een 
gerandorniseerde placebo-gecontroleerde intelventie-trial, gepresenteerd. De ROMEO 
trial werd uitgevoerd met het doel de effecten van eeo twee jaar durend sequentieel 
gecombineerd regime van araal 17p-oestradiol plus desogestrel en een combinatie van 
geconjugeerde oestrogenen plus norgestrel te vergelijken met placebo) ten aanzien van 
verschillende cardiovasculaire risicofactoren in perimenopauzale vrouwen. Binnen het 
kader van deze studie onderzochten wij de dynamische en structurele eigenschappen 
van de arteria cat'otis communis. In hoofdstuk 4.1 worden de resultaten beschreven 
van het onderzoek naar twee veelgebruikte dynarnische aneriele karakteristieken: dis-
tensibiliteit en compliantie. In de ROMEO studie namen 121 vrouwen deeI) die waren 
gerecruteerd uit de algemene bevolking. De trial was dubbelblind ten aanzien van de 
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17~-oestradiol plus desogestrel groep en de placebogroep, en open ten aanzien van de 
geconjugeerde oestrogenen plus norgestrel groep. Na de 6e cyclus werd de blindering 
losgelaten en werd de trial vooltgezet als een open trial gedurende 18 cycli. Bij 
aanvang van de studie werden distensibiliteit en compliantie niet-invasief gemeten met 
behulp van echografie en een vaatwandbewegingsdetectiesysteem en werden de dis-
tensibiliteitscoi'fficient (DC) en de compliantiecoefficient (CC) berekend. De metingen 
werden herhaald na 6 en na 24 cycli. Veranderingen in DC en CC in de behandelde 
groepen werden vergeleken met die in de placebogroep. Na 24 maanden waren de re-
latieve verancieringen ten opzichte van de placebogroep klein. In de 17~-oestradiol 
groep waren de relatieve veranderingen -1.4 X 10-3 / kPa (95% BI -4.4 ; 1.7) in DC en 
0.26 mm' / kPa (95% BI -0.01 ; 0.53) in Cc. Relatieve veranderingen voor de ge-
bruiksters van geconjugeerde oestrogenen bedroegen 0.4 x 10-3 / kPa (95% BI -1.0 ; 
1.9) in DC en 0.11 mm' / kPa (95% BI -0.14 ; 0.37) in CC. Ook voor veranderingen in 
systolische en diastolische bloeddruk werden tussen de groepen geen statistisch signi-
ficante verschillen gevonden. 
In hoofdstuk 4.2 wordt het onderzoek naar de effecten van de (Wee behan-
delingen op de structurele eigenschappen van de vaatwand beschreven. De vaatwand-
dikte en de lumendiameter van de arteria Cal'otis cOinmunis werden gemeten met be-
hulp van echografie. Bij cyclus 24 werden kleine veranderingen in vaatwanddikte en 
lumendiameter gevonden. Ten opzichte van de veranderingen in de placebogroep 
werden een verandering van -0.016 mill (95% BI -0.055; 0.024) voor 171l-oestradiol en 
van -0.009 mm (95% BI -0.045 ; 0.027) voor gebnliksters van geconjugeerde oestro-
genen gevonden. Vaar de cinddiastolische lumendiameter werden relatieve verande-
ringcn van -0.125 mm (95% BI -0.820 ; 0.032) en -0.091 mill (95% BI -0.236; 0.055) ge-
vonden vaal' respectievelijk 17~-oestradiol en geconjugeerde oestrogenen vergeleken 
met placebo. Concluderend kan worden gezegd dat, hoewel de resultaten laten zien 
dat - overeenkomstig de bestaande hypothesen - het effect van honnoon substitutie 
therapie gunstig lijkt, in deze 2-jarige studie geen significant effect van honnoon sub-
stitutie therapie op de vaatwanddikte en lumendiameter kon worden aangetoond. 1\'10-
gelijk is de studie te kart am ecn effect aan te tonen, of mogelijk is het effect van hor-
moon substitutie therapie op atherosclerose in de arteria carotis communis in peri-
rnenopauzale vrouwen inderdaad klein. 
In hoofdstuk 5, de algemene disclIssie, worden de resultaten van de in dit proefschrift 
beschreven studies samcngevat en worden verschillende methodologische aspecten 
besproken. \Vij concluderen dat de menopauze ongunstige gevolgen heeft voor vef-
schillende cardiovasculaire risicofactoren, vaal' de arteriele elaSticiteit, voor de kans op 
atherosderosc en voor de kans op het krijgen van een hartinfarct. Honnoon substihltie 
therapie, die in eerdere shldies vrouwen lijkt te beschennen tegen ha1't- en vaatziekten, 
lijkt in onze observationele studies bescherming te bieden tegen atherosderose in de 
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beenvaten en de arteria camtis conununis. Bovendien Iijkt het gunstiger atheroscleroti-
sche profie! bij vrouwen die in het verleden hormoon substihltie therapie hebben 
gebruikt te blijven bestaan na het stoppen met de therapie. Mogelijk is dus de renuuing 
van het proces van atherosclerose een van de mechanismen waardoor honnool1 sub-
stitutie therapie vrouwen beschennt tegen halt- en vaatziekten. De resultaten van de 
gerandomiseerde ROMEO studie konden de effecten van hon11oon sllbstitlltie therapie 
op de remming van atherosclerose in de alteria carotis niet bevestigen. De resultaten 
lieten wel zien l overeenkomstig de bestaande hypotheseo) dat het effect van hormoon 
substitlltie therapic) hoewel niet statistisch significant l gunstig leek. Mogelijk was deze 
studie te kort om een effect aan te tonen in perimenopauzale vrouwen. 'fotdat grote 
gerandomiseerde onderzoeken het guostige effect van honnaon substitutie therapie op 
het optreden van hart-en vaatziekten bevestigen l kunnen hieromtrent geen definitieve 
candusies worden getrokken en kan honnoon substitlltie therapie niet ,vorden aange-
raden voor dit doe I. 
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In het voorjaar van 1995 begon ik rnijn werk aan de Erasmus Universiteit Rotterdam. 
Vol enthousiasme st011te ik mij op mijn academische werk) waarvan de resultaten zijn 
bijeengebraeht in dit proefsehrift. Elj dezen wil ik hen bedanken die mij hebben gehol-
pen mijn beseheiden bijdrage (steentje) te leveren aan de wetensehap. 
Allereerst wiI ik mijn co-promotor elf if J.C.M. \Vitteman bedanken. Jacqueline, jij 
was altijd daar voor ovel'1eg, de laatste maanden zelfs op zondag (al dan niet bij 
DomllS Artis) als dat noodzakelijk bleek voor het afronelen van het proefsehrift. Door 
steeds met nieuwe ideeen en invalshoeken te kamen, werden mijn onderzoekingen 
tel kens weer verbeterd. Jij wist mijn aanvankelijk wat nonchalante aanpak om te zetten 
in een weloverwogen aeademisehe benadering. lk ben je dankbaar voor de degelijke 
vanning in de epidemiologie die je me gegeven hebt. 
Oak mijn promotores, Prof. elr A Hofman en Prof. elf D.E. Grobbee, ben ik zeer 
erkentelijk voor hun aandeel in de begeleicling. Bert, jellw enthousiasme en inzet vaar 
de epidemiologie werkten heel motiverend; en Rick, ondanks je overstap naar Utrecht 
heb je steeds een aogje in het zei! weten te houden. Oak onze muzikale sam en-
werking heb ik zeer gewaardeerd. 
In de eerste jaren van mijn onderzoek heb ik veel tijd doorgebracht in Onulloord. 
Dit proefschrift was niet magelijk geweest zander ERGO-onderzoek. In de eerste plaats 
ben ik dankbaarheiel versehuleligel aan de 7983 ERGO-deelnemers en aan de huisaltsen 
in en am Ommoord die zo gastvrij hun medewerking verleenden aan mijn status-
onderzoek. Vereler aIle medewerkers op het ERGO-centrum dank voor het verzamelen 
van de gegevcns en Vaal' de gezelligheid, en Inge en Taos voor hun enthousiasme en 
vakkundigheiel bij de vaatwanelmetingen. Deirelre van der Kuip, jij hebt een heel 
nieuwe impuls aan het ERGO-anderzoek gegeven. Dank voor je betrokkenheid, niet 
aileen bij het ERGO-onderzoek, maar oak bij mijn project, en Vaal' je stim.ulerende 
aanwezigheid. Bas, dank Vaal' je hulp bij het veldwerk, dat het begin vonnde van onze 
samenwerking. Ook Jurgen Akkerhuis, Mathilde Wisse en Arjan Baelden dank hier-
voor. Uiteraard wil ik de initiatiefnemers van het ERGO-onderzoek noemen: Prof. dr A. 
Hofman, Prof. dr D.E. Grobbee, Prof. elr P.T.V.M. de Jong en Prof. elr H.A.P. Pols. Huib, 
dank voor het verrijken van een aantal van mijn concept-altikelen met je kritische op-
en aanmerkingen. 
Op het lnstituut Epidemiologie & Biostatistiek heb ik een goede tijd gehael. Een 
speciaal woord van dank wiI ik richten tot mijn mede-onderzoekers, die, hoewel ik ze 
bij e1kaar noem, ieeler hun eigen bijZondere bijdragen geleverel hebben: Sandra 
Kalmijn, ro'lartine de Bruyne, Nicole van Popele, Jan Cees de Groot, Liesbeth Hak, 
Jeanne van def Schoot, Bas In 't Veld, Lydia Arends, Raan Ramrattan, Caroline van 
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Rossum, Marianne Geleijnse, Huib Burger, Carl Moons, Ber Pleumeekers, Paul van def 
Linden, Melanie van Riemsdijk, Ben Cost en Hans Feenstra. Daarbij waren oak vele 
anderen op de afdeling cen voottdurende en Zeer gewaardeerde bron van intellectucle 
uitdaging en steun. Met Michiel Bats, wiens heldere inzicht en efficiente werkwijze 
vaak erg prettig waren, heb ik fljn samengewerkt. Anna Oldenhave stand voor de bij-
kans onrnogelijke taak de enorme hoeveelheid ovarium-gegevens te orcienen, en heeft 
zich daar heel kundig (en dapper) doorheen geslagen. Hielvoor heel veel dank. 
Miriam de Kleijn, bedankt Vaal' de goede en aangename samenwerking. Gnze hotline 
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